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Abstract
Two cell lines, SCC12F and SCC12B were derived from the same squamous cell 
carcinoma of the facial epidermis and shown to display different phenotypes. SCC12B is 
more resistant to the induction of terminal differentiation and also more tumorigenic than 
SCC12F. The aim of this thesis was to investigate any genetic differences between 
SCC12B and SCC12F that could be responsible for their different phenotypes and 
therefore possibly be an important genetic event in the progression of squamous cell 
carcinomas of the head and neck (SCC-HN).
Microsatellite analysis of SCC12B and SCC12F revealed no differences in loss of 
heterozygosity (LOH) at the loci investigated on chromosome 3p and 9 which have 
previously been reported to show frequent LOH in SCC-HN. No overexpression of 
cyclin D1 was observed in the two cell lines and others have reported the absence of any 
H-ras mutations or abnormalities in Rb-1. Analysis of the tumour suppressor gene p53 
however revealed different levels of the protein between the two cell lines. SCC12B was 
shown to express much higher levels of p53 protein than SCC12F. Sequencing of p53 
revealed a novel heterozygous mutation at codon 216, a T—>G transversion substituting 
a valine for a glycine. Interestingly, whilst the mutant allele was visible in both cell lines 
SCC12B appeared to express much more mutant p53 than SCC12F which mostly 
retained wild-type p53 expression. Dot blot analysis suggested that mutant p53 
expression in SCC12B was double that of SCC12F.
Investigations were then undertaken to investigate whether the variations in this 
mutant to wild-type gene dosage could explain the different abilities of SCC12F and 
SCC12B to undergo suspension induced terminal differentiation. A clone of SCC12F, 
clone 19, expressing low levels of p53 and therefore presumably expressing a more 
normal phenotype was used as a target for alterations in mutant p53 expression. The use 
of this clone had the advantage that it retained a related genetic background to SCC12F 
and SCC12B and therefore is a more relevant target cell for investigating the effects of 
increased mutant p53216 on terminal differentiation.
X
The results in this thesis show that increasing the mutant p53216 dosage in clone 19 
decreased the cells ability to express involucrin and form comified envelopes and 
increased cell survival in response to suspension induced terminal maturation. An 
increase in tumorigenicity was however not observed.
Taken together these results therefore suggest that thej acquisition of a p53 
mutation is an early event in this SCC and its accumulation leads to a dramatic 
progression of this cancer. Inactivation of p53 appears to inhibit the cells ability to 
terminally differentiate and the possible roles of p53 in tumour progression are discussed.
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Chapter 1 
Introduction
1.1. Squamous cell carcinoma of the head and neck 
(SCC-HN).
Squamous cell carcinomas of the head and neck (SCC-HN) are still today a major 
cause of death in developing nations. It appears to be more frequent in India and SE 
Asia, comprising 40-50% of total malignancies (Pinborg, 1984), than in the West 
where it comprises only 5% of all malignancies (Million et al., 1989). Premalignant 
lesions which can progress to SCC-HN are papillomas, leukoplakias and erythroplakias 
although 50% of SCC tend to develop without the prior premalignant lesion. Tumours 
develop at a low frequency from leukoplakias (1-5%) but there is a higher probability of 
progression from erythroplakias (30-55%) and for this reason the erythroplakias are the 
only premalignant lesion that is surgically removed. Squamous cell carcinomas can 
develop into the more aggressive spindle cell carcinoma although these tend to be 
recurrent or metastatic tumours.
The aetiological risk factors of development of SCC-HN in India appears to be 
chewing tobacco (Jussawalla and Deshpande, 1971) whilst in the West cigarette 
smoking, the use of snuff and alcohol have proved to be the main causes (Wynder and 
Stellman, 1977). Although the epidemiology of SCC-HN has been studied, the genetic 
mechanisms that are involved in its progression are poorly understood.
1.1.1. Cultivation of SCC-HN cell lines.
Rheinwald and Green, 1975b, developed an efficient method for the cultivation of 
normal HEK’s as well as squamous cell carcinomas by growing them on a lethally 
irradiated 3T3 feeder layer. Several oral SCC cell lines have been established 
(Rheinwald and Beckett, 1981; Easty et al., 1981a&b; Rupniak <2/., 1985; Prim ed 
al., 1990; Tatake et al., 1990). However most of these lines (except Rheinwald and 
Beckett, 1981) were developed under suboptimal conditions in the absence of a feeder 
layer or cholera toxin rendering the selection of fitter variants or more aggressive 
phenotypes likely (Rheinwald and Beckett, 1981). Most were also derived from
recurrent or irradiated tumours; normal tissue from the same patient is not available for 
comparison and tumour stage has not been recorded. These cell lines therefore do not 
provide a good system in which to study the genetic changes that give rise to SCC-HN. 
Recently a more detailed collection of cell lines have been cultivated from both 
premalignant erythroplakias and SCC-HN at different stages of tumour progression 
(Edington et a l, 1994). These cell lines are currently being examined to highlight the 
phenotypic and genetic changes which occur during development and progression of 
SCC-HN.
Cell lines derived from premalignant erythroplakias retain many of the properties 
associated with cultured normal keratinocytes such as a requirement for high serum 
levels, hydrocortisone, cholera toxin, anchorage and an irradiated 3T3 feeder layer for 
optimal in vitro growth. (Edington et al, 1994). They also have a normal diploid 
karyotype, a limited lifespan ending in senescence and are non-tumorigenic. They differ 
from normal HEK’s in that they form poorly stratified cultures and also appear to be 
resistant to suspension-induced terminal differentiation and cell death (Edington et al, 
1994). These latter phenotypes are also characteristic of later stage SCC cultures 
(Parkinson et a l, 1983; Edington et al, 1994) and therefore resistance to terminal 
maturation appears to be a phenotype acquired early in SCC-HN development.
Cells from more advanced tumours possessed an altered morphology and all gave 
rise to immortal cell lines (Edington et al, 1994). This late development of in vitro 
immortality is also observed in colon cancer (Paraskeva et al., 1984) and melanoma 
(Mancianti and Herlyn, 1989). SCC cell lines also displayed an aneuploid karyotype and 
a reduced requirement for serum growth factors. The majority of cell lines from 
advanced SCC-HN formed tumours in nude mice and there appears to be a correlation 
between stage of tumour from which the cell line is derived and degree of tumorigenicity 
(Edington et al, 1994).
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1.1.2. SCC12B and SCC12F: A target system in which to study the 
affect of tumour suppressor genes in SCC progression.
SCC12B and SCC12F were originally derived from the same SCC tumour of the 
facial epidermis (SCC12) (Rheinwald and Beckett, 1981). This tumour was taken from a 
60 year old male kidney transplant recipient who had been treated with 
immunosuppressive drugs for the previous seven years. SCC12 was shown to be 
partially defective in its ability to undergo terminal differentiation in response to 
suspension culture. Compared to normal HEK, SCC 12 cells exhibited a reduced rate 
and extent of comified envelope formation. Only 40% of cells developed comified 
envelopes after five days in suspension compared to 80% of normal HEK’s (Rheinwald 
and Beckett, 1980). SCC12 also had a much longer survival half-life in suspension than 
normal keratinocytes. The colony forming ability of normal HEK after 24 hours in 
suspension is completely lost. SCC 12 cells showed a rapid decay during the first day 
followed by a stable retention of colony forming ability of the remaining cells (Rheinwald 
and Beckett, 1980). This sharp drop in survival was due to the presence of a non- 
tumorigenic fraction of cells in SCC12 that were also immortal in culture. SCC12 was 
therefore divided into two cell lines, one of which appeared to have a more malignant 
phenotype (SCC12B) than the other (SCC12F). These two cell lines therefore represent 
phenotypically distinct cell populations within the same tumour that are at different 
stages of tumour progression.
SCC12B and SCC12F have been shown to share common traits which is 
important evidence in support of their monoclonal origin. Both cell lines share identical 
rearrangements of the p-polymerase and EGF receptor (Weichselbaum et al., 1988) and 
do not express mutant ras (Clark et al., 1993). Cytogenetic analysis showed that both 
cell lines were triploid and had lost one copy of chromosomes 8,13, and 15 (Jaffe et al., 
1992).
Despite these similarities SCC12F and SCC12B differ in their tumorigenic 
potential and their ability to respond to terminal differentiation signals. SCC12B is 
highly tumorigenic (Parkinson et al., 1984) inducing tumours in all mice injected within
3
20 days (Jaffe et al., 1992). In comparison SCC12F is non-tumorigenic. SCC12B was 
much more resistant to the induction of terminal differentiation than SCC12F. SCC12B 
had a much longer survival half-life in suspension of 24 hours compared to that of 
SCC12F which showed loss of colony forming ability Tl/2 of 8.6 hours (Parkinson et 
al., 1983). Similar results were obtained when the cell lines were induced to terminally 
differentiate by exposure to PM A (Parkinson et al., 1983). Studies into the loss of 
colony forming ability in reponse to treatment with PMA showed that 70% of SCC12B 
cells were resistant to the effects of PMA compared to only 21% resistance of SCC12F 
cells. Consistent with this reduced ability to terminally differentiate, SCC12B had a 
lower degree of comified envelope inducibility (Rubin and Rice, 1986) and involucrin 
synthesis as compared to SCC12F (Jaffe et al., 1992). After exposure to lOOmM PMA 
for six days SCC12F showed a 10 fold increase in comified envelope formation over 
their controls whilst SCC12B only showed a three fold increase (Parkinson et al., 1983).
SCC12F can be converted towards a phenotype displayed by SCC12B by 
transfection with the Epstein Barr virus (EBV) latent membrane protein (LMP1) or Ha­
ras (Dawson et al., 1990). Both proteins were shown to impair the terminal 
differentiation of SCC12F but only Ha-ras gave rise to malignant transfectants.
Somatic cell hybrids generated by fusing SCC12F with SCC12B resulted in 
hybrids with a much lower tumorigenic potential than SCC12B suggesting that SCC12F 
has donated a tumour suppressor function to the hybrid (Jaffe et al., 1992).
Taken together these observations suggest that SCC12B was derived from a 
population of cells in the original tumour that had progressed further towards malignancy 
than the population from which SCC12F was derived. Comparisons of these two cell 
lines therefore provide an ideal system in which to investigate the genetic changes that 
occur in SCC-HN during tumour progression.
1.1.3. Terminal differentiation in keratinocytes : a good in vitro model
Normal HEK’s have been successfully cultured in the presence of a 3T3 feeder 
layer with an in vitro lifespan of more than 150 population doublings (Rheinwald and
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Green, 1975b). More efficient cell growth has been obtained by using a medium 
(DMEM) supplemented with 20% fetal bovine serum, hydrocortisone (Rheinwald and 
Green, 1975b), cholera toxin (Green, 1978) and EGF (Rheinwald and Green, 1977). By 
such a method each colony consists of keratinocytes forming a stratified squamous 
epithelium in which the dividing cells are confined to the lowest layer as in the epidermis 
in vivo.
A simplified diagram of the epidermis is shown in figure 1.1. The epidermis 
consists of several layers whose cells possess distinct properties. Cells in the lower basal 
layer are the only proliferating cells and as they mature they migrate up towards the 
surface of the skin losing their ability to multiply and begin to terminally differentiate. As 
the cells enter the spinous layer they increase in size (Rowden, 1975) and begin to 
synthesise involucrin (Watt and Green, 1981). As the cells enter the granular layer, they 
begin to destuct. The cytoplasmic organelles are eliminated (Lavker and Matoltsy, 1970) 
and their chromatin becomes marginated and clumped. The plasma membrane bcomes 
permeable to calcium and this influx activates an endogenous endonuclease which 
fragments the nuclear DNA into 200bp fragments- a hallmark of apoptosis (McCall and 
Cohen, 1991). Keratins of various types are present at all stages of differentiating 
keratinocytes (Sun and Green, 1978). The cells in the outer layers contain larger keratins 
than those of the inner layers (Fuchs and Green, 1980). The calcium influx activates the 
protein proflaggin to bundle keratin fibrils together (Fuchs and Byrne, 1994) and triggers 
the cross-linking of involucrin by a transglutaminase, ultimately forming an insoluble 
comified envelope (Sun and Green, 1976) surrounding a cytoplasm composed of mostly 
keratins. This comified layer acts as a mechanical waterproof barrier preventing damage 
to the underlying cells.
Studies have shown that loss of cellular contact with the basal lamina (Sun and 
Green, 1976) (perhaps by alterations in adhesion molecule expression) and alteration of 
cell shape are sufficient to trigger terminal differentiation (Watt et al., 1988). This 
response can be mimicked in vitro by suspending cells in methylcellulose which prevents 
cell to cell contact and the cells become unresponsive to mitogen stimulation. Basal cells 
mediate attachment to the basal lamina mostly via members of the integrin family
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receptors. Integrins are heterodimeric transmembrane proteins consisting of a  and (3 
subunits (Hynes, 1992). Different a  and |3 associations determine the ligand binding 
specificities of the integrin heterodimers for various extracellular matrix proteins 
including fibronectin, laminin and collagen. Alterations in ligand binding to the CC5P1 
fibronectin receptor has been implicated in epithelial cell proliferation and differentiation 
signalling. Terminal differentiation induced by suspension culture can be inhibited by 
immediate addition of fibronection (Adams and Watt, 1989) which binds to the integrin 
receptor and prevents negative growth signalling. However, any delay in this addition has 
no effect as the cells have already been committed to terminal differentiation and the 
ability of the receptor to bind fibronectin is decreased (Adams and Watt, 1990). 
Detachment of epithelial cells from extracellular matrix contacts or growth in suspension 
has also been shown to elicit an apoptotic response termed anoikis (Meredith et al.,
1993; Frisch and Francis, 1994). As well as being part of the terminal differentiation 
pathway this controlled cell death would also be important in preventing cells from 
becoming dislodged and inappropriately reattaching and thereby helps to maintain the 
polarity and organisation of the epithelium. The signalling pathway mediated by the 
integrin receptor is yet to be identified in detail but may be mediated via changes in 
cellular pH, calcium fluxes and tyrosine phosphorylation events (Meredith et al., 1993; 
reviewed in Juliano and Haskill, 1993).
In order to study terminal differentiation of keratinocytes in an in vitro situation it 
is important to establish to what extent these cultures resemble normal epidermis. They 
retain the fundamental characteristics in that they are stratified, with proliferation 
restricted to the lowest layer and cells undergoing terminal differentiation as they move 
upwards through the layers. However in culture morphology is poor compared to 
normal epidermis in that the basal cells tend to be flattened, no proper stratum comeum 
is formed and culture shed nucleated squames (Green, 1977). Proper comified and 
granular layers similar to those in vivo can be restored to cultures by depleting the 
culture medium of vitamin A which has been shown to suppress keratinocyte 
differentiation (Fuchs and Green, 1981). In vitro the spatial distribution of involucrin 
(Watt, 1983) and keratins (Kopan et al., 1987) are changed. In culture cells express only
small keratins, no large keratins are expressed in the outer layers (Fuchs and Green,
1980) and certain keratins are not seen at all (Sun and Green, 1978).
The complete in vivo differentiation program can best be seen in vitro by 
culturing the keratinocytes on collagen rafts (Kopan et al., 1987). Once confluent, the 
epithelium becomes raised above the medium and is only fed through the collagen and 
the ventral surface of the epithelium. It is thought that in this situation a vitamin A 
gradient is set up across the layers similar to an in vivo situation and therefore normal 
morphology and protein expressions are regained.
Keratinocytes grown in vitro are therefore a very good system in which to study 
the terminal differentiation programme. Cells grown in a monolayer show the majority 
of the characteristics of terminal differentiation. But this can be improved by growing 
cells on a raft culture or be induced by placing cells from the monolayer into suspension 
culture. Many markers of terminal differentiation are available for study using this 
system namely, involucrin synthesis; comified envelope formation; loss of colony forming 
ability, which is usually the first indicator of terminal differentiation as keratinocytes kept 
in suspension culture lose their ability to form colonies with a half-life of 3 hours 
(Rheinwald, 1980) and apoptosis.
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1.2. Carcinogenesis is a multistage process
It is clear from analysis of the phenotypes of tumours in experimental models that 
there are three distinct stages involved in tumour progression i.e. initiation, promotion 
and progression. It would therefore be surprising if only one genetic event was 
responsible for all stages and it is more likely that a number of genetic changes act in 
concert with each other to develop a malignant phenotype. Such a model for a 
multistage process was first proposed by Foulds in 1954 and only recently has 
technology made it possible to identify the molecular events involved in carcinogenesis.
Early evidence to support this multistep model came from the transformation of 
primary rat embryo fibroblasts (REF) with cooperating oncogenes. Transfection of both 
ras and myc into REF cells lead to their transformation (Land et al., 1983), but neither 
oncogene could act on its own. It was proposed that each step in the tumorigenic 
process reflects a mutation leading to the activation of one or more cellular oncogenes. 
The resulting oncogenes then work together to induce the full neoplastic phenotype.
Weinberg (1985) proposed that for full transformation to occur one oncogene 
should be nuclear and one cytoplasmic i.e. myc being the nuclear protein and ras the 
cytoplasmic one in the above experiment. It is now thought that the nuclear oncogene 
can be substituted by an inactivated tumour suppressor gene (reviewed by Weinberg, 
1989) and this has been confirmed by the ability of the tumour suppressor gene p53 to 
cooperate with ras in the transformation of REF cells in its mutant form (Eliyahu et al., 
1984; Parada et al., 1984), but suppress transformation in its wild-type form (Finlay et 
al., 1989; Eliyahu ef al., 1989).
Until recently the only tumorigenic mutations studied in detail were those that 
activated oncogenes. Oncogenes, which are mutant alleles of the wild-type genes proto­
oncogenes, have acquired novel or aberrant activities that promote malignancy. Their 
ability to function in a genetically dominant manner and the selective growth advantage 
that they confer have facilitated the identification of a long list of oncogenes e.g. src,fos, 
myc.
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More recent efforts have been made to identify tumour suppressor genes e.g.p53, 
Rb-1, CDKN2/pl6INK4. These tumour suppressor genes or anti-oncogenes normally act 
to inhibit growth and therefore are more difficult to identify. The inactivations of tumour 
suppressor genes by mutations was first observed by Knudson in 1971 from studies on 
familial retinoblastoma, who proposed that inactivation of both copies of the gene was 
required and this occurred by a ’two hit' mechanism. In inherited Rb, one mutant allele is 
inherited from the parent. A second mutation occurs in the other allele as an independent 
event in the offspring. In sporadic Rb, both mutations occur as two events in the same 
cell population. If a person has an initial recessive mutation in one copy of Rb, reduction 
to homozygosity can be obtained by several chromosomal mechanisms (Cavenee et al., 
1983). Firstly, mitotic nondisjunction with loss of the wild-type allele would result in 
hemizygosity at all loci on the chromosome. Mitotic nondisjunction with duplication of 
the mutant chromosome would result in homozygosity at all loci on the chromosome. 
Alternatively mitotic recombination may occur between chromosomal homologues, with 
a breakpoint between the tumour locus and the centromere which would result in 
heterozygosity at loci in the proximal region and homozygosity throughout the rest of 
the chromosome including the tumour locus. Additionally other genetic events such as 
gene conversions, deletions and mutations can also occur.
In line with the proposal that carcinogenesis is a multistep process, inactivation of 
one gene by the mechanisms previously described is not enough and additional events are 
required to move this homozygous defective cell towards full neoplasia. It has been 
proposed (Nowell, 1976) that neoplasms develop from a sequential selection of mutant 
subpopulations from a single cell origin. In such a model an initial genetic event will give 
a cell a growth advantage over its neighbours. This pre-neoplastic cell proliferates 
further and from time to time as a result of genetic instability in the expanding 
population, genetic variants acquiring other genetic events are produced. Nearly all 
these variants are eliminated because of metabolic disadvantage or immunologic 
destruction, but occasionally one has an additional advantage and becomes the precursor 
of the new predominant subpopulation. This sequential selection proceeds over time until 
a clone has arisen that has a full aneuploid malignant phenotype. Some genetic events
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are common among different tumours e.g. p53 mutations, but others are specific to that 
cell type.
It is well known that primary mouse fibroblasts grown in culture frequently 
produce immortalised clones of cells (Hermann and Rice, 1983). However the 
spontaneous immortalisation of human cells in culture is very rarely seen (Baden et al.,
1987). The interpretation of this observation maybe that fewer independent mutations 
are required in mice than in humans and therefore they become immortalised much more 
frequently.
Studies of cells from premalignant and malignant SCC-HN indicate that 
acquisition of an immortal phenotype in this cancer is normally a late event (Edington et 
al, 1994) and cell hybrid experiments have also shown that immortality was genetically 
recessive to senescence (Berry et al., 1994) thereby supporting the existence of tumour 
suppressor genes. These results therefore support the hypothesis that multiple genetic 
changes are required for HEK immortality. This is in line with a recent model of 
tumorigenicity proposed for colorectal cancer (Fearon and Vogelstein, 1990) in which at 
least four genetic alterations involving both tumour suppressor genes and oncogenes 
must occur befor the onset of tumour formation. Studies are currently being undertaken 
to identify these genetic events in SCC-HN and the results are discussed further in 
section 1.3.
Other evidence for the requirement of multiple mutations in carcinogenesis come 
from the study of transgenic mice. Transgenic mice have been bred that express c-myc at 
high levels in breast epithelial cells (Leder et al., 1986). Although these mice express a 
large amount of myc protein, they do not develop breast tumours until late in life. 
Therefore c-myc predisposes breast epithelial cells to become tumorigenic but this is 
delayed until other genetic mutations have accumulated. In much the same way, p53 
knockout mice are viable but do not develop tumours until they are six months old 
(Donehower et al., 1992). Again suggesting that a p53 mutation alone is not sufficient 
for malignancy. The latent period is increased in mice heterozygous for p53 
(Donehower et al., 1992) presumably because they have to also acquire loss of the p53 
wild-type allele.
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1.2.1. SV40 model of immortalisation (Ml and M2)
Normal human fibroblasts infected with SV40 virus show an extended lifespan in 
culture and after a period of crisis, immortal variants occasionally appear. It was shown 
by two independent groups that this effect was due to the expression of SV40 T antigen 
(Wright et al., 1989; Radna et al., 1989) and its continued expression was required for 
cells during the extended lifespan prior to crisis and following immortalisation. These 
results led to a proposal of a two stage model to explain this escape from senescence 
(Wright et al., 1989) figure 1.2. The first stage of this so called mortality mechanism, 
Ml, leads to senescence and it can be inactivated or bypassed by SV40 T antigen. This 
allows cells to continue proliferating until crisis occurs. Crisis is caused by the onset of 
stage two (M2) of this mortality mechanism. Rare inactivations of unknown genes in 
this stage give rise to immortal variants.
SV40 large T antigen has been shown to bind to both Rb-1 (De Caprio et al.,
1988) and p53 (Lane and Crawford, 1979; Linzer and Levine, 1979). By use of T 
antigen mutants it has been shown that the binding of p53 and Rb-1 is involved in the 
bypass of the Ml mechanism (Figure 1.2) and that both activities of the T antigen are 
required for proliferation (Shay et al., 1991). Furthermore adenovirus E1B and El A, or 
HPV E6 and E7 (each pair of which is known to bind to p53 and Rb-1 respectively) are 
able to replace T antigen functions and permit cell proliferation (Shay et al., 1991). This 
remarkable similarity between these viruses cannot be by chance and highlights the 
necessity of p53 and Rb-1 inactivation for continued cell proliferation and the bypass of 
Ml.
The genetic events that occur in order to overcome M2 are less well characterised. 
Recent experiments have implicated the necessity for reactivation of the enzyme 
telomerase in immortal cells. Telomerase activity is absent in somatic cells and is only 
normally found in germline cells (Allsopp et al., 1992) where its function is to maintain 
chromosome length (Greider et al., 1990). In human cells transfected with SV40, the 
telomeres continue to shorten as in a normal cell even though the cell now has an 
extended lifespan (Counter et al., 1992). When these cells pass through crisis telomere
12
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shortening is arrested and the cells have the potential to become immortal (figure 1.2). 
Telomerase has indeed been shown to be re-activated in ovarian carcinoma cells in vivo 
(Countered/., 1994).
Genes other than Rb-1 and p53 whose inactivation is essential for immortalisation 
are continually being discovered. The first step in their discovery is by identifying areas 
of frequent loss on chromosomes suggesting the presence of a frequently inactivated 
tumour suppressor gene (section 1.4.1.).
Somatic cell genetics have also shown that when fibroblasts immortalised by SV40 
virus are fused with normal fibroblasts, hybrids which senesce result (Pereira-Smith and 
Smith, 1981). These hybrids were shown to continue expression of SV40 T antigen in 
their nucleus. This is evidence for the presence of recessive tumour suppressor genes or 
senescence genes which are donated to the hybrid by the normal cells and which must 
also become inactivated for immortalisation to ensue. Micro-cell mediated chromosome 
transfer; where a chromosome induces a senescent phenotype when transferred into a cell 
line, is also currently being used to identify such genes.
Genes and chromosomal regions discovered to be important in immortalisation in 
SCC-HN are discussed further below and are fitted into the M1/M2 mechanism in figure 
1.2 .
1.3 The genetic analysis of immortalisation of human 
squamous cell carcinoma.
1.3.1. ras
Mutations in the ras gene at amino-acids 12 jor 61 produce a protein that binds 
GTP and is constantly signalling for cell growth. Mutations in all three family members 
N-ras, K-ras and more rarely H-ras have been detected at different frequencies in 
different cancer types. It also appears that cancers have a preference for activation of 
only one of the ras proteins, for example 50% of colorectal carcinomas and large 
adenomas harbour a K-ras mutation (Vogelstein et al., 1988). Experimental models 
have also shown that chemically induced mouse tumours exhibit H-ras mutations at an
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early stage and are thought to be the initiating event in carcinogenesis (Balmain et al., 
1984).
In SCC-HN conflicting results have been obtained as to whether ras mutations 
are an important step in carcinogenesis of this tumour type. In India 35% of SCC-HN 
were found to have H-ras mutations (Saranath et al., 1991). However the incidence of 
H-ras mutations in patients from the West were not detected (Clark et al., 1993) or 
detected at an extremely low rate (Sheng et al., 1990). This discrepancy may be 
explained by the exposure of the patients in India to different carcinogens (Chang et al.,
1991) or tumour promoters (Clark et al., 1993). Although this has yet to be tested, the 
chewing of betel quid in India is a common habit that does not exist in the West and this
1 may contain a carcinogen that causes ras mutations and gives these cells a 
selective advantage analagous to the mouse epidermal model (Clark et al., 1993). 
Therefore it appears that ras mutations are not a common genetic event in the initiation 
or progression of SCC-HN although it is clear that when they occur such mutations can 
give a selective advantage to keratinocytes in SCC.
1.3.2. Epidermal growth factor receptor (EGFr).
The EGFr binds the ligands epidermal growth factor (EGF) (Savage et al., 1972) 
and transforming growth factor-a (TGF-a) (DeLarco and Todaro, 1978) which 
activate the intracellular domain tyrosine kinase and promotes cellular growth. Studies 
have shown that the EGFr is frequently overexpressed in SCC-HN (Stanton et al., 1994; 
Weichselbaum et al., 1989; Cowley et al., 1984 and 1986; and Ozanne et al.,1986). 
Inhibition of ligand binding to the EGFr by specific antibodies prevents growth of SCC in 
culture (Masui et al., 1984) and therefore it has been suggested that overexpression of 
the EGFr may enable cells to respond to low levels of EGF and TGF-a and give them a 
selective growth advantage over their neighbours.
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1.3.3 Cyclin D1
The human CCNDl/cyclin D1 gene, also known as PRAD1, is found on 
chromosome llq l3  (D11S287) and has been identified as a G1 cyclin due to its 
induction in G1 by growth factor stimulation (Matsushime et al., 1991; Won et al.,
1992). There are three members of the D-type cyclins, Dl, D2 and D3 all of which have 
been shown to interact with Rb-1 (see section 1.4.2) (Dowdy et al., 1993; Kato et al.,
1993). The D type cyclins bind Rb-1 together with their catalytic partners cdk-4 or cdk- 
6 (Matsushime et al., 1994; Meyerson and Harlow, 1994) causinglRbphosphorylation 
and allow cells to enter S phase (Kato et al., 1993). These G1 cyclins are therefore 
putative proto-oncogenes as their overexpression would lead to deregulation of the cell 
cycle.
Deregulated expression of CCND1 was first identified in parathyroid adenomas 
(Arnold et al., 1989) by a translocation event that had fused the DNA from D11S287 to 
the 5' regulatory region of the parathyroid hormone resulting in a dramatic increase in 
cyclin Dl expression. Chromosomal translocations of llq l3  have also been identified in 
B-cell lymphomas and leukemias (Tsujimoto et al., 1985) and called BCL-1. CCND1 
has since been identified as the gene in this BCL-1 region (Rosenberg et al., 1991; 
Withers et al., 1991) and CCND1 mRNA has been shown to be overexpressed in B-cell 
lines carrying this translocation. The chromosomal region of llq l3  has also been shown 
to be amplified in a variety of human tumours (Lammie and Peters, 1991) such as breast 
cancer (Fantl et al., 1990), bladder cancer (Proctor et al., 1991), SCC of the lung 
(Berenson et al., 1990) and esophageal cancer (Jiang et al., 1992). The cyclin Dl gene 
is also amplified in SCC-HN (Jiang et al., 1992). A more recent study of the above 
SCC-HN cell lines (section 1.1.1.) has also shown a consistent increase in the level of 
cyclin Diexpression (Nickolic et al., submitted). This overexpression of cyclin Dl does 
not correlate with elevated levels of EGFr.
Cyclin Dl overexpression therefore appears to be an important event in 
progression of SCC-HN.
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1.4 Involvement of tumour suppressor genes in SCC-HN.
1.4.1. Identification of potential tumour suppressor genes by
amplification of microsatellites.
The use of microsatellite markers has become favoured over other methods for 
detecting loss of heterozygosity (LOH) on chromosomes e.g. restriction fragment length 
polymorphisms (RFLPs), because it is a faster method and as it is polymerase chain 
reaction (PCR) based it uses relatively small quantities of DNA. Microsatellite 
sequences are CA-GT repeats of unknown function. They are highly polymorphic in 
length and occur approximately every 30-60kb throughout the genome (Weber and May,
1989). Their frequency allows most regions of every chromosome to be examined in 
detail. They are inherited in a Mendelian fashion and therefore due to their differences in 
length, the paternal and maternal microsatellite sequences can be distinguished.
The sequences are amplified using PCR and are separated on a polyacrylamide 
gel. If the individual is heterozygous for a particular marker then both alleles will be seen 
(Weber and May, 1989). Any LOH can be identified by comparing amplified sequences 
from the tumour DNA with that from the same patients normal DNA. If however a 
patient is not heterozygous at a particular marker then only one allele will be seen and it 
is then impossible to identify any LOH. In this case the microsatellite is said to be 
uninformative and another has to be used. PCR allelotyping is not suitable for the 
detection of gene amplifications, small deletions or point mutation and therefore this 
method used in combination with one that does e.g comparative genomic hybridisation 
(Kallioniemi et al., 1992) would be more sensitive.
Although identification of LOH does not confirm the existence of a gene involved 
in malignancy, repeated LOHjat any locus in several different tumours is strong evidence 
supporting the involvement of loss of this gene in carcinogenesis. However a gene 
deletion could also be due to genomic instabilty and not an important genetic event in 
cancer. The comparison of various tumour stages and the identification of sequential 
events is more successful in identifying relevant genes. Identifying regions of LOH is not
sufficient to identify novel suppressor genes. These genes have to be cloned and their 
function and inactivation studied in more detail.
1.4.1.1. Identification of regions of LOH in SCC-HN
Loss of heterozygosity studies have been carried out on the above SCC-HN cell 
lines (Edington et al., 1994; Loughran et al., 1994 and by others) Frequent loss has 
been observed at chromosome 17pl3 (Edington et al., unpublished data) corresponding 
to the p53 gene and on further investigation nearly all immortal SCC-HN were found to 
have p53 missense mutations (Bums et al., 1993). The relevance of inactivation of p53 in 
the progression of SCC-HN is discussed further in section 1.4.3. and by the results in this 
thesis.
Frequent LOH have been shown on chromosome 9. LOH between markers 
D9S171 and D9S157 on 9p21 was identified in 100% of immortal SCC-HN cell lines 
(Loughran et al., 1994) but in none of the senescent cultures. Other reports have shown 
similar LOH at 9p21 in SCC-HN (Zhang et al., 1994; Van der Riet et al., 1994b;
Nawroz et al., 1994), melanoma (Holland et al., 1994), bladder cancer (Cairns et al., 
1993) and malignant mesotheliomas (Cheng et al., 1993). Further support for the 
importance of deletions in this region comes from experiments that introduce a normal 
chromosome 9 into mouse A9 cells by monochromosome transfer which showed that it 
was not tolerated without deletions between the markers IFN and D9S171 (Cuthbert et 
al., 1995).
Recently the Multiple Tumour Suppressor 1 (MTS-1) gene has been mapped to 
this region and found to encode the p l6INK4 gene (Kamb et al., 1994; Nobori et al., 
1994; Serrano et al., 1993). p l6INK4 is a specific inhibitor of cdk4 which is known to 
interact with cyclin D. Loss of p l6INK4 would therefore enhance the cyclin D-cdk4 
kinase activity. This complex is known to phosphorylate and inactivate Rb-1 (see section 
1.3.3) and therefore allow progression of the cell into S phase.
Frequent LOH has also been shown on chromosome 9q in SCC-HN. Several 
markers have shown high frequency of loss between 9q22.3-9q33 (between markers
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D9S127and GSN) (Loughran et a l,1994). Other studies have also shown similar loss on 
9q in SCC-HN (Ah-see et a l, 1994; Quinn et a l, 1994) and in basal cell carcinomas 
(Van der Riet et a l, 1994a) but as yet no gene has been identified.
Consistent losses have also been identified on chromosome 3 in immortal SCC- 
HN cultures (Loughran et a l, unpublished data) at 3p25-pter, 3p21 and 3pl3-14.
Similar losses have been reported in SCC-HN by others. Latif et a l, 1992 showed loss 
at 3pl4-3p26; Maestro et a l, 1993 showed loss mapping to 3p24-ter, 3p21,3 and 3pl4- 
cen and El-Naggar et a l, 1993 showed losses at 3p21 and 3p24 in SCC-HN. A putative 
tumour suppressor gene has been mapped to 3p21, namely the receptor protein-tyrosine 
phosphatase y (LaForgia et a l, 1991) which functions by controlling the levels of 
phosphorylation in the cell cycle. Loss of one allele has been shown in renal and lung 
carcinomas but further investigations are required to study whether its loss plays any part 
in SCC-HN. Interestingly, introduction of normal chromosome 3 by microcell-mediated 
chromosome transfer into an ovarian carcinoma cell line induced senescence and growth 
arrest as well as suppression of tumorigenicity (Rimessi et a l, 1994). Tumours induced 
by chromosome 3 monochromosomic hybrids consistently showed loss in two regions 
3p23-24.2 and 3p21.1-21.2. Taken together these results strongly suggest the presence 
of an as yet unidentified tumour suppressor gene on 3p that is inactivated in a variety of 
cancers including SCC-HN.
Further studies have recently shown that there is also LOH on chromosomes 
lq42, 6ql3-15,7q and 4q in SCC-HN, but not on the X chromosome (Loughran et a l,
In preparation). Interestingly, putative senescence genes have been proposed to reside 
on these chromosomes (chromosome 1, Sugawara et a l, 1990; chromosome 4, Ning et 
al, 1991; chromosome 6, Volz et a l, 1994; chromosome 7, Ogata et a l , 1993 and 
chromosome X, Wang et a l, 1992) but it is not yet clear if these genes are involved in 
SCC-HN.
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1.4.2. Rb-1
The functional inactivation of the retinoblastoma gene (RB-1) in many cancers 
suggests that it operates as a tumour suppressor gene and a negative regulator of cell 
growth (Weinberg et al., 1991). Rb-1 protein is highly regulated during the cell cycle by 
phosphorylation (Buchkovich et al., 1989; Chen et al., 1989). The underphosphorylated 
form of Rb-1 is present in early G1 and prevents progression into S phase by interaction 
with growth promoting proteins via its pocket domain e.g. E2F (Chellappan et al.,
1991). Rb-1 becomes hyperphosphoiylated by cyclin-cdk complexes such as cyclin E- 
cdk-2, or cyclin D-cdk4 (Kato et al., 1993) in mid to late G1 and remains 
phosphorylated until the cells exit mitosis. This hyperphosphorylation has been shown to 
release proteins bound in the pocket domain and thereby allow entry into S phase. 
DNA tumour virus oncoproteins i.e. SV40 large T antigen (Decaprio et al., 1988), 
adenovirus El A (Whyte et al., 1988) and human papilloma virus E7 (Dyson et al., 1989) 
all prevent the growth suppressive effect of Rb-1 by binding to the underphosphorylated 
form in early G1 and displacing the bound growth promoting proteins.
Loss of heterozygosity on 13q has been identified in 50% of SCC from the 
esophagous (Boynton et al., 1991; Huang et al.,1993). A high incidence of loss on 13q 
has also been identified in SCC-HN (Yoo et al., 1994). This loss did not correlate with 
absence of Rb-1 protein suggesting that the loss seen in these studies is associated with 
another as yet unknown tumour suppressor gene which lies distal to the RB-1 gene. The 
Rb-1 protein also appeared normal in the series of SCC-HN cell lines described in section 
1.1.1. (Edington et al., 1994) displaying normal phosphorylation patterns and nuclear 
expression (Nikolic et al., submitted). These cell lines were also shown not to be 
infected with HPV 16 or 18 and therefore Rb-1 has not been inactivated by the E7 
oncoprotein (Edington et al., 1994).
D-type cyclins have been shown to interact with Rb-1 protein (Dowdy et al., 
1993; Kato et al., 1993) and as described in section 1.3.3. cyclin Dl is overexpressed in 
SCC-HN. There has also been shown to be LOH as the p l6INK4 locus in SCC-HN 
(section 1.4.1.1.) and this inactivation of p l6INK4 protein indirectly promotes
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phosphorylation of RB-1 through continuous cyclin D activity. Therefore the functional 
inactivation of Rb-1 has not occurred through direct mutation of Rb-1 in SCC-HN but 
instead via overexpression of cyclin Dl and inactivation of p l6INK4.
1.4.3. p53
More mutations have been reported in the tumour suppressor gene p53 than in 
any other gene to date. Such mutations have arisen in a wide variety of cancers 
(reviewed by Caron de Fromentel and Soussi, 1992) and have outlined the importance of 
p53 inactivation in tumour progression.
1.4.3.1. p53 mutations in human cancer.
The most frequent method of p53 inactivation is by a missense mutation or 
deletion with concurrent loss of the remaining p53 allele. It has been shown that the 
wild-type p53 is phenotypically dominant to mutant p53 (Chen et al., 1990) highlighting 
the necessity for inactivation of both alleles before malignancy can proceed. This is 
however not always the case and rare heterozygous mutations, as reported in this thesis, 
have been reported. It is believed that in these situations the mutation has not lead to a 
functionally inactive p53 protein but to one that can override the effect of the wild-type 
allele and has also possibly gained a function giving the cell a selective advantage.
Conflicting evidence has implied that mutation of p53 is both an early and late 
event in tumorigenesis depending on the type of cancer studied. In colon cancer 75% of 
carcinomas show loss of chromosome 17p in the region of the p53 gene (Vogelstein et 
al., 1988) but such loss is relatively infrequent in adenomas. Similarly p53 mutations 
were found to be more common in carcinoma than adenoma (Baker et al., 1989).
Several groups have documented the occurrence of p53 mutations in astrocytomas. 
Ohgaki et al., 1993, reported that 3 of 11 low grade astrocytomas harboured p53 
mutations and a similar rate was also documented in grade II and El tumours (Von 
Deimling et al., 1992). In another study one group of tumours showed that pairs of low
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grade and recurrent tumours contained the same p53 mutation (Sidransky et al., 1992). 
However another group of tumours in the same study showed that while at first 
appearance, progression to high grade was associated with a de novo p53 mutation, 
closer analysis revealed that a subpopulation of cells were present in the low grade 
tumour containing this same mutation, | therefore supporting the idea that progression is 
associated with a clonal expansion of cells that have acquired a p53 mutation giving them 
a selective growth advantage. A third low grade tumour was shown to have a small 
population of cells with a heterozygous mutation and progression to a higher grade 
occurred by acquiring a different p53 mutation in the second allele. P53 mutations 
therefore seem to occur as both early and late events in astrocytomas.
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder which 
progresses from an initial long chronic phase to an accelerated phase, eventually leading 
to a blast crisis when acute leukemia supervenes. In CML the p53 gene is not 
inactivated by a single point mutation as described in the previous cancers; instead a high 
occurrence of gross structural changes, rearrangements or deletions have been reported 
to occur in the late blastic phase (Feinstein et al., 1991; Ahuja et al., 1991 and Kelman et 
al., 1989).
Some types of cancer arise because of obvious aetiological contributions from 
exogenous as well as endogenous mutagens. In hepatocellular carcinomas (HCC) for 
example, hepatitis B and aflatoxin Bl, a potent liver carcinogen, are well known risk 
factors. Murakami et al., 1991, found that p53 mutations were only present in advanced 
HCC. Studies also identified a mutational hotspot at codon 249, a G—>T transversion 
shown to be caused by exposure to aflatoxin Bl (Hollstein et al., 1991).
P53 mutations have been shown to occur as relatively early steps in non-small 
cell lung cancer (NSCLC) with G—»T transversion also being a common event (Suzuki et 
al., 1992). This mutation has been shown to correlate with exposure to carcinogens in 
tobacco such as benzopyrene (Hollstein et al., 1991).
This thesis is concerned with the role that p53 mutations play in the progression 
of squamous cell carcinomas of the head and neck (SCCHN) and it has become clear 
from a variety of studies that this is a very common event. Work in our group has shown
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that 33% of our human squamous cell carcinomas (SCC) and 50% of our cell lines 
derived from SCC overexpressed p53 protein. 80% of these cell lines were found to 
harbour p53 mutations (Bums et al., 1993) and the remainder fail to express a normal 
level of p53 protein (Edington et al., 1995) In this study we could not detect a 
correlation between tumour stage, p53 mutation or treatment history. Our group has 
also shown that p53 mutations detected in primary SCC of the tongue are also detected 
in the corresponding lymph node metastases indicating that keratinocytes harbouring 
these p53 mutations possess a selective advantage throughout SCC progression. Other 
studies showed similar results to ours (Gusterson et al., 1991) and slightly higher cases 
of elevated p53 expression were reported by Field et a/.,(l 991) and Maestro et al.,(1992) 
of 67% and 60% respectively. In the case of SCC of the upper aerodigestive tract 
mutations were commonly G—>A transitions or G—»T transversions consistent with the 
known mutational spectra produced by cigarrette smoke (Bums et al., 1993; Maestro et 
al., 1992 and Sakai et al., 1992). SCC of the epidermis have also been reported to have 
a high incidence of p53 mutations (Brash et al., 1991; Pierceall et al., 1991 and Moles et 
al., 1993). Mutations in these SCC were commonly CC—»TT double base changes 
suggesting UV light to be the aetiological risk factor.
Inactivation of p53 not only occurs by genetic mutations but also by the 
interaction of viral oncoproteins. SV40 large T antigen, Adenovirus E1B and human 
papilloma vims (HPV) E6 oncoproteins have all been shown to sequester p53. The 
DNA of certain HPV types including HPV 16,18, 31, 33 and 39 is found in 85% of 
cervical carcinomas (Riou et al., 1990). These viruses are considered to be high risk 
because of their association with cancer and high grade intra-epithelial lesions. Low risk 
HPV types e.g. HPV 6 and 11 have a similar tissue specificity, yet a lower affinity for 
p53 and are associated primarily with benign lesions that are low risk for malignant 
progression. In primary HPV positive cervical carcinomas, the p53 gene is wild-type 
(Wrede et al., 1991). E6 forms a protein complex with p53 and targets it for ubiquitin- 
mediated degradation (Scheffner et al, 1990). In HPV negative tumours p53 mutations 
are frequent (Srivistava et al., 1992a; Crook et al., 1992, and Kaebling et al., 1992) and 
these tumours are associated with poor prognosis.
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Families have been discovered with inherited autosomal dominant p53 mutations. 
This has been termed the Li-Fraumeni syndrome (LFS) after its discoverers (Li et al., 
1988) and families are defined as containing an individual (the proband) with a sarcoma 
diagnosed before 45 years, a first degree relative with cancer before 45 and with an 
additional first or second degree relative with cancer before 45 or a sarcoma at any age. 
LFS patients display diverse tumour types such as soft tissue sarcomas, breast 
carcinoma, brain tumours, osteosarcoma, leukemia and adrenocortical carcinoma. Such 
tumours develop at an unusually early age and multiple primary tumours are common.
Germline p53 mutations were first reported by Malkin et al., 1990, all of which 
occurred in exon 7 and were located between codons 245-258. More recently this 
region has been extended (Law et al., 1991; Malkin et al., 1992; Birch et al., 1994.) and 
a hotspot for mutation has emerged at codon 248. P53 is found in a heterozygous state 
in the normal cells of an LFS individual (Malkin et al., 1990; Srivistava et al., 1990 and 
1992b) and the same mutant allele is retained in tumours with loss of the wild-type allele. 
This finding supports the two hit hypothesis for tumour progression (Knudson et al., 
1971) in that the loss of p53 heterozygosity constitutes the “second hit” in tumours 
arising in LFS individuals. Mutant p53 protein and RNA is expressed at a low level in 
normal fibroblasts from family members (Malkin et al., 1990; Srivistava et al., 1992b) 
and does not exert a trans-dominant effect on the wild-type p53 present (Milner and 
Medcalf, 1991) stressing the need for loss of wild-type p53 during tumour progression. 
Indeed the murine P53245 mutant (corresponding to human P53248 hotspot mutant) has 
been shown to retain most of the properties of wild-type p53 but was found to be 
transcriptionally inactive (Hao et al., 1993) suggesting LFS mutations may be loss of 
function mutants.
It is also important to note that when normal fibroblasts from LFS individuals are 
placed in culture they develop changes in morphology, anchorage independant growth, 
chromosome abnormalities and escape senescence (Bischoff et al., 1990a) suggesting 
that the cells are prone to spontaneous mutations that predispose them to 
immortalisation. As with LFS fibroblasts, fibroblasts from p53 null mice when placed in
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culture also overcome senesence and become immortal (Harvey et al., 1993; Tsukada et 
a l, 1993).
Kemp et al., 1993 used p53 null and heterozygous mice to study the initiation, 
promotion and progression of carcinogenesis in vivo and to attempt to answer the 
question of whether p53 inactivation is an early, or initiating event in tumour 
development or a later event inducing progression. In this study mice treated with the 
chemical carcinogen DMBA followed by repeated treatments of the tumour promoter 
TPA developed well-differentiated benign skin papillomas. A proportion of such 
papillomas developed into SCC and further progression lead to a highly invasive spindle 
cell carcinoma. It was observed that papilloma yield was similar in wild-type and 
heterozygous mice but reduced in p53 null mice. In contrast, the rate of progression to 
carcinoma was increased in the null and heterozygous mice compared with the wild-type 
mice. The appearance of carcinomas in the heterozygous mice was associated with the 
loss of the wild-type allele. Therefore the loss of p53 does not increase the incidence or 
shorten the latency of appearance of papillomas but it does appear to greatly enhance the 
malignant progression. In this system then, p53 inactivation does not appear to act as an 
initiation event in carcinogenesis but allows the cells to progress towards a more 
malignant phenotype.
Asking the same question in a human in vivo study however suggested that p53 
mutations were an early and maybe an initiating event (Nees et al., 1993). This study 
identified p53 overexpression at epithelial sites distant from the primary SCC-HN tumour 
in cancer patients. Such overexpression was not due to a normal response to DNA 
damage and correlated with a p53 mutation, an increased proliferation rate and a 
dedifferentiated phenotype. Furthermore different p53 mutations were detected at 
different tumor-distant sites suggesting not a monoclonal but a multifocal polyclonal 
process occurs in SCC-HN development. These results strongly suggest that p53 
inactivation maybe an early event in carcinogenesis and these cellular changes remain 
inconspicuous until other genetic events have accumulated either from genetic instability 
or by exposure to a carcinogen such as alcohol in the oral cavity. These conclusions are 
in contrast to the findings using the mouse model described above. In this system H-ras
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mutations have been identified as an initiating event (Balmain et al., 1984) and as 
discussed in section 1.3.1. this has little relevance to SCC-HN except in the presence of a 
tumour promoter (Clark et al, 1993). It would be interesting to ascertain whether the 
timing of a p53 mutation is dependent on the presence or absence of a tumour promoter 
and therefore whether in the above mouse model a p53 mutation has occurred earlier but 
lies dormant until other genetic events induced by exposure to the tumour promoter have 
occurred
As the progression to malignancy is a multistep pathway involving the activation 
of oncogenes and inactivation of tumour suppressor genes, it appears to not be important 
when p53 is inactivated, as this appears to be different depending on the system studied.
It does however appear that its inactivation by whatever means is essential if 
carcinogenesis is to proceed.
1.4.3.2. Structure of p53.
The human p53 gene is found on chromosome 17pl3.1 (McBride et al., 1986) 
and this region is commonly deleted in tumours (Baker et al., 1989, Nigro et al., 1989) 
illustrating another mechanism for p53 inactivation. The gene is large (20kb in length) 
and is comprised of eleven exons, the first of which is non-coding and separated from 
the rest by a large intron (lOkb). The p53 gene has been conserved through evolution 
and comparison of sequences from man, rat, mouse, frog, chicken and bony fish has 
identified five highly conserved domains (Soussi et al., 1990) among amino acid residues 
13-19,117-142,171-181, 234-258 and 270-286 (I-V illustrated in figure 1.3). A 
comprehensive study of mutations found in various tumour types, as discussed in the 
previous section, has shown that the majority of p53 mutations occur in four of these 
conserved regions (II-V) indicating that these areas must be important functional areas of 
the p53 protein (Caron de Fromentel and Soussi, 1992). Several amino acid hotspots for 
mutations have also been identified as shown in figure 1.3.
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The amino-terminal region of p53 (residues 1-73) when fused to Gal 4 DNA 
binding domains has been shown to activate the transcription of a reporter construct in 
vitro (Farmer et al., 1992) and in mammalian cells (Fields and Jang, 1990; Raycroft et 
al., 1990; Kern et al.,1992). Various p53 mutants however were shown to be 
transcriptionally inactive or temperature sensitive in this assay (Raycroft 1991., Unger et 
al., 1992) suggesting that they are loss of function mutants or conformationally altered.
The central region of the p53 protein is very hydrophobic and proteolytic 
digestion of p53 has revealed a protease resistant fragment (residues 102-292) which is 
capable of binding DNA (Bargonetti et al., 1993; Pavletich et al., 1993). This DNA 
binding has been shown to be sequence specific and p53 consensus binding sites have 
been identified by a variety of groups. Bargonetti et al., 1991, first showed that p53 
recognises a GC-rich domain (gggCGG) near the origin of SV40 DNA replication. 
Another binding site was identified (Kern et al., 1991) in the ribosomal gene cluster 
(RGC) sequence (TGCCTTGCCTggactTGCCTggcctTGCCT) and binding was 
shown to be disrupted by guanine methylation (capitals represent essential nucleotides 
for p53 binding). A palindromic p53 binding sequence (ggaCaTGcccgggCATGtc) was 
isolated (Funk et al., 1992) by amplification of DNA bound to p53. By a similar method 
a different consensus binding site for p53 has been established (El-Deiry et al., 1992) 
consisting of two copies of a 10 bp motif PuPuPuC(A/T)(T/A)GPyPyPy separated by 
0-13 base pairs. The heterogeneity of these binding sequences outlines the complex 
nature by which p53 binds DNA in a sequence specific manner and hinders the finding of 
genes activated specifically by p53 (discussed further later).
The p53 protein has been shown to form homotetramers (Stenger et a l, 1992; 
Friedman et al.,1993). The region involved in this oligomerization (see figure 1.3) has 
been identified as an amphipathic alpha helix followed by a stretch of basic amino-acids 
at the carboxy-terminus of the protein (Sturzbecher et al., 1992). Use of the yeast two 
hybrid system showed that the smallest region in this fragment sufficient for 
oligomerisation is amino-acids 331-393 (Iwabuchi et al., 1993) and this has recently been 
shortened to residues 319-360 (Sakamoto et al., 1994). A 3D analysis of this 
oligomerisation domain (residues 319-360) by NMR spectroscopy (Clore et al., 1994)
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showed that it formed a symmetric tetramer made up of a dimer of dimers. Each 
monomeric unit contains a (3 strand and an a  helix. Each subunit interacts with another 
subunit such that the helices and [3 strands are antiparallel.
The carboxy terminal region of p53 (residues 330-393) which is highly basic 
appears to be involved in non-specific DNA binding (Pavletich et al., 1993; Wang et al., 
1993) and together with the oligomerization domain this region may facilitate the correct 
binding to DNA.
The conformation of p53 appears to be disrupted by metal chelating agents 
(Pavletich et al., 1993), an organic mercurial reagent which targets cysteinyl residues and 
low concentrations of soft metals such as mercury or cadmium (Hainaut and Milner,
1993) suggesting that metal ions, most probably zinc, bind to cysteinyl residues 
stabilizing the tertiary structure.
Recent determination of the 3D structure of p53 has helped understand how the 
above functional domains of p53 spatially fits together and has interestingly identified the 
physical relevance of the hotspot mutations discussed previously (see figure 1.4). The 
crystal structure of a complex containing the core domain of human p53 and a DNA 
binding site (El-Deiiy et al., 1992) has been determined by Cho et al., 1994. The core 
domain structure (see figure 1.4) consists of a |3 sandwich that serves as a scaffold for 
two large loops and a loop sheet helix motif (LSH) The two loops (L2 and L3) are 
indeed held together in part by a tetrahedrally coordinated zinc atom, the ligands for 
which are Cys176, His179 on L2 and Cys238, Cys242 on L3. It has been revealed that the 
structures involved directly in DNA binding correspond to the conserved regions of the 
core domain and contain the mutational hotspots. The LI loop and (3 hairpin that 
follows it correspond to conserved region II (residues 117-142) and the H2 helix motif 
corresponds to region V (residues 270-286). These two structures make contacts with 
the major groove of the DNA (figure 1.4). Minor groove contacts in the AT rich region 
of the binding site are made by L3 which corresponds to conserved region IV (residues 
234-258). L2 at the end of the f3 sandwich does not directly interact with DNA but is 
involved in extensive interactions with L3 and it coincides with region III (residues 163- 
195). Mutations are most frequent in L3 (30% of mutations in tumours), the LSH motif
29
Fi
gu
re
 
1.4
 
St
ru
ct
ur
e 
of 
the
 
p5
3 
M
on
om
er
 
Co
re
 
D
om
ai
n
tu
>oo
CC 
(D 
CC
Oz
CM
COi
CM
0)■oc
(0k_
0 )
GO.
c ^  a. 
< §  2
co
'5b£
CM
X
T3
s
Co
00
2
coJ
co
00
2
<NJ
Co • ^00<u
-o
<D
£<uai
COo
C/3T3
CO
C/3<u
fcoo
I
iI
(25%) and L2 (17%). Six hotspot mutations are known Arg248, Arg273, Arg175, Gly245, 
Arg249, Arg282 and two of these Arg248 and Arg273 which have the highest mutational rate 
directly contact the DNA The other four residues appear to play a critical role stabilizing 
the structure of the DNA binding surface of p53. The |3 sandwich is not a frequent target 
for mutation but some are found in the hydrophobic core closest to the DNA binding 
surface.
The conformation of the p53 protein can be identified by a variety of antibodies. 
PAb 1620 recognises the wild-type p53 protein whilst PAb240 recognises a so called 
"mutant" form of p53 and these are frequently used in immunocytochemical assays to 
detect mutant p53. The epitope for PAb240 (residues 212-217) (Stephen and Lane,
1992) has been shown in this crystal structure to lie in the hydrophobic core and is 
therefore inaccessible to an antibody. In order for the antibody to bind, the protein has 
to unfold and therefore this antibody recognises more a denatured form of p53 than a 
"mutant" form. Two classes of mutant have been identified by this study. Class I (e.g. 
Arg273) mutants which do not bind hsc70 are PAb240‘/1620+, yield a stable core upon 
proteolytic digestion and fail to bind DNA but still transactivate reporter constructs 
(Zhang et al.,1993; Chen et al., 1993). Class II mutants (e.g.Arg175) which are unfolded 
are PAb240+/1620", bind hsc70, are highly sensitive to proteolysis and do not 
transactivate.
The p53 protein is a nuclear protein and three nuclear localisation signals are 
clustered at the carboxy terminus (Shaulsky et al., 1990) as shown in figure 1.3. NLSI is 
the major nuclear localisation signal and is conserved between species. NLSII and III are 
less effective singularly and efficient nuclear localisation requires all three signals.
The p53 protein is extensively post-transcriptionally modified, mostly by 
phosphorylation. This enables the cell to control p53's many possible roles. Most 
known phosphorylation sites are at the N-terminus (see figure 1.3) where DNA-PK 
(double-stranded DNA activated protein kinase) phosphorylates human p53 at serines 15 
and 37 and mouse p53 at serines 4 and 15 (Lees-Miller et al., 1992) and 7, 9,18 and 37 
(Wang et al., 1992). Mutation of Ser-15 to Ala has been shown to partially block the 
ability of p53 to arrest cell cycle progression at Gl/S and also leads to stabilisation of the
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protein. Therefore phosphorylation at this site may contribute to the activation of p53 as 
a growth suppressor (Fiscella et al., 1993). Casein kinase I (CKI) has also been shown 
to phosphorylate the N-terminal region at serines 4, 6 and 9 in mouse p53 (Milne et al., 
1992a). A DNA repair-defective mutation in Saccharomyces cervisiae is linked to a 
protein kinase similar to CKI offering support for a link between DNA damage, p53 and 
phosphorylation (discussed in section I.4.3.6.). A third kinase, MAP (mitogen-activated 
protein) kinase has been shown to phosphorylate mouse p53 at threonine 73 and 86 
(Milne et al., 1994). It has been shown that MAP kinase can be activated by exposure of 
cells to UV radiation, possibly suggesting that regulation of gene transcription following 
UV damage may be mediated through the MAP kinase pathway.
The C-terminal DNA binding domain is phosphorylated in vitro at Ser-315 in 
humans and at the corresponding Ser-309 in mice by both the cyclin A and cyclin B 
associated forms of p34cc*c2 (Bischoff et al., 1990b; Sturzbecher et al., 1990) suggesting 
that p53 is regulated by cell cycle progression. Indeed p53 is known to become highly 
phosphorylated upon entry into S phase suggesting that/in facta Gl/S cyclin dependant 
kinase (which has as yet not been identified) may actually be the kinase that 
phosphorylates p53 in vivo. P53 is known to be a substrate for two isoforms of Protein 
kinase C (PKCII and HI) but as yet no sites have been defined although they are thought 
to lie within the C-terminal regulatory domain. Casein kinase II (CKII) targets many 
nuclear proteins involved in growth regulation e.g. jun, myc, max and also the 
transforming proteins of the DNA tumour viruses Adenovirus El A, HPV E7 and SV40 
large T antigen. It is constitutively active but also stimulated by growth factors and is 
therefore an important player in regulating growth. CKH has been shown to 
phosphorylate mouse p53 at Ser-389 and human p53 at Ser-392 (Meek et al, 1990). 
Binding by CKII and coincident phosphorylation activates the specific DNA binding 
function of p53 (see figurel.3). Hupp et al., 1992 has shown that this activation can be 
mimicked by other agents including deletion of the C-terminal 30 amino-acids, and by 
binding of dnaK (the bacterial homologue of hsp70) or the monoclonal antibody 
PAb421. It is thought that these interactions may cause a conformational shift in the C- 
terminus of p53 thereby exposing and activating a cryptic DNA binding activity.
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Mutation of this CKII phosphorylation site in mouse (Milne et al., 1992b) abolishes the 
growth suppressor activity of p53 in SV3T3 cells. However, apparently contradictory 
results showed that mutation of Ser-392 on human p53 produced a mutant that was 
indistinguishable from wild-type p53 (Fiscella et al., 1994) concluding that 
phosphorylation of Ser-392 was not necessary for wild-type functions in vivo. A 
possible explanation for this difference maybe that mouse and human p53 differ in their 
phosphorylation requirements and proper regulation may only occur on the appropriate 
cellular background. One other possible function of p53 not yet investigated maybe to 
target the CKII protein to specific intracellular locations. Phosphorylation may then 
release the enzyme after p53 has bound to specific DNA sites.
1.4.3.3. Wild-type p53 is anti-proliferative.
Early experiments showed that in conjunction with activated c-Ha-ras, wild-type 
p53 could transform early passage rodent cells (Eliyahu et al., 1984, Jenkins et al., 1984 
and Parada et al., 1984). However as more cDNA clones were sequenced it became 
apparent that these experiments were carried out using mutant p53’s. Wild-type p53 
was unable to cooperate with ras and furtherm ore wild-type p53 actually inhibited the 
transformation induced by other oncogenes and ras (Eliyahu et al., 1989 and Hinds et 
al., 1989). Introduction of wild-type p53 into colon (Baker et al., 1990) and bone 
tumour cell lines (Chen et al., 1990 and Diller et al., 1990) confirmed that 
overexpression of wild-type p53 was antiproliferative. When a wild-type p53 under the 
control of an inducible promoter was expressed in a human glioblastoma cell line 
expressing an endogenous mutant p53, the cells were induced to growth arrest in G1 
(Mercer et al., 1990). These experiments were elegantly confirmed by using a mouse 
temperature sensitive p53 (p53 vall35) which behaves as a mutant at 37.5-39.5°C and as 
a wild-type at 32°C. Rat embryo fibroblasts were found to be transformed by this 
mutant and an activated ras gene at 37°C, but were growth arrested in G1 when shifted 
to 32°C (Michalovitz et al., 1990; Ginsberg et al., 1991; Martinez et al., 1991). P53
33
was therefore termed as negative regulator of cell growth and classed as a tumour 
suppressor gene.
Both p53 mRNA and protein levels are low in normal mouse 3T3 fibroblasts 
growth arrested in GO by serum starvation (Reich et al., 1984), or in G1 by isoleucine 
depletion (Steinmeyer et al., 1990), in resting diploid fibroblasts (Mercer et al., 1984) 
and in resting peripheral T lymphocytes (Calbretta et al., 1986). When cells are 
stimulated to enter the cell cycle the level of p53 mRNA and rate of protein synthesis 
increases reaching a peak near the Gl/S boundary just before the onset of DNA 
replication. Normal p53 protein has a short half-life of 5-20 minutes but this is 
dependent on the cell type’for example the p53 protein in normal human keratinocytes 
has a half-life of 3-5 hours (Hubbert et al., 1992 and Delmolino et al., 1993). Many p53 
mutations give rise to a highly stable protein with an increased half life. This stabilised 
protein,unlike the rapidly turned over wild-type form,can be detected by 
immunohistochemical techniques and this is frequently used as an early and easy 
indicator for the presence of a mutation.
As well as its antiproliferative function many investigators believe that p53 can 
also promote growth. It is believed that these opposing functions can be achieved by 
alternating conformations of the p53 protein (Reviewed by Milner 1994 and Ullrich et 
al., 1992). It has been observed that p53 can adopt at least three different forms as 
determined by antibody reactivity. One form suppresses cell growth and maintains 
quiescence, a second form activates and promotes cell proliferation whilst a third form 
allows ongoing cell proliferation (see figure 1.5) and acts as a sensor ready to switch in 
response to positive or negative growth regulatory signals.
As described in the previous section modification of the carboxy terminus of p53 
has been shown to be a negative regulator for DNA binding (Hupp et al., 1992). The 
carboxy terminus was shown to be important during growth suppression by its loss of 
reactivity with the antibody PAb421 (Ullrich et al., 1992) which recognises an epitope at 
the carboxy terminus. This loss of reactivity was accompanied by increased 
phosphorylation possibly by CKII. When cultured in serum free medium quiescent 
primary lymphocytes continually synthesize the p53 421-  form (Milner et al., 1984).
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When these cells were exposed to mitogens there was a conformational switch in 
synthesis from 421" to 421+reactive forms of p53 (figure 1.5). Evidence for the 
requirement of p53 during mitogenic activation came form early experiments which are 
frequently overlooked. The micro-injection of anti-p53 antibodies (PAbl22) into nuclei 
of serum starved fibroblasts, early (2-3 hours) after re-stimulation with serum, prevented 
the entry of the cells into S phase (Mercer et al., 1982). Injection any later and cell cycle 
progression was not interrupted. The epitope for the antibody PAbl22 overlaps with 
that of PAb421 and therefore this experiment recognises the presence of the 421+ form.
Therefore as shown in figure 1.5 p53 421" is functional in cell growth 
suppression and in the maintenance of quiescence. On mitogenic stimulation p53 
switches to a 421+ form which plays a positive role in the early cell growth response. 
(Step 1). There is also conformation switching of p53 recognised by a different antibody 
PAbl620. The form of wild-type p53 most commonly detected in proliferating cells is 
the 421+/1620+ and this form is called the sensor form awaiting modification in order to 
promote or suppress growth. The above form associated with mitogenic commitment is 
indistinguishable from the conformation 421+/1620" which promotes cell growth. In 
order to function as a suppressor the sensor form looses 421 reactivity and is 
phosphorylated at its carboxy terminus (step 3) 421"/1620+. This 1620+ conformation is 
a prerequisite for DNA binding. Stabilisation of p53 in the sensor form is believed to be 
dependant on the presence of metal ions (Hainaut and Milner, 1993). Oxidizing and 
chelating agents reversibly disrupt the tertiary structure in favour of the promoter form 
1620" (step 2b). Recovery to the sensor form is energy dependant and may require the 
interaction with hsc70 and reducing agents (step 2a).
Heat shock proteins are a ubiquitous group of proteins often present at low levels 
in normal cells. Upon physiological stress, the synthesis of these proteins is dramatically 
increased. Hsc 70 (74kDa) was first shown to bind to mutant but not wild-type p53 
(Hinds et al., 1987). Hsc 70 complexes with dimers and possibly monomers of p53 and 
requires the terminal 28 amino-acids of p53 for this interaction. Using the temperature 
sensitive mutant p53va1135, Hainaut and Milner, 1992 showed that hsc70 binds to the 
1620" conformation and is released when p53 is induced to re-fold into the 1620+
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conformation. This observation implies that hsc 70 is involved in regulation of p53 
conformation and its ultimate function.
1.4.3.4. Molecular properties of p53 mutants.
Unlike wild-type p53, mutant p53 has lost its growth suppressive properties. 
(Baker et al., 1990; Chen et a l, 1990; Frebourg et al., 1992). Studies have shown that 
several mutants have lost this normal p53 function by their inability to' transactivate _ 
genes either by losing their capacity to bind sequence specific DNA (Bargonetti et al., 
1992; Zhang et al., 1993) or by loss of their transcriptional activity (Raycroft et al., 
1991; Scharer and Iggo, 1992). However, mutational analysis has shown that not all 
p53 mutants are purely loss of function mutants. Several tumours have been shown to 
carry heterozygous p53 mutations and in these cases it has been proposed that the 
mutant p53 inactivates the wild-type function in a trans-dominant negative fashion. In 
contrast to wild-type p53, mutant p53-^^ when transfected into primary rat embryo 
fibroblasts can cooperate with ras to cause transformation of the cells in culture (Hinds 
et al., 1990; Slingerland et al., 1993) and this has also been shown for other p53 
mutants (Finlay et al., 1988; Halevy et al., 1990). In order to achieve this the mutant 
p53 must be able to inactivate the endogenous wild-type p53. Sun et al., 1993 showed 
that the dominant negative effect of mutant p53 is dosage dependant. Wild-type and 
mutant pSS^^SO were cotransfected into Saos-2 cells and tested for their ability to 
transactivate a reporter construct. As more mutant p53 was transcribed the level of 
transcription decreased and complete inhibition was achieved at a ratio of one wild-type 
to three mutant p53 molecules. This dose-dependant dominant negative effect was also 
seen for loss of growth suppression. Expressing the same mutant p53 into JB6 
promotion resistant P'cells that contained endogenous wild-type p53, promoted growth 
of cells in soft agar in the presence of TP A (Sun et al., 1993). This dominance of the 
mutant p53 over the endogenous wild-type p53 was also shown to be dose-dependant. 
Further studies have shown that this effect is only seen in situations where mutant and 
wild-type p53 proteins are co-translated and does not occur simply by mixing (Milner
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and Metcalf, 1991). Other dominant negative mutants identified are p53ser151} 
p53lle247j p53pro273
Wild-type p53 is known to exist as homotetramers and it has been proposed that 
mutant p53 acts in this dominant negative fashion by either forming mutant 
homotetramers or wild-type/mutant heterotetramers with one, two or three mutant p53 
molecules. Such complexes are thought to have a lower affinity for DNA binding or 
adopt a conformation with reduced transcriptional activity. This dominant-negative 
inhibition of wild-type p53 increases as more mutant p53's form the tetramer. Recently 
the in vivo existence of dominant negative mutant p53's has been questioned. In the 
above transfection experiments mutant p53 is expressed at much higher levels than the 
endogenous wild-type p53 and therefore may not be physiologically relevant. Frebourg 
et al., 1994 elegantly used a bicistronic vector to co-express equal amounts of wild-type 
and several different mutant p53's into Saos-2 cells. It was shown in this case that 
mutant p53 did not inhibit the transcriptional or growth suppressive activities of wild- 
type p53.
When mutant p53 alleles are introduced into non-tumorigenic cell lines such as 
the LI 2 Abelson murine leukemia virus p53 nonproducer cell line, the tumorigenic 
potential of these cells is enhanced (Wolf et al., 1984). In such cases the mutant p53 has 
not acted in a dominant negative manner and therefore seems to have gained a function. 
The ability of mutants to gain a function was confirmed using the murine fibroblast (10)3 
cell line which is devoid of endogenous wild-type p53 (Dittmer et al., 1993).
Introduction of p53 mutants 143ala, 175his, 248trp and 273his increased the 
tumorigenicity of this cell line and furthermore these mutants were shown to stimulate 
expression from the enhancer promoter region of the MDR gene. These mutant p53's 
therefore appear to not only have lost their wild-type p53 properties but have also gained 
a function enabling them to support cellular growth in the absence of endogenous wild- 
type p53. The p53 mutants 175his and 273his when co-transfected with wild-type p53 
were unable to bind to a p53 specific DNA binding region suggesting that these mutants 
have inactivated the wild-type p53 activity in a dominant negative manner (Bargonetti et 
al., 1992). In the same experiment the Li-Fraumeni mutant p53^^trP was unable to
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inactivate the wild-type p53 protein and the complex displayed nearly wild-type levels of 
DNA binding. Other assays showed the same mutant had lost its growth suppressive 
property (Frebourg et al., 1992) and was unable to activate transcription (Scharer and 
Iggo, 1992). This mutant is expressed in a heterozygous state in the normal cells of Li- 
fraumeni patients (Malkin et al., 1990) and is tolerated because it cannot abolish wild- 
type p53 activity in a dominant negative manner (Milner and Metcalf, 1991). Instead this 
mutant appears to predispose the cell to transformation by selecting for loss of the wild- 
type p53 allele and acquiring a gain of function (Dittmer et al., 1993) that acts to 
promote transformation in the absence of the wild-type p53 allele.
These observations suggest that the phenotype of mutant p53 is variable 
depending on the particular mutation and several mechanisms have been identified by 
which each mutant p53 can overcome the wild-type p53 properties and promote 
transformation.
1.4.3.5. Molecular functions of wild-type p53
How p53 actually exerts its anti-proliferative effect is currently being investigated 
in a huge number of laboratories. Two hypotheses have been suggested. The first 
implicating a direct interaction of p53 on the DNA replication machinery and therefore 
having a direct effect on the cells DNA replication. The second suggests that p53 may 
also/ or alternatively regulate directly the expression of other genes involved in negative 
growth regulation or generally by interacting with transcription factors.
Co-transfection of p53 and plasmids with the SV40 origin of replication into T 
antigen expressing Cosl cells inhibited the replication of these plasmids (Braithwaite et 
al., 1987; Friedman et al., 1990). In vitro experiments have shown that murine wild- 
type p53 can block the binding of DNA polymerase a  to the large T antigen (Gannon 
and Lane, 1987) and also inhibit its helicase activity (Wang et al., 1989) whereas mutant 
p53 could do neither. Therefore from these experiments it could be envisaged that p53 
may directly affect the assembly and function of DNA replication complexes during S
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phase. This inhibition was, however,shown to require equimolar concentrations of large 
T and p53. In a situation (in vivo) where large T antigen is in an excess to wild-type p53 
(i.e. primary rhesus kidney cells), it was found that wild-type p53 exerted no inhibitory 
effect on SV40 DNA replication as compared to a mutant p53 that was deficient in 
binding large T antigen (Von der Weth and Deppert, 1993) Therefore in an in vitro 
system where wild-type p53 is not at physiological concentrations, SV40 DNA 
replication is probably inhibited by the complexing of all the T antigen to p53, a situation 
never encountered in vivo. Also when cells expressing a temperature-sensitive mutant 
p53 were released from the temperature block they continued to the next cycle rather 
than stopping in S phase even when wild-type p53 was expressed (Martinez et al., 1991). 
If p53 interacts with DNA polymerase it would be expected to act more like a DNA 
synthesis inhibitor (e.g. aphicolin) which when added to cells, abruptly arrests them in S 
phase (Mercer etal., 1991).
More recently p53 has been shown to physically interact with and inhibit a 
cellular DNA replication factor, the ssDNA binding protein complex, RPA (Dutta et al.,
1993). RPA is the first cellular factor recruited to the initiation complex and its ability to 
bind to ssDNA is essential for the unwinding of DNA at the origin of replication. 
Interaction of p53 with RPA inhibits the ability of RPA to bind to ssDNA in vitro. 
However mutant p53 has also been shown to bind and abolish RPA binding to ssDNA 
and the in vivo relevance of this has yet to be investigated.
The structure of the p53 protein as discussed above has all the hallmarks of a 
transcription factor. The p53 protein has been shown to regulate the transcription of a 
variety of genes containing p53 responsive elements. The promoter for the hsc70 
protein, shown above to regulate the conformation of p53, is repressed by wild-type p53 
(1620+ form) therefore providing a feedback loop whereby hsc70 is only expressed when 
the 1620" form is more abundant. It is believed that this repression may occur via direct 
interaction of p53 with CBF, the CCAAT binding factor (Agoff et al., 1993). Wild-type 
p53 has also been shown to repress the promoters of c-fos (Kley et al., 1992), IL-6, (3- 
actin and MHC (Santhanam et al., 1991) in vitro. As no sequence specific p53 binding
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sites have been identified in any of these genes, repression by wild-type p53 may be 
mediated by its ability to bind to TBP, the TATA box binding subunit of the RNA 
polymerase II general initiation factor TFTID (Truant et al., 1993; Chen et al., 1993; 
Mack et al., 1993). However, only monomeric p53 has been shown to bind to I TBP 
although most of p53 in vivo exists as tetramers and this interaction is relatively weak. It 
is possible that what is observed is a consequence of p53 overexpression and has little 
relevance in vivo. It may in factbe that overexpression of p53 in these systems 
sequesters TBP therefore preventing its use in any specific transcription and a general 
downregulation in transcription is seen as a consequence. The fact, however}that p53 
binds TBP at all is consistent with its role as a transcriptional activator as it has been 
suggested that this association is a general characteristic of transactivators (Truant et al.,
1993).
Several other target genes for p53 have been identified by the presence of a p53 
specific DNA binding site. One such gene GADD45 (see below) has a p53 responsive 
element located in its third intron and has been shown to be induced by wild-type p53 
(Kastan et al., 1992). Another genomic p53 responsive element has been identified in 
the murine muscle-specific creatine kinase (MCK) gene (Weintraub et al., 1991). This 
element has been shown to closely match the consensus binding site for p53 (El-Deiry et 
al., 1992) and is activated in vitro by wild-type but not mutant p53. A p53 responsive 
element has also been identified in the first intron of the gene Thy 1. The biological 
relevance of p53 regulation of these two genes, MCK and Thy 1, is not yet clear but it is 
of interest to note that both genes are expressed in differentiation pathways (MCK in 
muscle differentiation and Thy 1 in T lymphocytes and the brain) and may highlight a 
possible role for p53 in differentiation (see section I.4.3.8.).
1.4.3.6. p53 recognises DNA damage.
Studies now indicate that p53 may play a role in the cellular response to DNA- 
damaging agents that specifically induce strand breaks such as actinomycin D, X-rays 
and y-irradiation. Irradiation of cells rapidly increases the levels of p53 (Maltzman and
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Cyzyk, 1984; Kastan et al., 1991a; Kuerbitz et al., 1992) and initiates a G1 arrest 
(figure 1.6). This growth aiTest may allow cells time to undergo necessary repair to 
damaged DNA before proceeding to DNA synthesis. Failure to repair damaged DNA 
may result in point mutations or deletions being incorporated into the genome during 
DNA replication and division. Cells lacking wild-type p53 or expressing mutant p53 do 
not undergo radiation induced G1 arrest (Kastan et al., 1991a; Kuerbitz et al., 1992) 
nor do cells immortalised with the HPV16 E6 oncoprotein (Kessis et al., 1993). The 
mechanism by which wild-type p53 causes G1 arrest may be by its DNA binding activity 
as this has been shown to increase in response to even very low levels of radiation (Price 
and Calderwood, 1993; Lu and Lane, 1993). One such target for p53 is the GADD45 
gene (growth arrest and DNA damage inducible protein) which is turned on in cells 
exposed to stresses that cause DNA damage (figure 1.6). The cell's ability to turn on this 
protein is dependant on the presence of wild-type p53 (Kastan et al., 1992). GADD45 
has been shown to bind to PCNA (proliferating cell nuclear antigen) which is a necessary 
component of the DNA replication machinery (Smith et al., 1994). PCNA is also needed 
for the re-synthesis of DNA after damaged portions are removed by the cells nucleotide 
excision repair system. Removal of GADD45 decreases this excision repair.
The ability of wild-type p53 to apparently monitor genome integrity may be a 
mechanism by which cells prevent gene amplifications. Whilst undetectable in normal 
diploid fibroblasts, gene amplification occurs at a high frequency in transformed cells 
(10'3-10"5). This ability to amplify is a recessive genetic trait (Tlsty et al., 1992) 
suggesting normal cells contain gene/s that modulate the ability to amplify. By using the 
resistance to the drug PALA, via the amplification of the CAD gene, to measure gene 
amplification, it has been shown that cells lacking endogenous p53 show detectable 
levels of gene amplification (10"5-10"4) and fail to arrest in G1 (Livingstone et al., 1992; 
Yin et al., 1992). In contrast, cells homozygous for wild-type p53 or LFS cells 
heterozygous for p53 showed no gene amplification and arrested in the presence of 
PALA. Transfection of wild-type p53 into tumour cells containing mutant p53 restored 
G1 arrest and reduced the frequency of gene amplifications (Yin et al., 1992). Although 
some human tumorigenic cells show detectable gene amplification despite the presence
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of wild-type p53 these observations suggest that p53 can prevent cells becoming 
aneuploid by monitoring and preventing gene amplifications.
The upregulation of p53 in response to DNA damage, the subsequent growth 
arrest and activation of the DNA repair machinery by p53 seems to therefore be an 
important safety step in preventing the cells from accummulating genetic alterations 
which would result in mutations, aneuploidy and the progression of malignant clones 
(figure 1.6). If the DNA damage is too severe for the cell to repair, it has been 
suggested that p53 may trigger cell suicide (see below).
1.4.3.7. The control of apoptotic cell death by p53.
Initial experiments to study the effect of overexpression of wild-type p53 failed 
due to loss of viability of the cell caused by p53. Experiments where p53 was 
conditionally expressed under an inducible promoter, or was temperature sensitive,proved 
to be more successful and in certain cell types showed p53 to be involved in controlled 
cell death or apoptosis rather than a reversible growth arrest. Myeloid leukaemic Ml 
cells transfected with the temperature sensitive p53^^ lost viability rapidly at 32°C 
when the protein is in the wild-type form (Yonish-Rouach etal., 1991). This process of 
cell death had the hallmarks of apoptosis, such as chromatin condensation, nuclear 
fragmentation and DNA laddering. Overexpression of wild-type p53 was also shown to 
elicit apoptosis in other cell types. Wild-type p53 was transfected into the human colon 
derived cell line EB under the control of the metallothionein promoter (Shaw et al., 
1992). Upon induction of wild-type p53 with ZnCl2 , the cells developed morphological 
features of apoptosis. This cell line was also used to form tumours in nude mice which 
underwent regression upon induction of wild-type p53. These regressing tumours 
showed features of apoptosis occurring in vivo. However these studies only 
demonstrated p53 linked apoptosis in arteficial situations where wild-type p53 is forcibly 
overexpressed . The development of p53 null mice showed direct evidence that p53 was 
involved in any real apoptotic process. Although the viability and normal development 
of p53 deficient mice indicated that p53 is not essential for apoptotic processes during
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development. A closer examination of thymocytes from such mice showed that they are 
resistant to the induction of apoptosis by radiation unlike normal controls (Lowe et al., 
1993a; Clarke et al., 1993). |This agreed with the observations in the previous section that 
p53 is required for a response to DNA damage whether it is growth arrest or apoptosis.
There are also other pathways that induce apoptosis completely independantly of 
p53.*for example Ml cells will undergo apoptosis without any functional p53 upon serum 
starvation (Yonish-Rouach et al., 1993) and thymocytes from p53 null mice undergo 
normal apoptosis in response to glucocorticoids and dexamethasone (Lowe et al., 1993a; 
Clarke ef al., 1993).
Signals other than DNA damage have been suggested to trigger p53-dependant 
apoptosis, namely the withdrawal of survival factors from the cells enviroment and also 
cellular response to viral infection. The IL-3 dependent murine lymphoma cell line DA-1 
which expresses wild-type p53 dies rapidly upon withdrawal of IL-3 (Gottlieb et al.,
1994). However when these cells were infected with retroviruses expressing either a p53 
miniprotein encompassing the C-terminus of the protein only, or the p53135 temperature- 
sensitive mutant (both of which act on the wild-type p53 in a dominant-negative 
manner), the cells showed extended survival without IL-3. Also excess wild-type p53 
activity failed to elicit apoptosis as long as IL-3 was present. Wild-type p53 was also 
required for apoptosis on withdrawal of haemopoietic growth factors from AML blasts.
In the presence of antisense p53 oligonucleotides)however) apoptosis was suppressed 
despite the absence of growth factors (Zhu et al., 1994). These findings therefore 
suggest that p53 plays a role in mediating the dependence of cells on hematopoietic 
survival factors at least. However, unlike the p53 response to DNA-damage, the 
upregulation of p53 is probably not the trigger for apoptosis on survival factor 
withdrawal as excess wild-type p53 activity failed to elicit any apoptotic response as long 
as IL-3 was available (Gottlieb et al., 1994). It is probably more likely that the presence 
of p53 provides the necessary pathway for the apoptotic response and loss of this activity 
allows cell survival without the appropriate survival factors signals facilitating the 
survival of neoplastic cell clones.
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Apoptotic death in response to viral infection would be an effective host defense 
mechanism for early protection against an infection. Infection of rodent fibroblasts with 
adenovirus El A protein causes the cells to upregulate p53 in response and to lose 
viability by apoptosis (Lowe et al., 1993b). The virus however appears to counteract 
this defense by expressing another early protein E1B. E1B binds and inactivates p53 
thereby preventing p53-dependant death of the infected cell. The expression of a 
dominant-negative mutant p53 inhibits this El A-mediated cell death by blocking the 
action of wild-type p53 (Debbas et al., 1993). In the same way as adenoviruses other 
viruses have evolved mechanisms for inactivating p53 i.e. HPV E6 and SV40 large T 
antigen all bind and inactivate p53 thereby aiding cellular transformation by the virus.
1.4.3.8. Does p53 play a role in normal cellular differentiation ?
In vitro and in vivo experiments have suggested that wild-type p53 plays an 
important role in normal development and in several differentiation pathways. The 
investigation of the normal function of p53 is complicated by the fact that p53 is 
expressed at low levels in the cell and is obviously tightly regulated. The expression of 
wild-type p53 from an exogenous promoter leads to high levels of p53 and tends to 
result in either growth arrest or apoptosis as described in the previous sections.
However, when p53 was transfected into a p53 non-producer early pre-B cell line (L12), 
stable cell lines were produced (Shaulsky et al., 1991) in which the effects of p53 could 
be studied. These cell lines showed an altered cell cycle in which more cells were found 
in the G0/G1 phase. When injected into syngeneic mice they induced a lower incidence 
of tumours which were less aggressive than the parental controls. Interestingly, the cell 
lines had also appeared to progress to a more differentiated phenotype with expression of 
the cytoplasmic immunoglobulin \i heavy chain and increased levels of the B cell specific 
surface marker B220. A separate study showed that treatment of a pre-B cell line that 
had retained expression of wild-type p53 (70Z/3) with a differentiation agent such as 
LPS resulted in the expression of the rearranged x light chain gene. This differentiation 
step was preceded by increased expression of p53 (Aloni-Grinstein et al., 1993).
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Furthermore' introduction of mutant p53 interfered with this differentiation process. It can 
be concluded from these findings that wild-type p53 is involved in the normal maturation 
and differentiation of pre-B cells. This was further substantiated by showing increased 
transcription from a CAT gene driven by a p53 promoter upon differentiation of the 
70Z/3 cell line. Furthermore, wild-type p53 was shown to transactivate the promoter 
control sequences of the x light chain gene (Aloni-Grinstein et al., 1993).
Other investigators have shown a similar involvement of p53 in differentiation. 
Induced differentiation of ML-1 cells showed increased levels of p53. Low levels of p53 
protein were also detected in the nonproliferative mature lymphoid, granulocytic and 
monocytic cell lineages but not in the more immature proliferating counterparts (Kastan 
et al., 1991b). An acute phase CML cell line (K562) was induced to express 50 fold 
more haemoglobin upon transfection with wild-type p53 (Feinstein et al., 1992).
Infection of primary human foreskin keratinocytes with a retrovirus encoding wild-type 
p53 induced premature cell flattening and increased involucrin expression, a marker of 
terminal differentiation, although other differentiation proteins were not affected 
(Woodworth etal., 1993).
Taken together all these experiments suggest that p53 plays a vital role in the 
decision to embark on a terminal differentiation programme. It is interesting to note that 
the B cell differentiation pathway involves several events of DNA rearrangements.
During this process it is likely that repair to the DNA will be required due to strand 
breakage and faulty pairing of DNA fragments. This provides a connection to the 
observation that p53 is required for repair to DNA damage, (as discussed above) and it is 
likely that the trigger for p53 intervention is identical in both cases.
Very little is known of the function of p53 during development. The viability of 
mice null for p53 suggests that p53 is redundant in this process and is only required for 
repair later in life. However such p53 null mice develop tumours by the age of six 
months and the most frequent are of a lymphoma type (Donehower et al., 1992; Jacks et 
al., 1994). As pointed out above development of the lymphoid lineage involves gene 
rearrangements and further supports the role for p53 in this development pathway.
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In order to examine the normal expression pattern of p53 during development, 
transgenic mice were used that carried a construct in which p53 promoter sequences in 
amplified copy number regulated the expression of the CAT gene. Such mice were 
found to express CAT activity predominantly in the testes (Almon et al., 1993). In situ 
hybridization indicated that the p53 gene is expressed during spermatogenesis and is 
confined to the tetraploid primary spermatocytes at the meiotic pachytene stage during 
the first round of spermatogenesis (Schwartz et al., 1993). Primary spermatocytes 
double their DNA contents immediately after the last mitotic division and embark on a 
long meiotic prophase before two further meiotic divisions of the tetraploid 
spermatocytes generates four haploid spermatids. The pachytene stage is the longest 
meiotic phase which involves cell replication not coupled with DNA duplication. The 
expression of p53 at this stage and the observations that p53 can arrest DNA replication 
(discussed above) suggests that p53 functions in spermatogenesis by halting DNA 
replication and allowing successful meiosis which involves pairing of chromosomes, 
recombination and repair of DNA to be completed. The conclusion that p53 plays a role 
in halting DNA replication and allowing DNA repair is further substantiated by the 
observation that transgenic mice carrying the multiple p53 promoter CAT transgenes, 
exhibit the giant cell degenerative syndrome (Rotter et al., 1993). These giant cells arise 
due to the inability of tetraploid spermatocytes to undergo meiosis generating haploid 
sperm cells. Instead these cells undergo additional DNA replications giving rise to 
multinucleated giant cells. Such cells are shown to have a reduction in the endogenous 
level of p53 brought about by a squelching effect whereby the extra promoter binding 
sites lead to reduced activity and therefore the pachytene stage which requires p53 
malfunctions. P53 null mice however do not develop such giant cells and it is generally 
assumed that in the case of jmice null for p53 and also other vital genes, for example 
Myo-D (Rudnicki et al., 1992), which appear to develop normally, that these pathways 
have become functionally redundant and other parallel pathways are utilised.
Investigations into the functions of p53 in normal development and differentiation 
have uncovered an interesting connection between the already established roles of p53 in 
inhibition of DNA replication and DNA repair triggered by strand breaks. It is therefore
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likely that p53 plays an important role in many cellular pathways in which such events are 
vital.
1.4.2.9. Identification of p53 associated proteins.
The MDM-2 gene was originally identified by virtue of its amplification in a 
spontaneously transformed derivative of mouse BalB/c cells (3T3DM) (Fakharzadeh et 
al., 1991) and was found to bind to p53 in rat cells transfected with p53 (Hinds et al., 
1990; Momand et al., 1992). Human MDM-2 was also found to bind to both wild-type 
and mutant human p53 in vitro. The human MDM-2 gene was localised to chromosome 
12ql3-14 and this gene was amplified in over a third of sarcomas studied (Oliner et al.,
1992) offering another mechanism by which the cell can overcome p53 regulated growth 
control.
MDM-2 is a putative transcription factor and has been shown to inhibit the 
transactivating abililty of p53 (Momand et al., 1992) by binding to a region coinciding 
with the N-terminal p53 acidic activation domain (Oliner et al., 1993; Picksley et al.,
1994). The MDM-2 protein has a short half-life of approximately 20 minutes and is 
localised to the nucleus. In resting cells stimulated with serum, MDM-2 levels and 
MDM-2/p53 levels increase in late G1 (Olson et al., 1993) and as MDM-2 negatively 
regulates p53, the binding of MDM-2 and p53 may signal entry into S phase.
Irradiation of mammalian cells with UV light, as discussed previously, results in a 
dose dependant accumulation of p53 within 2 hours. There is also a dramatic increase in 
p53 specific transcriptional transactivation activity and an increase in expression of 
MDM-2 (Perry et al., 1993). However this UV stimulated MDM-2 expression does not 
directly correlate with the level of stimulated p53 protein. MDM-2 induction is 
delayed, occurring along with the recovery of normal rates of DNA synthesis presumably 
after DNA repair, whereas p53 levels rise immediately. Cells in which p53 is mutated or 
deleted have been shown not to respond to UV light by increasing their expression of 
MDM-2 (Price et al., 1994). Wild-type p53 has been shown to bind sequence 
specifically to DNA residing downstream of exon 1 on the MDM-2 gene and activates
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transcription (Juven et al., 1993). Taken together these experiments suggest that MDM- 
2 is part of a p53 negative feedback loop as shown in figure 1.6. On exposure to UV 
irradiation, p53 protein levels increase and the cell becomes arrested in Gl. Once the 
DNA damage is repaired p53 stimulates expression of MDM-2 which in turn binds and 
inactivates p53 allowing the cells to continue into S phase.
Activation of MDM-2 by p53 involves the promoter (P2) located within the first 
intron of the murine MDM-2 gene This promoter gives rise to distinct transcripts which 
lack the entire first exon and a few nucleotides from the second exon of murine MDM-2 
(Barak et al, 1994). P2 activation is strongly dependant on p53 both in vitro and in vivo. 
In comparisorijthe transcription from the upstream, constitutive MDM-2 promoter (PI) 
is only mildly, if at all, induced by wild-type p53. The sequence of these two MDM-2 
transcripts varies in their 5' non-coding regions but suggests that they should encode 
identical products. Howeveqin vitro translation gives rise to distinct proteins varying in 
their p53 binding abilities. This therefore implies that p53>through activation of an 
alternative promoter^an potentially modulate the amount and nature of the MDM-2 
proteins.
MDM-2 may not modulate p53 function merely by binding to p53. Otto et al., 
1993, showed that after expression of wild-type p53 into Meth A tumour cells a few cells 
survived that expressed wild-type p53. These cells were also shown to overexpress 
MDM-2 mRNA and protein but the majority of MDM-2 and p53 were not in a complex 
together. A possible explanation yet to be substantiated is that MDM-2 as a 
transcription factor itself may regulate the transcription of other growth promoting or 
p53 inhibiting genes.
In an effort to identify wild-type p53 responsive genes one has recently been identified 
independantly by a number of groups. El-Deiry et al., 1993 described a wild-type p53 
induced gene, wild-type p53 activated fragment (WAF-1). WAF-1 was shown to be 
induced by wild-type but not mutant p53 and can itself suppress tumour cell growth in 
culture. The gene is localised on chromosome 6p21.2 and encodes a 21kDa protein with 
a structure suggesting it to be a potential transcription factor. At the same time an
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identical 21kDa protein, CIP-1 was identified when looking for potential cdk2 regulators 
(Harper et al, 1993) and also published by other investigators as p21 (Xiong et al.,
1993). CIP-l/p21 was shown to be a potent tight-binding inhibitor of cdks and inhibits 
the phosphorylation of Rb by cyclin A-cdk2, cyclin E-cdk2, cyclin Dl-cdk4 and cyclin 
D2-cdk4 complexes (figure 1.6). CIP-l/p21 mRNA is ubiquitously expressed in all adult 
human tissues and levels do not appear to vary throughout the cell cycle. In cells lacking 
functional p53, CIP-l/p21 is absent from cyclin-cdk complexes and mRNA levels in 
fibroblasts derived from null p53 mice showed 50 fold lower levels than normal embryo 
fibroblastSpagreeing with other groups that this protein is regulated by the p53 pathway. 
Rapid induction of CIP-l/p21 has been shown to occur by treating a variety of cells with 
differentiating agents such as TPA, IL-6 and G-CSF (Steinman et al., 1994). 
Differentiating cells have a prolonged G1 arrest and Rb is hypophosphorylated 
suggesting that such agents may function by inducing p21 expression which causes 
growth arrest in response to p53 and inhibits the cyclin-cdk complexes from 
phosphorylating Rb and progression of the cell cycle.
This same protein was identified by two other groups whilst looking for a 
melanoma differentiating gene (mda-6) (Jiang et al., 1994) and as an inhibitor of DNA 
synthesis expressed at high levels in senescent non-dividing human cells (SDI) (Johnson 
et al., 1994). Mda-6 was shown to be induced in terminally differentiating human 
melanoma cells and also in HL60 cells within 1-3 hours of treatment with TPA, retinoic 
acid or DMSO.
As HL60 cells and other cells shown to induce p21 on differentiation are null for 
p53, and p53 levels are low in senecent cells^t has been suggested that there are possibly 
two kinetic profiles for the induction of mda-6/SDI/p21/CIP-l/WAF-l. The first is p53 
dependant occurring early enough to cause cell cycle arrest. The second method is 
independant of p53 and may occur during the normal course of terminal differentiation.
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1.5. Aims
The initial aim of this thesis was to identify the genetic differences between cell 
lines SCC12B and SCC12F which could be responsible for their different phenotypes. 
Such genetic alterations could ultimately be important in the progression of squamous 
cell carcinomas of the head and neck. A novel heterozygous p53 mutation at codon 216, 
substituting a glycine for a valine, was detected in SCC12B and SCC12F. On closer 
examination, the two cell lines appear to express different mutant and wild-type p53 
gene dosages. The p53^16 mutant protein was characterised at a biological and 
molecular level to distinguish any different properties from wild-type protein.
The subsequent aims of this thesis were then to study the affect of this mutant 
p53 on keratinocyte terminal differentiation by expressing the mutant in a clone of 
SCC12F that expressed little endogenous p53 protein in order to assess directly whether 
it could affect the progression of SCC12F to the less differentiated and more tumorigenic 
phenotype displayed by SCC12B.
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Chapter 2 
Materials and Methods
2.1. MATERIALS
2.1.1. Tissue Culture
Cell Lines
Saos
Swiss 3T3 feeders 
3T3 Ml Neo Beatson Institute, R9 stocks. Produced by 
infection of Lesch-Nyhan human diploid 
fibroblast strain 5-BR with the amphotropic 
retrovirus pmos'3 neo (Berry et al, 1994) 
Rheinwald and Beckett, 1981 
Rheinwald and Beckett, 1981 
Rheinwald and Beckett, 1981 
Dr. D. Lane.
Beatson Institute, R9 stocks.
Dr. E.K. Parkinson.
ATCC HTB 
ATCC CCL92
SCC12F.AC3
SCC12B 
SCC4 
SVK14 
HFF 9 
BICR3
Aldrich Chemical Company, U.K.
Methylcellulose
Poly (2-hydroxyethylmethacrylate) (Polyhaem A) 
Beatson Institute Central Services.
Becton Dickinson U.K. Ltd.
Sterile plastic flasks and plates
Boehringer-Mannheim, Germany
DOTAP lipofection reagent
BDH Analar, U.K.
High vacuum silicone grease
Clonetics, U.S.A.
Bovine pituitary extract
Amphotericin B
Penicillin
Streptomycin
5 3
Costar Corporation, U.S.A.
Transwells
Flow Laboratories, U.K.
Mycoplasma removal agent 
Donor calf serum
Gibco Europe Life Technologies Ltd., U.K.
Dulbecco's modified Eagles medium
Epidermal growth factor (recombinant)
Fetal calf serum
Glutamine
G418 Sulphate
Keratinocyte SFM
Sodium bicarbonate
Sodium pyruvate
Harlan Olac Ltd., U.K.
MF-1 NuNu mice
Hughes and Hughes Ltd., U.K.
Histomount
Nitta Gelatin Inc., Japan.
Cellmatrix
Nunc, Denmark.
Cryotubes
Chamber slides (glass and permanox)
Sigma Chemical Company Ltd., U.K.
Cholera toxin 
Hydrocortisone 
Rhodamine B
Surgipath Medical Industries Inc., U.S.A.
Eosin
Harris' Haematoxylin 
Scotts tap water
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Unipath Ltd., U.K.
Phosphate buffered saline (PBS)
Worthington Biochemical Company, U.K.
Trypsin
2.1.2. Immunocytochemistry 
Antibodies
p53 antibodies PAbl620, PAb421, PAb240, CM-1 were a gift from Prof. D. Lane when 
stated. p53 antibodies PAbl801, PAbl620, PAb240 were obtained from Oncogene 
Science when stated.
Rabbit anti-involucrin antibody was a gift from Dr. F. Watt.
BDH Analar, U.K.
Aquamount
Formaldehyde
Chance Propper Ltd., U.K.
Coverslips
Sigma Chemical Company Ltd., U.K.
Acrydine Orange 
Bovine serum albumin fraction V 
Diaminobenzine tablets 
Hydrogen peroxide 
Tween 80
Vector Laboratories, U.K.
Alkaline phosphate substrate kit 1 (red)
Vectastain ABC peroxidase and phosphatase kits 
Vectashield mountant for fluorescence staining
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2.1.3. Protein Biochemistry
Antibodies
Cyclin D antibody 287-3 was a gift from Dr. G. Peters. 
p53 antibodies as above.
Amersham International pic., U.K.
Anti rabbit Ig, horseradish peroxidase linked F(ab')2 fragment (from donkey) 
Anti mouse Ig, horseradish peroxidase linked whole ab (from sheep)
ECL western detection agent
Rainbow colour markers (14,300-200,000 Da)
BDH, Analar, U.K.
40% Acrylogel 3 solution (Acrylamide 29.1: 0.9 N N’Methylene 
bisacrylamide) used for protein gels.
Ammonium peroxodisulphate (APS)
Bio-rad Laboratories Ltd., U.K.
Protein Assay DC
Oncogene Science Inc., U.S.A.
Protein G plus agarose
p53 antibodys PAbl801, PAbl620 and PAb240 used when stated.
Millipore Corporation, U.S.A.
Immobolin P nitrocellulose
Sigma chemical Company Ltd., U.K.
Aprotinin 
Bromophenol blue 
(3-mercaptoethanol 
Hydrogen peroxide 
Leupeptin
Nonidet P-40 (NP40)
Phenylmethylsulfonyl fluoride (PMSF)
Ponceau's solution 
Sodium Fluoride
TEMED (N,N,N' ,N'-tetramethylethylenediamine)
Xylene cyanol
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2.1.4. Molecular Biology
Vectors
pCMV-Neo, pC53-SN3 and pC53-SCX3 were all a kind gift from 
Dr. B. Vogelstein.
Aldrich Chemical Company, U.K.
Ammonium chloride 
Potassium carbonate
Amersham International PLC, U.K.
35SdCTPaS 400Ci/mmol 
a  32P dCTP 3000Ci/mmol 
7 32PdATP 
Hybond nylon filter
Beatson Institute Central services
L-Broth
Beta Laboratories, U.K.
Yeast Extract
Bethesda Research Laboratories, U.S.A.
LMP agarose
d> X 174 Hae Ill-digested DNA
Agarose
Protease K
lkb Ladder
BDH Analar, U.K.
Acetone
Butan-l-ol
Chloroform
Repelcote silicone treatment 
Sodium dodecyl sulphate (SDS)
Sodium dihydrogen phosphate
Bibby-Sterilin Ltd., U.K.
Sterilin bacteriological plates
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Bio 101, Inc., U.K.
Geneclean 2® kit
Biolabs, New England, U.S.A.
Bio-rad Laboratories Ltd., U.K.
Muta-gene® M13 In vitro mutagenesis kit, version 2
Boehringer-Mannheim, Germany.
Caesium chloride 
DNAse-free RNAse
IPTG (Isopropyl-[3- D- thiogalactopyranosid)
Protease K 
Tris-HCL 
Tris base
Xgal (5-bromo-4-chloro-3-indolyl-p-D galactopyranosid)
Cinna/Biotecx Laboratories Inc., U.S.A.
RNAzolB
Cruachem Ltd., U.S.A.
Oligonucleotide purification cartridges 
Triethylamine Acetate (TEAA)
Trifluoroacetic acid (TFA)
DIFCO Laboratories, U.S.A.
Agar
Bactotryptone
Bactoagar
Dynal Ltd., U.K.
Dynabeads® M-280 Streptavidin 
Dynal MPC®
Eastman Kodak Company, U.S.A.
X-OMATAR X-ray film 
X-OMAT S X-ray film 
DUP1 duplicating
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Flowgen Instruments Ltd., U.K.
Nusieve® agarose
Fluka Chemika-Biochemika AG, Switzerland
Tetramethyl ammonium chloride (TMAC)
Fisons Scientific Equipment, U.K.
Acetic acid 
EDTA (sodium salt)
Isopropanol 
Magnesium sulphate 
Methanol 
Sodium acetate 
Sodium chloride 
Sodium citrate 
Sodium hydroxide 
Urea
Gibco Europe Life Technologies Ltd., U.K.
E.coli DH5a competent cells 
Bam HI 
Eco R1
T4 DNA ligase
James Burrough Ltd., U.K.
Ethanol
Lab-Scan Ltd., Ireland, U.K.
Acetonitrile
Northumbria Biologicals Ltd., U.K.
Alkaline phosphatase 
Pvull
T4 polynucleotide kinase 
Xba 1
Perkin-Elmer Cetus, U.S.A.
GeneAmp® DNA PCR kit 
GeneAmp® RNA PCR kit
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GeneAmp® thin walled reaction tubes 
AmpliTaq DNA polymerase
Pharmacia AB, Sweden
Ficoll 400
Sephadex G-25 NICK columns 
dNTP set
Rathburn Chemicals Ltd., U.K.
Phenol
Severn Biotech Ltd., U.K.
30% (w/v) acrylamide : 0.8% bisacrylamide
Sigma Chemical Company, U.K.
Ampicillin
Ammonium chloride
Bovine serum albumin (fraction V)
Chloramphenicol
Ethidium Bromide
Lysozyme
Polyvinylpyrrolidone
Thiamine
Technical Photo Systems, U.K.
Fuji RX medical X-ray film
United States Biochemical Corporation, U.S.A.
Sequenase® version 2 kit
Whatman International Ltd., U.K.
Whatman 3MM filter paper
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2.1.5. Cytogenetics.
BDH, Analar, U.K.
Methanol
Boehringer-Mannheim, Germany.
Sheep antidigoxigenin antibody
Jackson Immunoresearch Lab. Inc., U.S.A.
FTTC conjugated donkey anti-sheep antibody.
Oncor Inc., U.S.A.
Chromosome 17 centromere probe (aCHAD 9) 
p53 DNA probe (P5106-DIG)
Sigma Chemical Company, U.K.
Acetic acid
Demecolcine (cat no. D7385)
Streck Lab. Inc., U.S.A.
Streck tissue fixative.
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2.2. Methods
2.2.1. Tissue culture
2.2.1.1. Culture of Swiss mouse 3T3 feeder cells
Swiss 3T3 fibroblast cells were grown in Dulbecco's modified Eagle's medium 
(DMEM) containing 10% (v/v) donor calf serum, 0.23% sodium bicarbonate, |2mM 
glutamine, 37.5pg/ml penicillin and jlOjig/ml streptomycin. Cells were seeded at 
104/9cm dish, incubated in a moist atmosphere at 37°C and gassed with air containing 
5% (v/v) CC>2. Medium was changed on day 11 and cells used for feeders on day 14.
For use as feeders, cells were trypsinized with 0.1% (w/v) trypsin in phosphate 
buffered saline (PBS, 0.14M NaCl, 27mM KC1, lOmM Na2HP04,15mM K2HP04) and 
resuspended in fresh growth medium. Cells were then lethally irradiated by exposure to 
60Gy of y- irradiation from a 60Co source. This prevents further cell divisions. The cells 
were then either used immediately or stored for up to 48 hours at 4°C without loss of 
feeding capacity. Feeder cells are usually plated at a density of 1x106/ 9cm dish.
Feeder cells were removed from keratinocyte cultures as required by vigorously 
washing the dish with 0.02% (w/v) EDTA in PBS, followed by rinsing with PBS.
2.2.1.2 Derivation and culture of Human Epidermal Keratinocytes 
(HEK)
Normal HEKs were prepared from new-born human foreskins obtained from 
Yorkhill hospital, Glasgow. The tissue was washed in PBS, cut into thin strips and 
trypsinized overnight at 4°C using 0.125% (w/v) trypsin, 0.01% EDTA in PBS. 
Epidermal cells were separated from mesenchyme by scraping a scalpel along the 
epidermal layer. Cells were centrifuged at lOOOrpm for 5 minutes and resuspended as a 
single cell suspension in growth medium.
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HEKs were grown in serum-free Keratinocyte-SFM supplemented with bovine 
pituitary extract (50pg/ml) and recombinant epidermal growth factor (5ng/ml) which 
stimulates migration of the growing keratinocytes out of the centre of the colonies 
(Barrandon and Green, 1987) and has also been shown to increase the culture lifetime of 
epidermal cells (Rheinwald and Green, 1977).
Alternatively, HEKs were grown in serum-containing medium in the presence of a 
3T3 layer as described above. The 3T3 layer is necessary for keratinocytes to initiate 
colony formation (Rheinwald and Green, 1975a). The medium consists of DMEM 
supplemented with 20% (v/v) foetal calf serum, 0.3% (w/v) sodium bicarbonate, 2mM 
glutamine, 37.5pg/ml penicillin, lOpg/ml streptomycin, 0.4pg/ml hydrocortisone and 
lOng/ml cholera toxin. Hydrocortisone is required to make colony morphology more 
orderly and maintains an increased proliferation rate (Rheinwald and Green, 1975b). 
Cholera toxin, by raising cyclic AMP levels, seems to oppose the tendency of 
keratinocytes to increase in size (Green, 1978) and may therefore oppose the onset of 
terminal differentiation (Sun and Green, 1976).
Squamous cell carcinoma (SCC) cell lines were also grown on a 3T3 feeder layer 
in the above medium supplemented with 10% foetal calf serum and without cholera 
toxin. Epidermal growth factor and cholera toxin which are potent mitogens for normal 
keratinocytes, can be inhibitory to SCC. The medium was changed every 3-4 days.
All cells were incubated in a moist atmosphere at 37°C and gassed with air 
containing 5% (v/v) CO2.
Cells were passaged by firstly removing the feeder layer and rinsing with PBS. The 
cells were removed from flasks or plates with trypsin (0.1% (w/v) trypsin, 0.01% (w/v) 
EDTA in PBS). Trypsin was inactivated by adding ten volumes of serum-containing 
medium and removed by centrifugation at lOOOrpm for 5 minutes at room temperature. 
The supernatant was removed and cells resuspended in fresh growth medium and 
replated as required.
Stocks of all cells were kept frozen in liquid nitrogen. Cells trypsinized as above 
were resuspended at a concentration of 106 cells/ml in ice-cold medium containing 10% 
serum (above) plus 10% (v/v) dimethyl sulphoxide (DMSO). Care was taken to ensure
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all solutions were ice-cold as DMSO is toxic to cells at room temperature. Cells were 
aliquoted into cryotubes and the ampoules wrapped in cotton wool and placed in a 
plastic box. Cells were frozen slowly, firstly at -20°C for 30 minutes and then at -70°C 
overnight. Cells were then stored in liquid nitrogen. The cotton wool insulation ensures 
gradual cooling of the cells and therefore increases the viability of the cells on thawing.
Cells were thawed by transferring the ampoule directly from liquid nitrogen to 
water at 37°C. Once thawed cells were added to a large volume of pre-warmed growth 
medium, centrifuged, resuspended in fresh growth medium and plated onto an irradiated 
feeder layer.
2.2.1.3. Growth of keratinocytes on raft cultures
Collagen gel type I (rat tail, pH3 acetate) was prepared by adding 20mM Hepes, 
5mM NaOH, lx SF12 medium2mMglutamine and 0.2% (w/v) sodium bicarbonate . The 
gel was seeded with 3x105 3T3 fibroblasts/ml, mixed well, trying to avoid air bubbles 
and 2mls were placed into transwell inserts (3.0pm pore membrane). The gel was 
incubated at 37°C for 30 minutes, then overlaid and underlaid with growth medium and 
incubated for a further 24 hours. The growth medium was changed and the gel seeded 
with lxlO6 keratinocytes/well. The cells were grown submerged for at least 24 hours at 
37°C in a humid incubator. The wells were then transferred to a sterile beaker and 
underlaid with growth medium. Any medium above the confluent keratinocytes was 
removed, the rafts were covered and cells grown for a further 14 days. Cryostat sections 
of the raft cultures were prepared by Dr. I Macmillan (Veterinary department, Glasgow 
University).
2.2.1.4 Transfection of cells.
Keratinocytes were plated on an irradiated feeder layer at 2xl05/5cm dish and 
incubated at 37°C until cells were 80% confluent. 30pl DOTAP (lmg/ml) was diluted to 
lOOpl with HBS (20mM Hepes, 150mM NaCl pH7.4). This was mixed with an
64
equivolume of DNA (5pg) in HBS and incubated at room temperature for 10 minutes. 
This lipofection mixture was added to 5mls fresh growth medium containing serum, 
placed on the cells and incubated overnight at 37°C. The medium was replaced with 
fresh growth medium and cells incubated again overnight. The cells were trypsinized as 
described above and plated at low density on neomycin resistant feeders (3T3 Ml Neo). 
The cells were incubated until small colonies were visible and then selected with 
400ug/ml G418. Resistant colonies were visible within 14 days.
Single resistant colonies were marked using a microscope ring marker attachment. 
The medium was aspirated and feeders gently removed as described above. Cloning 
rings were lightly greased and placed over the marked colonies. Pre-warmed 
trypsin/EDTA was gently dropped into the cloning rings and incubated for 10 minutes. 
Using a pasteur pipette, medium was added to the trypsin and gently mixed to resuspend 
the cells. The trypsin/medium mixture was transferred to pre-warmed medium and spun 
at lOOOrpm. The cells were resuspended and plated onto a fresh feeder layer. Cells were 
kept under selection until checked for the required protein expression. Prior to any 
further experiment transfectants were removed from selection, washed thoroughly with 
PBS and grown without selection for at least a week.
Saos cells were grown in growth medium supplemented with 10% serum without a 
feeder layer. They were transfected as described above using 30pl DOTAP and lOpg 
DNA. Cells were trypsinised 24 hours after transfection and plated at 4xl05cells / 10cm 
dish. The cells were incubated at 37°C for 2 days and then selected with 500pg/ml 
G418. Resistant colonies were visible after 21 days. Single colonies from each 
transfection were ring cloned and checked for protein expression as described above. In 
order to analyse the growth suppressive function of some p53 mutants whole plates of 
transformed cells were selected and stained for p53 expression as described in section
2.2.2.I.
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2.2.1.5 Growth of keratinocytes in suspension culture.
Keratinocytes can be induced to terminally differentiate in vitro by culturing them 
in methylcellulose. This prevents cell to cell contact, causes the cells to round up and 
become unresponsive to mitogen stimulation (Green, 1977).
Methylcellulose (1.3% w/v) was dissolved in unsupplemented medium (DMEM 
containing ImM sodium pyruvate, 0.3% (w/v) sodium bicarbonate, pH7.2) pre-heated 
to 60°C. Once cooled to room temperature 10% (v/v) fetal calf serum, 37.5pg/ml 
penicillin, 1 Ojig/ml streptomyciii2mM glutamine and 0.4pg/ml hydrocortisone were 
added and stirred for 30 minutes at room temperature and at 4°C overnight. This was 
then centrifuged at 15000g at 4°C for 30 minutes. The supernatant was decanted into 
fresh, sterile bottles and frozen at -20°C.
Sterilin bacteriological dishes were treated with polyhaem A to prevent cells from 
attaching to the dish. Polyhaem A (10% in 95% ethanol) was diluted to a working stock 
of 0.4% in acetone (50%), 95% ethanol (50%) and used to wash dishes which were then 
air-dried. Before use dishes were rinsed in DMEM.
Cells were seeded at either 2x106 /5cm dish (high density) or 3x105 /5cm dish (low 
density) without feeders and were incubated at 37°C for four days. Cells were 
trypsinised and diluted to lx l06/ml. 1 part cell suspension was mixed with 9 parts pre­
warmed methylcellulose (final cell concentration was 105/ml methylcellulose). Cells 
were suspended in methylcellulose evenly taking care not to produce air bubbles. The 
cell suspension was then pipetted into polyhaem A coated petri dishes and incubated for 
the required length of time in a humid incubator at 37°C.
Cells were recovered from methylcellulose by washing the cells and methylcellulose 
off the plates with cold PBS. The mixture was diluted 20 fold with PBS and centrifuged 
at 2000rpm for 10 minutes. The supernatant was aspirated off, the cells were re-washed 
in PBS and counted.
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2.2.1.6 Comified envelope formation assay.
Comified envelopes are formed as keratinocytes terminally differentiate (Sun and 
Green, 1976). Cells were induced to differentiate by placing them in suspension culture 
as described above for up to 5 days. Cells were removed from the methylcellulose and 
diluted to 3xl05/ml in 5% SDS. Cells were solubilised by adding 1% p-mercaptoethanol 
and boiling for 5 minutes. Comified envelopes were visualised and counted on a 
haemacytometer under a light microscope. Each count was an average of 16 large 
squares on a haemacytometer xl04/ml. Experiments were carried out at least in triplicate 
for each cell line.
2.2.1.7 Cloning efficiency.
Cells were induced to differentiate by placing them in suspension culture as 
described above for up to 24 hours. Cells were removed from the methylcellulose and 
counted. Cells that had not been placed in suspension culture were plated at 500 cells/ 
T25 on an irradiated feeder layer. Cells removed from the methylcellulose after 24 hours 
were plated on an irradiated feeder layer at 103/T25. Cells were incubated at 37°C until 
colonies were large but still individual (approximately 20 days). Cells were then washed 
in PBS and fixed in 10% formalin (10% formaldehyde in PBS) for 30 minutes in a 
fumehood. The formalin was removed and the cells stained with 1% (w/v) rhodamine B 
for 30 minutes. The cells were then washed, air-dried and the colonies counted by eye. 
Cells from each time point were plated onto feeders in duplicate for each experiment. 
Experiments were repeated at least in triplicate for each cell line. Colony counts are 
given per 500 cells plated.
2.2.1.8 Tumorigenicity in nude mice.
Cells were removed from selection and expanded at identical cell densities. The 
cells were then trypsinised and washed twice in serum-free DMEM. 5x106 and 1.6xl06
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cells were resuspended in 200pl serum-free DMEM and subcutaneously injected into the 
left or right flank respectively of four week old nude mice (MF1 NuNu mice). Three 
mice were used per cell line tested. Mice were examined by animal house staff weekly, 
for tumour presence and the tumour volumes were recorded. A progressively growing 
tumour which remained for 3 months was scored as positive. After this time or when the 
tumour became 1cm3 the mice were sacrificed and cryostat sections prepared from the 
tumour.
2.2.1.9. Haematoxylin and Eosin staining
Cells or tissue sections where counterstained with haematoxylin, which stains the 
nucleus blue and eosin, which stains the cytoplasm pink, to enhance cellular morphology 
for examination and photography.
Tissue sections were fixed twice in 100% ethanol, once in 70% ethanol, then 
placed in water. Individual cells were either trypsinised or removed from suspension 
culture, washed in PBS and resuspended in 100% ethanol. Cells were then dropped onto 
glass slides and air-dried. The slides were placed into 100% ethanol, then 70% ethanol, 
followed by water.
Slides were placed in Harris' Haematoxylin for 10 seconds, washed in running tap 
water and developed in Scott's tap water until the nucleus was sufficiently dyed. The 
intensity of the stain can be adjusted by washing in 1% HC1 in 70% ethanol. The slides 
were washed in tap water and dipped briefly in Eosin stain followed by further washing 
in tap water. Once the required dye intensities had been achieved the cells were 
dehydrated once in 70% ethanol, twice in 100% ethanol, then cleared in xylene and 
mounted in histomount.
2.2.1.10. Aery dine orange staining
Nuclear DNA was stained with acrydine orange. Cells were removed from 
methylcellulose and stained with 5pg/ml acrydine orange in PBS for 10 minutes. Cells
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were pelleted, resuspended in H2O and air-dried onto slides. Cells were mounted in anti­
fade medium (Vectashield) and sealed with nail varnish. Nuclear staining was visualised 
under a narrow band FITC filter in fluorescent light. Cells were photographed using 400 
ASA daylight film, pushed to 1600 on camera and developed twice in initial developing 
solution.
2.2.2. Immunocytochemistiy
2.2.2.1 p53 staining
Cells were seeded in an 8 well chamber slide at 104cells and 2x104 3T3 feeders per 
well. Cells were incubated in a humid incubator at 37°C until 60% confluent.
The plastic wells were removed from the slides taking care to retain the plastic 
gasket which defines the boundaries between wells. The slides were then washed briefly 
in PBS and drained. The cells were fixed for 20 minutes in -20°C methanol on ice and 
air-dried for 40 minutes or until completely dry.
Normal horse blocking serum (1:10 dilution in 0.1% BSA in PBS, pH7.6) from the 
mouse vectastain peroxidase kit was added to each well and the slide incubated in a 
humidified box at room temperature for 20 minutes. The slides were drained and lOOpl 
diluted p53 antibody added to each well. PAb 1801 (Banks et al, 1986) which 
recognises the wild-type conformation of p53 was used at a final concentration of lp  
g/ml. PAb 240 (Gannon et al, 1990) which recognises the mutant conformation of p53 
was used at a final concentration of 3pg/ml. The slides were then incubated for 1 hour in 
a humidified box. Excess antibody was removed by washing in a high salt buffer (0.15M 
Nacl, 0.05% Tween 80 in PBS, pH7.6) for 30 minutes, changing the buffer every 10 
minutes. The secondary antibody, anti-mouse IgG biotinylated antibody, was diluted 
1:200 in 0.1% BSA/PBS buffer and lOOpl added to each well. The slides were again 
incubated in a humidified box for 1 hour at room temperature and then washed as above. 
The biotinylated antibody was detected using a complex between avidin and a further 
biotinylated enzyme (ABC reagent). This complex is formed at least 30 minutes before
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required. One drop (50pl) of reagent A (Avidin) and one drop reagent B (Biotinylated 
enzyme) was added to 5mls 0.1% BSA/PBS and lOOpl added to each well. The slides 
were incubated for another hour in a humidified box and again washed as before. The 
substrate diaminobenzene was dissolve in PBS (0.6mg/ml) containing 0.06% H202  and 
added to each slide, in the dark, for 7.5 minutes or until a brown stain was visible. The 
slides were then washed in water, mounted in aquamount and sealed with nail varnish.
The cells were photographed with panotomic X film under phase contrast or bright 
field with a green filter.
2 2 2 2  Involucrin staining
Cells were either grown on chamber slides as above or cells pre-washed in PBS 
were air-dried onto slides. Cells were fixed in -20°C methanol on ice for 20 minutes and 
then air-dried. Goat blocking serum from the rabbit alkaline phosphatase Vectastain kit 
was diluted 1:10 in 0.1% BSA/PBS and added to the cells for 25 minutes in a humidified 
chamber at room temperature. The excess blocking serum was removed and the rabbit 
anti-involucrin antibody (diluted 1:5000) added to the cells overnight in a humidified box 
at 4°C. The slides were then washed in NaCl/PBS/Tween as above for 30 minutes. The 
slides were drained and the goat anti-rabbit secondary antibody from the kit (diluted 
1:200) was added for 1 hour at room temperature. The slides were again washed and 
drained. The ABC reagent diluted as above was added for 1 hour in a humidified box 
and then the excess removed by washing in NaCl/PBS/Tween buffer as before. The 
alkaline phosphatase substrate kit I (red) was used to visualise antibody reactivity. 
Reagent 1, 2 and 3 were mixed in equal amounts, as directed, in lOOmM Tris-HCL 
pH8.2. This was added to the cells for 5 minutes or until the required staining intensity 
was achieved. Slides were washed in water, mounted in aquamount and sealed with nail 
varnish.
Cells were photographed with colour slide film under phase contrast or bright field 
optics.
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2.2.3. Protein Biochemistry
2.2.3.1 Western Blot
a) p53
Cells were trypsinised when 50% confluent and washed twice in PBS. lx l06 cells 
were lysed in 100pi ice cold lysis buffer (1% NP40, 20mM Tris, 2mM EDTA, lOOmM 
Nacl, pH8.0) containing protease inhibitors (0.01% PMSF, lpg/ml Aprotinin, ljxg/ml 
Leupeptin, 5mM NaF). Note, sodium orthovanadate has been shown to alter the 
conformation of p53 (Landesman et al, 1994) and was therefore not used in the lysis 
buffer. Cells were lysed on ice for 30 minutes and then centrifuged for 15 minutes at 
4°C. The supernatant was transferred to a fresh eppendorf tube. The protein 
concentration was determined using the Bio-rad DC protein assay. SDS-sample buffer 
(50mM Tris, pH6 .8 , 10% glycerol, 2.5% SDS, 0.1% bromophenol blue) and 2.5% 
(3-mercaptoethanol were added to 50 or 250ug protein and boiled at 100°C for 30 
minutes. The samples were centrifuged briefly and run on a 10% SDS-polyacrylamide 
gel along with rainbow markers as described in section 2.2.3.2.
The protein was transferred onto Immobilin-P nitrocellulose filter, also described in 
section 2.2.3.2. After washing briefly in TBS (lOmM Tris, 150mM Nacl, pH8.0), the 
filter was stained for 5 minutes in Ponceau's stain, then de-stained for 5 minutes in 5% 
(v/v) acetic acid to check for consistency of protein transfer and loading. The filter was 
rinsed again in TBS and blocked overnight at 4°C in TBS-T (0.1% Tween 20 in TBS) 
containing 5% Marvel (milk fat) and 0.025% sodium azide.
The filter was incubated with the primary p53 mouse monoclonal antibody 
PAbl801 (lpg/ml in TBS-T plus 5% Marvel, Oncogene science) for 2 hours at 4°C, 
then washed 3 times, each for 15 minutes in TBS-T plus marvel. The secondary 
antibody, anti-mouse Ig horse-radish peroxidase linked whole antibody, was incubated 
with the filter at a 1:5000 dilution in TBS-T/Marvel for 20 minutes. The filter was again 
washed as above and rinsed twice more in TBS for 15 minutes each. The antibody was
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detected by immersing the filter in ECL detection reagent for 1 minute, wrapping in 
SaranWrap and exposing it to Kodak X-Omat fast film for up to a minute.
b) Cyclin D.
Semi-confluent dishes of cells were washed twice with PBS and the cells lysed by 
adding 1ml ice-cold lysis buffer (50mM Tris pH7.4,150mM NaCl, 20mM EDTA, 0.5% 
NP40) containing protease inhibitors (ImM PMSF, 25pg/ml leupeptin, 25pg/ml 
aprotinin, ImM benzamidine, 10p,g/ml trypsin inhibitor, ImM sodium fluoride) to each 
dish for 30 minutes on ice. The cells were scraped from the dish and centrifuged for 5 
minutes at 4°C. The supernatant was removed to a fresh eppendorf tube. The protein 
concentration was measured using the Bio-rad DC protein assay kit. 30pg protein was 
run on a 10% SDS-polyacrylamide gel and blotted onto immobilin-P nitrocellulose as 
described in section 2.2.3.2. The filter was washed briefly in PBS-T (PBS plus 0.1% 
Tween 80) and the protein visualised in Ponceaus’ stain as described above. The filter 
was blocked in PBS-T plus 5% marvel overnight. The primary antibody, rabbit 
polyclonal cyclin-D (287-3), was added to the filter at 1:500 dilution in PBS-T/Marvel 
for 3 hours at 4°C, then the filter was washed three times in PBS-T/Marvel each for 15 
minutes. The secondary antibody, anti-rabbit Ig, horseradish peroxidase linked F(ab')2 
fragment, was diluted 1:3000 and added to the filter for 1 hour at room temperature.
The filter was again washed as before and rinsed in PBS-T for 15 minutes. The filter was 
immersed in ECL detection reagent for 1 minute, wrapped in SaranWrap and exposed to 
Kodak X-Omat film for up to 1 minute.
2.2.3.2. SDS-polyacrylamide gel electrophoresis and blotting.
10% SDS-polyacrylamide gel (10% acrylogel, 375mM Tris, pH 8.8, 0.1% SDS, 
0.1% ammonium persulphate, 0.03% TEMED) was poured between gel plates, covered 
with H2 0 -saturated butan-2-ol, and allowed to polymerise for 1 hour. The gel front was 
washed with H20  and blotted dry. The stacking gel (4.8% Acrylogel, 125mM Tris,
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pH6 .8 , 0.1% SDS, 0.1% ammonium persulphate, 0.03% TEMED) was poured on top of 
the resolving gel, a comb inserted and allowed to polymerise. Due to the difference in 
pH between the stacking and resolving gel, the stacking gel should only be poured up to 
1 hour before use to minimise merging of the pH's. The gel was run at 30mA in running 
buffer (25mM Tris, 19ImM glycine, 3.5mM SDS) for 3-4 hours.
The gel was carefully removed from the glass plates, discarding the resolving gel and 
soaked in transfer buffer (25mM Tris, pH8.3,191mM glycine, 20% (v/v) methanol) for 
30 minutes. The protein was transferred in the above buffer onto immobilin-P 
nitrocellulose using a bio-rad wet trans-blot apparatus run at 30 volts overnight.
2.2.3.3. Immunoprecipitaton of p53.
Semi-confluent plates of cells were washed twice in PBS and 1ml ice-cold lysis 
buffer (150mM NaCl, 50mM Tris, pH8.0, 5mM EDTA, 1% NP40) containing protease 
inhibitors (ImM PMSF, 5mM sodium fluoride, lpg/ml aprotinin, lpg/ml leupeptin) was 
added to each dish for 30 minutes on ice. The cells were scraped from the dish, 
centrifuged for 30 minutes and the supernatant transferred to a fresh eppendorf. The 
protein concentration was measured using the Bio-rad DC protein assay kit. 20pl 
protein G plus agarose beads were added to the lysate and rotamixed for 40 minutes at 4 
°C. The supernatant was removed and split equally between antibodies used, lul 
antibody (either DO-1, PAbl620 or PAb240 all a kind gift from Dr. D. Lane) was 
incubated with the cell lysate overnight at 4°C. 20pl protein G agarose beads were 
added and the samples rotamixed for 40 minutes at 4°C. After brief centrifugation, the 
supernatant was removed and the beads washed 3 times with ice-cold lysis buffer taking 
care to remove all the buffer. The beads were resuspended in 20pi sample buffer (50mM 
Tris, pH6.8, 10% glycerol, 2.5% SDS, 0.1% bromophenol blue) and 2.5% (3- 
mercaptoethanol and boiled for 10 minutes at 100°C. Samples were run on a 10% SDS- 
polyacrylamide gel as described above. The protein was transferred onto Immobilin-P 
nitrocellulose and probed as described in the western protocol (section 2.2.3.1a.) using 
the rabbit polyclonal p53 antibody CM-1 (1:250 dilution, a gift from Dr.D.Lane) as the
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primary antibody and anti-rabbit Ig, horseradish peroxidase linked whole antibody 
(1:5000 dilution) as the secondary antibody.
2.2.4. Molecular Biology
2.2 A.I. Preparation of genomic DNA from SCC cell lines.
DNA was prepared using the salting out method as described by Miller et al, 1988. 
Cells were lysed in 3ml lysis buffer (lOmM Tris-HCl, 400mM NaCl, 2mM EDTA, 
pH8.0) and digested overnight at 37°C with 0.2ml 10% (w/v) SDS and 0.5ml protease K 
solution (lmg protease K in 1% SDS, 2mM EDTA). After digestion 1ml saturated NaCl 
(approximately 6M) was added and the tube shaken vigorously for 15 seconds, followed 
by centrifugation at 3000g for 5 minutes to pellet the protein. The DNA was 
precipitated from the supernatant with 2 volumes of room temperature absolute ethanol. 
The DNA strands were spooled out on a glass pipette, air-dried and dissolved in 100-200 
pi TE (lOmM Tris-HCl, 0.2mM EDTA, pH7.5). DNA concentrations were determined 
by measuring absorbance at 260nm and using the conversion of 1 OD unit at 260nm is 
equivalent to a concentration of 50pg/ml. The absorbance ratios 260nm/280nm should 
be 1.8-2.0 showing good deproteinization of the DNA sample. Genomic DNA was 
stored at 4°C.
2.2.4.2. Preparation of RNA from SCC cell lines.
Cells were lysed directly in the culture dish by the addition of RNAzol B 
(lml/3.5cm dish). The RNA was solubilized by passing the lysate a few times through 
the pipette. 0 .2ml chloroform was added per 2ml lysate, the tubes were covered with 
parafilm, vigorously shaken for 15 seconds then incubated on ice for 5 minutes. The 
samples were centrifuged at 12,000g, 4°C for 15 minutes after which the upper 
colourless aqueous phase was transferred to a fresh tube and an equal volume of 
isopropanol added. The samples were stored at 4°C for 15 minutes and the RNA
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precipitate pelleted by centrifugation at 12,000g, 4°C, for 15 minutes. The RNA pellet 
was washed once with 1ml 75% ethanol by vortexing and centrifugation at 7,500g, 4°C, 
for 8 minutes. The RNA was re-dissolved in 200-300pl diethylpyrocarbonate (DEPC) 
treated RNase-free H2O. The RNA was re-precipitated by adding 1/10 volume 3M 
NaAc, pH5.2 and 2 volumes ethanol for 1 hour at -20°C. Note, all solutions and tubes 
should be pre-treated with DEPC to prevent RNase contamination. The RNA 
concentration was determined by measuring the absorbance at 260nm and using the 
conversion of 1 OD unit being equivalent to 40pg/ml. RNA was stored in aliquots at 
-70°C.
2.2.4.3. Minipreps of plasmid DNA
Small amounts of plasmid DNA were prepared using the alkaline lysis method as 
described by Maniatis et al, 1989.
Single colonies of bacteria carrying the required plasmid were picked using a sterile 
toothpick and grown in 2ml L-Broth (1% w/v bactotryptone, 0.5% w/v yeast extract, 
NaCl) containing antibiotic (50pg/ml ampicillin or 30pg/ml chloramphenicol) at 37°C in 
a shaking incubator. Bacteria were pelleted from 1.5ml of overnight culture by brief 
microcentrifugation and resuspended in lOOpl lysozyme solution (50mM glucose, 25mM 
Tris-HCl, pH8.0, lOmM EDTA containing 2mg/ml lysozyme) for 5 minutes. 200pl 
freshly made solution 2 was added (0.2M NaOH, 1% w/v SDS), mixed gently and left at 
room temperature for 5 minutes. 150pl ice-cold 3M KAc pH 4.8 was then added, mixed 
thoroughly and stored on ice for 5 minutes. The precipitated cell debris was pelleted by 
microcentrifugation for 2 minutes and the supernatant removed to a fresh eppendorf 
tube. The nucleic acids were precipitated by adding 2 volumes of cold ethanol to the 
supernatant, standing for 5 minutes at room temperature and microcentrifugation for 10 
minutes. The pellet was washed in 1ml -20°C 70% ethanol, microcentrifuged for 5 
minutes and all ethanol removed using a drawn out pippette. The pellet was air-dried 
and dissolved in 20pl TE containing DNase-free RNase A (20pg/ml) and incubated at 
37°C for 30 minutes. The DNA solution was made up to 200pl with TE, extracted with
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an equal volume of phenol/chloroform (1:1) and re-precipitated with 1/10 volume 3M 
NaAc pH 5.0 and 2 volumes ethanol at -70°C for 1 hour. The DNA was pelleted by 
microcentrifugation, washed in 70% ethanol and dissolved in 20pl TE. Plasmid DNA 
was stored at -20°C.
2.2.4.4. Large scale preparation of plasmid DNA
10 ml overnight culture was transferred to 500ml L broth containing antibiotic 
(50pg/ml ampicillin) and shaken at 37°C overnight.
If the plasmid requires amplification then the culture was grown at 37°C until the 
absorbance at 600nm reached 0.4-0.6. Chloramphenicol was then added (170pg/ml) and 
the culture shaken at 37°C for a further 16-20 hours.
Cells were pelleted from the overnight culture at 5000rpm, 4°C for 10 minutes, 
rinsed with 50mM Tris-HCl pH 8.0 and resuspended in 25ml lysozyme solution (25mM 
Tris-HCl pH 8.0, lOmM EDTA, 50mM glucose containing 5mg/ml lysozyme) for 30 
minutes at room temperature. 40 ml solution 2 (0.2M NaOH, 1% SDS) was added, 
mixed well and placed on ice for 15 minutes. 20 ml 3M KAc pH4.8 was then added, 
mixed by inversion and left on ice for another 15 minutes. The flocculates were 
centrifuged at 10,810g for 5 minutes at 0°C. The supernatant was filtered through gauze 
and the DNA precipitated by adding 0.6 volumes of -20°C isopropanol and immediately 
centrifuged at 10,810g, room temperature for 5 minutes. After discarding the 
supernatant, the pellet was left to drain for 10 minutes and then resuspended in 5ml TE, 
pH8.0.
Plasmid DNA was purified on a CsCl gradient. 7.5g CsCl was dissolved in the 5ml 
DNA solution and 5mg ethidium bromide added. The refractory index was adjusted to 
1.3860-1.3900 with TE pH 8.0. The CsCl solution was balanced in oakridge tubes and 
centrifuged in a sorvall ultracentrifuge (rotor T1270) at 146,600g for 40 hours at 20°C.
The plasmid band was removed from the gradient using a syringe with a 19 gauge 
needle and extracted with an equal volume water-saturated isobutanol until all the 
ethidium bromide had been removed. The DNA was precipitated by adding an equal
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volume H20  and 2 volumes room temperature ethanol and standing at room temperature 
for 15 minutes. The DNA was pelleted in glass corex tubes by centrifugation at ll,950g, 
4°C for 15 minutes. The pellet was resuspended in 1ml deionised water and 
reprecipitated with 0.1 volumes 3M NaOAc pH 5.0 and 2 volumes ethanol at -20°C for 1 
hour. DNA which was used for transfection of cells in culture was purified further by 
phenol/chloroform extraction before precipitation. The DNA was pelleted as above, 
rinsed with 70% ethanol, freeze-dried and dissolved in TE. The DNA concentration was 
measured as described in section 2.2.4.1.
2.2.4.5. Restriction enzyme digestion of DNA.
Plasmid DNA was incubated with 5-10 units enzyme/pg DNA in a buffered 
solution as specified and supplied by the manufacturer for 1-2 hours at 37°C. The 
digestion fragments were analysed by agarose gel electrophoresis as described below.
2.2.4.6. Agarose gel electrophoresis.
Flat bed electrophoresis apparatus from Pharmacia was used. Agarose gels (0.7%- 
4% (w/v) agarose) were cast in lxTAE buffer (40mM Tris base, 16mM acetic acid,
ImM EDTA, pH8.0) containing 0.5pg/ml ethidium bromide. Low melting point agarose 
was used in order to isolate and purify required DNA restriction fragments. 4% Nusieve 
agarose gels were used for greater separation of PCR products. Stop and dye buffer 
(0.45% (w/v) bromophenol blue, 1% (w/v) SDS, lOOmM EDTA, 2.5% w/v Ficoll 400 in 
TE) was added to each sample. The gel was submerged in lxTAE buffer containing 
0.5pg/ml ethidium bromide, the samples were loaded into each well along with an 
appropriate size marker (i.e. either 0X174 Hae-III digested DNA or 1Kb ladder) and 
run at 100V for 30-60 minutes. The separated DNA was visualised by illumination with 
short wave (312nm) UV light and photographed through a red filter using polaroid type 
57 high speed film or using an Appligene Imager.
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2.2.4.7. Isolation of specific restriction fragments from digested 
DNA
a) Using a low melting point agarose gel and Geneclean 2® kit
Digested DNA was run on a low melting agarose gel at 4°C as described above. 
The required DNA fragment was excised from the gel and the agarose block containing 
the fragment was weighed and volume calculated (lg = 1ml). 2.5 volumes of 6M Nal 
was added and the agarose melted at 55°C for 5 minutes. 5pl glassmilk®, a suspension 
of silica matrix in water which binds single and double-stranded DNA without binding 
contaminants, was added for every 5pg or less DNA. The mixture was vortexed and left 
on ice for 5 minutes to allow binding. The glassmilk was pelleted by brief centrifugation 
and washed 3 times by mixing with 300pl NEW wash (a Tris and EDTA-buffered 
solution of NaCl, ethanol and water), pelleting the glass milk and removing the 
supernatant. Finally half the desired volume of TE was added to the cleaned pellet and 
heated to 55°C for 2 minutes. The glassmilk was pelleted and the TE containing DNA 
was removed to a fresh eppendorf. This was repeated to elute all the DNA.
b) Directly from an agarose gel using filter paper.
The restricted DNA was run on a 1-2% agarose gel as described in section 2.2.4.6. 
An incision was made just below the required DNA fragment in the gel. Filter paper was 
backed with dialysis tubing and cut to the size of the incision. This was placed carefully 
into the gel with the filter paper nearest the DNA fragment and the capillary tubing 
facing away. The gel was re-submerged into the buffer and run until the DNA fragment 
was collected on the filter paper. The capillary tubing prevents the DNA from running 
straight through the filter paper. The filter paper was then removed from the gel and 
placed in an eppendorf with a hole in the bottom standing in another eppendorf tube.
The tubes were briefly centrifuged to elute the DNA. 30pl TE was added to the filter 
paper, allowed to stand for a few minutes and the centrifuged again. The DNA solution 
collected in the bottom eppendorf tube was made up to 80pl with TE and was either
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collapsed for double-stranded sequencing as described in section 2.2.4.12 or ethanol 
precipitated.
2.2.4.8. Ligation of DNA fragments.
Vector DNA was digested as described in section 2.2.4.5. The DNA fragment to 
be inserted was also digested as above and then isolated by gel electrophoresis as 
described in section 2.2.4.7.
To prevent the vector DNA from ligating back to itself without an insert it was 
firstly dephosphorylated. The vector DNA was digested with the required enzyme as 
directed by the manufacturer and an aliquot removed to check that digestion was 
complete. The reaction mixture was adjusted by adding dephosphorylation buffer 
(50mM Tris-HCl, O.lmM EDTA, pH 8.5) and 1 unit alkaline phosphatase. This was 
incubated at 37°C for 1 hour, after which the reaction was stopped by adding 50mM 
EDTA pH8.0 followed by phenol/chloroform extraction. The DNA was re-precipitated 
by adding 0.5x volume 7.5M NH4AC and 2x volume ethanol at -70°C for 30 minutes. 
The DNA precipitate was microcentrifuged for 10 minutes, washed with 70% ethanol 
and redisssolved in TE.
The insert was ligated to the dephosphorylated vector (lOOng) at a ratio 3:1 
respectively. The vector and insert DNA were incubated together in a reaction 
containing 50mM Tris-HCl pH 7.6, lOmM MgCl2, ImM ATP, ImM DTT, 5% (w/v) 
polyethylene glycol-8000 and 1 unit T4 DNA ligase at 4°C overnight.
2.2A.9. Transformation of competent bacterial cells
Ligation mixtures were firstly diluted 5 fold and l|_il of this (containing l-10ng of 
ligated DNA) was added to 20pl DH5a competent cells in chilled microcentrifuge tubes, 
shaken gently and placed on ice for 30 minutes. The cells were heat shocked by placing 
in a 42°C waterbath for 40 seconds and then placed directly on ice. 80pl SOC medium 
(2% (w/v) bactotryptone, 0.5% (w/v) yeast extract, lOmM NaCl, 2.5mM KC1, lOmM
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MgC^, lOmM MgS0 4 , 20mM glucose) was added to the cells and shaken at 225 rpm 
for 1 hour at 37°C. All the cells were spread onto an L-Broth agar plate (15g Bacto- 
Agar/litre L-Broth) containing antibiotic and incubated overnight at 37°C. Plasmid DNA 
was prepared from transformed colonies as deescribed in section 2.2.43.
2.2.4.10. Oligonucleotide synthesis and purification.
Oligonucleotides were either ordered from Research genetics or synthesised on an 
Applied Biosystems 381A DNA Synthesiser or 392 DNA/RNA Synthesiser using the 
manufacturers protocols and Cruachem reagents. Primers from Research Genetics 
arrived ready for use at 20pM in TE pH8.0. Other primers were synthesised with or 
without trityl group protection. All these primers were firstly deprotected by incubating 
overnight at 55°C.
"Trityl on" primers were detritylated using an Applied Biosystems oligonucleotide 
purification cartridge. 5ml acetonitrile was passed through the column to waste at a rate 
of 1 drop/sec using a syringe. This was followed by 5ml 2M triethylammonium acetate. 
The deprotected oligonucleotide ammonia solution was diluted with an equal volume of 
distilled water and passed through the column the same way. The eluate was collected 
and passed through a second time. The cartridge was then flushed through with 5ml 
10% (v/v) ammonia and 10ml distilled water. The oligonucleotide was detritylated while 
bound to the support by passing 2.5ml 2% (v/v) trifluoroacetic acid through the column, 
allowing it to stand for 5 minutes and repeating. The cartridge was then flushed with 
10ml distilled water. The oligonucleotide was eluted drop-by-drop with 3ml 20% (v/v) 
acetonitrile, freeze-dried overnight and dissolved in 250ml TE pH8.0. Primer 
concentration was determined by measuring absorbance at 260nm and using the 
conversion that lQD260nm is equivalent to 24pg/ml. Primers were stored at -20°C.
"Trityl off" primers were either stored after deprotection in ammonia at -20°C and 
purified as needed, or kept at 4°C and deprotected and purified as needed. The primers 
were purified by desalting them by precipitation with butan-l-ol. 1ml butan-l-ol was 
added per 150pl primer solution and microcentrifuged at 13,000g for 20 minutes at room
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temperature. Excess butanol was removed by centrifugation under vacuum and the 
primer dissolved in 150pl TE pH8.0. Primer concentrations were calculated as above.
2.2.4.11. Polymerase chain reaction (PCR)
a) Amplification from RNA.
Firstly cDNA was synthesised from RNA by reverse transcription using the Perkin- 
Elmer Cetus RNA PCR kit. The reaction was carried out in a final volume of 20pl 
comprising of 5mM MgCl2, lx  PCR kit buffer II (50mM KC1, lOmM Tris-HCl), ImM of 
each of dATP, dGTP, dTTP, dCTP, 1 unit RNase inhibitor, < lpg RNA, 2.5pM random 
hexamers and 2.5 units reverse transcriptase. This was incubated at room temperature 
for 10 minutes allowing the extension of the hexameric primers by reverse transcriptase. 
All samples were placed in the thermocycler and further incubated at 42°C for 15 
minutes, 99°C for 5 minutes and soaked at 4°C for 5 minutes.The cDNA was then 
amplified by using specific primers as detailed in table 1. The above reaction volume was 
increased to lOOpl by adding 2mM MgC^, lx kit PCR buffer II, 0.15pM of each of the 
upstream and downstream p53 primers (detailed in table 1 and figure 2.1) and 2.5 units 
Taq polymerase. Amplification proceeded for 35 cycles of 95°C for 30 seconds and 
60°C for 30 seconds plus a 1 second extension per cycle followed by a final extension at 
60°C for 7 minutes using the Perkin-Elmer cetus 9600 thermocycler. The samples were 
then analysed by agarose gel electrophoresis as described in section 2.2.4.6 to ensure 
correct amplification.
b) Amplification of DNA.
All reagents were provided in the Perkin-Elmer Cetus DNA PCR kit. Primer 
sequences are detailed in table 2 .
The reaction mixture comprising of 200pM of each dATP, dCTP, dTTP, and 
dGTP, buffer J (50mM Tris pH 9.0,50mM KC1,1.5mM MgCl2, 0.01% gelatin),
81

Re
fe
re
nc
e
Ro
dr
igu
es
 e
r a
l, 
19
90
 
Ro
dr
igu
es
 e
t a
l, 
19
90
Ro
dr
igu
es
 e
f a
l , 
19
90
 
Ro
dr
igu
es
 e
r a
/, 
19
90
M
ur
ak
am
i 
et
al
, 
19
91
M
ur
ak
am
i 
al,
 1
99
1
M
ur
ak
am
i 
et 
al
, 
19
91
 
Bu
ms
 e
f a
/, 
19
93
£6614/o;asuina
Pr
im
er
 s
eq
ue
nc
e
5'C
A
GC
TC
CT
A
CA
CC
G
GC
GG
CC
CC
TG
CA
CC
A
G3
'
5fB
io
tin
-G
A
G
CC
A
A
CC
rC
A
A
G
G
CG
G
CT
CT
CA
TA
G
G
G
CA
CC
3'
5T
A
G
TG
TG
G
TG
G
TG
CC
CT
A
TG
A
G
CC
G
3'
5 'B
iot
in-
GT
GG
G 
AG
GC
TG
TC
AG
TG
GG
GA
AC
AA
3'
5'C
AC
CA
TC
AT
CA
CA
CT
G
GA
AG
3I 
as 
ab
ov
e
as 
ab
ov
e
5'B
io
tin
-C
TG
A
CG
CA
CA
CC
TA
TT
GC
A
A3
'
5T
CC
A
CG
A
CG
G
TG
A
CA
CG
CT
T3
'
5’B
io
tm
-A
AG
GG
AC
AG
AA
GA
TG
AC
AG
G3
'
5’C
TA
CA
AG
CA
GT
CA
CA
GC
AC
AT
3' 
as 
ab
ov
e
Fr
ag
m
en
t
am
pl
ifi
ed
44
7-
89
4b
p
85
5-
14
34
bp
97
0-
14
34
bp
85
5-
15
06
bp
15
5-
50
9b
p
70
0-
14
34
bp
U r—Hw Q
r— 4 
<4)
£ £ Qi 5 sfc- ed Qh a <  W q a S  o O !§ M O
Re
fe
re
nc
e
ON ON OS Os
*
a aV* «•»
•£ ■£ 
fi 2CO OQ
CO
a
<or .
2 <G QH ^
8 ^
h <G u3cD
& s |
8 P <u o -3H .2C Cn uo
co
*<£2
a
l.a> VO
B•mt aou rtOn W
u
F '3 £ QCu a VO vo
0.15pM of each primer and 200ng DNA, was aliquoted into GeneAmp PCR reaction 
tubes in a final volume of lOOpl. The tubes were placed into the PCR machine (Perkin- 
Elmer Cetus type 9600) and heated to 94°C for 5 minutes to inactivate DNases and 
ensure all DNA duplexes were melted. The samples were cooled to 85°C and 2.5 units 
Taq polymerase (a thermolabile DNA polymerase from Thermus aquaticus) was added. 
The DNA was then amplified (using Perkin-Elmer cetus 9600 thermocycler) for 35 
cycles at 94°C for 30 seconds, 55°C for 1 minute, to allow the primers to anneal to the 
template DNA, followed by 72°C for 1 minute, to allow extension of the amplimer 
sequences. After completion of the cycles, the reaction was incubated at 72°C for a 
further 7 minutes to ensure full extension and then cooled to 4°C. 5pi of each sample 
was analysed by agarose gel electrophoresis (as described in section 2.2.4.6.) to check 
the correct product was amplified.
c) PCR of DNA containing microsatellite sequences.
Amplification of all microsatellite sequences were carried out the same way and not 
as specified in the original reference. Primers used are described further in table 3.
Reactions were carried out in 25 pi final volumes containing 40ng DNA, lOmM 
Tris-HCl pH8.3, 50mM KC1,1.5mM MgCl2, 0.001% (w/v) gelatin, 10% (v/v) DMSO, 
140ng of each amplimer, 200pM of each of dATP, dTTP, dGTP, dCTP, and lp l  a (32P) 
dCTP (diluted 1:30). This was heated to 94°C for 5 minutes then cooled to 85°C before
2.5 units Taq polymerase was added. Each reaction tube was placed in the thermocycler 
(Perkin-Elmer Cetus 9600) and subjected to 6 cycles of 94°C for 30 seconds, 60°C for 
30 seconds, followed by 28 cycles of 94°C for 30 seconds, 55°C for 30 seconds and 
72°C for 30 seconds. Extensions were completed by incubating finally at 72°C for 7 
minutes and then cooling to 4°C.
5pl of each reaction was analysed by electrophoresis as described in section 
2.2.4.6. on a nusieve agarose gel to check the product size.
Loss of heterozygosity at microsatellite positions were analysed by polyacrylamide 
gel electrophoresis as described in section 2.2.4.13.
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Table 3
Microsatellite primers
Chromosome 9
Primer Primer position Reference
D9S 156 9p23-p22 Weissenbach et al, 1992
D9S 157 9p23-p22 Weissenbach et al, 1992
D9S 199 9p23 Graw and Kwiathowski, 1993
D9S 168 9p23-p22 Weissenbach et al, 1992
D9S 162 9p21 Weissenbach et al, 1992
Interferon a 9p21 Weissenbach et al, 1992
D9S 171 9p21 Weissenbach et al, 1992
D9S 55 9pll-pl2 Sharma etal, 1991
D9S 127 9q31 Lyallefa/, 1992
D9S 109 9q31 Furlong et al, 1992
D9S 116 9q31-q34 Kwiatkowski and Gusella, 1992
GSN 9q33 Kwiatkowski et al, 1993
ABL 9q34.1 Kwiatkowski, 1991
D9S 66 9q34-qter Kwiatkowski et al, 1992
Chromosome 3
Primer Primer position Reference
D3S 1038 
D3S 1478 
D3S 1076 
D3S 1067 
D3S 1477
3p26.1-p25.2
3p21.3-p21.2
3p21.2-p21.1
3p21.1-pl4.3
3pl4
Joneses/, 1992
Human genome mapping project
Jones et al, 1992
Jones et al, 1992
Human genome mapping project
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2.2.4.12. Sequencing.
a) Sample preparation from PCR reaction.
Amplification of DNA or cDNA was carried out as described in section 2.2.4.11. 
using a biotinylated "downstream primer" as detailed in tables 1 and 2
For each PCR reaction 20pl (200pg) of washed Dynabeads M-280 Streptavidin® 
was used. The beads were pre-washed by placing 20pi beads (lOpg/pl) into an 
eppendorf and placing in a Dynal Magnetic Particle Concentrator (MPC). The beads are 
collected on one side of the tube and the supernatant removed. The beads were 
resuspended in 20pl TES (lOmM Tris-HCl pH8.0, ImM EDTA, lOOmM NaCl), placed 
in the MCP and the supernatant again removed. The beads were finally resuspended in 
40pl TES to a final concentration 5pg/pl. The prewashed beads were added to an equal 
volume of PCR reaction and incubated for 15 minutes keeping the beads resuspended. 
The tube was placed in the MCP and the supernatant removed. lOOpl 0.15M NaOH was 
added, the beads resuspended and left at room temperature for 5-10 minutes. This 
converted the DNA to single-stranded form, the biotinylated strand being held onto the 
beads and the unbiotinylated strand was removed by placing the tube in the MCP and 
removing the NaOH solution (the unbiotinylated strand could be ethanol precipitated 
from this and used directly for sequencing). The beads were washed once with lOOpl 
TES, once with lOOpl H2O and resuspended in 7pi H2O for use in the sequencing 
reaction as outlined below.
b) Preparation of double-stranded plasmid DNA for sequencing.
Supercoiled DNA was separated from open-circular and linear DNA, RNA and 
other contaminants by separation on and purification from a 1% agarose gel as described 
in section 2.2.4.7b. The DNA spun from the filter paper was made up to 80pl with TE, 
denatured by adding 200mM NaOH, 0.2mM EDTA for 5 minutes at room temperature 
and precipitated by adding 0.5x volume 4M NH4AC and 2x volume ethanol at -20°C
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overnight. The DNA precipitate was microcentrifuged for 10 minutes, washed with 70% 
ethanol, dried and redissolved in 7pl H2O ready for sequencing as described below.
c) Sequencing reaction.
Sequencing was carried out essentially as described in the Sequenase® kit supplied 
by United State Biochemicals. 7pi DNA prepared as above was added to a solution 
containing 40mM Tris-HCl pH7.5, 20mM MgCl2,50mM NaCl and 20ng primer 
(detailed in table 4). The primer was annealed by incubation at 65°C for 2 minutes and 
slowly cooling to room temperature. The annealed DNA was labelled by adding lpl 
DTT (0.1M), lpl labeling mix (diluted 5 fold) and 0.5pCi (35S) dATP. 2pl Sequenase® 
version 2 enzyme (diluted 8 fold) was added to the mixture and incubated at room 
temperature for 5 minutes. 3.5pl of this labelling reaction was added to each termination 
mixture (2.5pl) pre-heated to 37°C and incubated at 37°C for a further 5 minutes. The 
reactions were stopped by adding 4pl stop solution. The samples were heated to 75°C 
for 2 minutes immediately prior to loading onto a polyacrylamide gel as described in 
section 2.2.4.13.
2.2.4.13. Polyacrylamide gel electrophoresis,
a) Analysis of amplified microsatellite PCR samples.
Polyacrylamide gels were used to separate radiolabelled amplified DNAs differing 
in size by approximately 4-20 base-pairs. 5-11% polyacrylamide gels (ratio 30% 
acrylamide : 0.8% bisacrylamide) were cast in lx TBE (90mM Tris, 90mM boric acid, 
2mM EDTA) buffer and polymerised with 420ptl APS and 42pl TEMED. The gel was 
poured between glass plates, pre-treated with repelcote, separated by 0.4mm spacers and 
a comb was inserted. After polymerisation the gel was placed in a vertical tank 
(Flowgen) with each end submerged in a reservoir of lxTBE.
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DNA samples (5ptl) were loaded into each well in loading buffer (30% glycerol, 
0.25% bromophenol blue, 0.25% xylene cyanol) and run at 25W until the bromophenol 
blue dye (lower dye front) reached the bottom of the gel. Gels were of a percentage 
such that the microsatellite band ran halfway between the bromophenol blue and xylene 
cyanol bands in order to achieve maximum separation. The gel was then removed from 
the apparatus and transferred onto Whatman 3MM paper. It was covered in SaranWrap 
and exposed to Kodak X-OMAT S or X-OMAT AR film with intensifying screens at -70 
°C.
Loss of heterozygosity (LOH) was scored by comparing the number of allele bands 
between cell lines (SCC12B, SCC12F and swiss 3T3 fibroblast). Where two bands were 
clearly visible a cell line was marked as informative. If one of these bands has been lost 
in another cell line then this was regarded as LOH. If all the cell lines showed only one 
band then these were scored as either uninformative or loss in all cell lines.
Microsatellite analysis at each locus was repeated at least twice.
b) Analysis of sequencing reactions.
Sequencing reactions were analysed by denaturing gel electrophoresis. An 8% 
polyacrylamide gel (ratio acrylamide to bisacrylamide 29.1:0.9) in TBE containing 50% 
(w/v) urea was polymerised with 0.04% APS and 0.05% TEMED between gel plates 
pretreated with repelcote. The gel was then placed in a vertical apparatus (Flowgen) 
with both ends submerged in lxTBE buffer. Samples were heated to 75°C for 2 minutes 
and loaded onto the gel using a sharks-tooth comb. The gel was run at 40W for 
approximately 3 hours. The gel was transferred onto 3MM Whatman paper, covered 
with SaranWrap and dried at 80°C for 2 hours. The gel was exposed directly onto 
Kodak X-OMAT AR or S film at room temperature. Autoradiographs were read from 
the bottom (51 end of DNA) upwards.
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2.2.4.14. Dot Blot analysis
DNA or cDNA was amplified by PCR as above and serial dilutions of each sample 
made. 20pl of diluted DNA was denatured by adding lOOpl 0.4M NaOH, 25mM EDTA 
and heating to 95°C for 2 minutes. The samples were then placed on ice and lOOpl lOx 
SSC (1.5M NaCl, 0.15M sodium citrate pH7.0) was added. The Hybond nylon filter 
was moistened in 20x SSC (3M NaCl, 0.3M sodium citrate, pH 7.0) and fitted into a dot 
blot manifold attached to a vacuum. Each denatured DNA solution was added to the 
appropriate well followed by lOOpl lOx SSC and allowed to dry under a vacuum for a 
further 10 minutes. The filter was removed from the manifold and allowed to dry 
overnight.
Oligonucleotides (synthesised as described in section 2.2.4.10) specific to either 
wild-type (5 ’ ACATAGTGTGGTGGTGCCCT 3’) or the 216 p53 mutant 
(5’ ACATAGTGGGGTGGTGCCCT 3’) were labelled with y 32P dATP. lOOng of each 
oligonucleotide was incubated with 50mM Tris-HCl pH7.5, lOmM MgC^, 5mM DTT, 
O.lmM spermidine, O.lmM EDTA, 50pCi y 32P dATP and 20 units T4 polynucleotide 
kinase for 45 minutes at 37°C. The labelled probe was purified on a sephadex G-25 nick 
column. Prior to use the column was washed with 1ml TE and the probe added and 
eluted in the second volume of 400pl TE added to the column. Radioisotope 
incorporation in the probe was measured using a scintillation counter.
The filter was cut into strips and crosslinked on a UV lightbox, DNA side down, 
for 5 minutes and the other side for 1 minute. The filters were pre-hybridised in 
hybridisation buffer containing 5x SSPE (0.75M NaCl, 44mM NaH2P0 4 , 5mM EDTA), 
5x Denhardts solution (0.1% (w/v) ficoll 400, 0.1% (w/v) polyvinylpyrrolidone, 0.1% 
(w/v) BSA), 0.5% SDS, and lOOmM sodium pyrophosphate pH 7.5, for 1-2 hours at 
37°C. 5xl06 cpm/ml of labelled probe was incubated with the filter in hybridisation 
buffer for at least 2 hours at 37°C. The filters were then washed in 6x SSC twice, each 
time for 10 minutes at room temperature. Non-specifically bound probe was removed by 
washing the filters at exactly 61°C in 3M tetramethylammonium chloride (TMAC),
50mM Tris, pH 8.0, 2mM EDTA and 0.1% SDS for 20 minutes. This removed any
90
oligonucleotide mismatched by even 1 base pair. Monitoring the filter whilst washing 
ensured adequate washing. The filters were then washed again in 6x SSC at room 
temperature for 10 minutes, sealed in plastic and autoradiographed at -70°C for 2-16 
hours. Each dot blot was repeated at least twice.
2.2.4.15. Oligonucleotide site-directed mutagenesis
Mutagenesis was carried out as described in the Muta-gene® M l3 mutagenesis kit 
from Bio-rad and outlined briefly below. All bacterial strains and vector DNAs were 
supplied in the kit. Oligonucleotides were synthesised as described in section 2.2.4.10. 
and are detailed in table 5.
a) Cloning of DNA into Ml 3 vector
Wild-type p53 was removed from the vector pC53-SN3 by a Bam HI digest and 
was inserted into the Bam HI site in the vector M13mpl8 as described in sections
2.2.4.5 to 2.2.4.8.
b) Preparation of competent MV1190 cells and transformation with 
M13mpl8/p53
E.coli MVI190 is unable to utilise lactose or biosynthesis proline. The F  plasmid 
carries the proline synthesis gene and a truncated (3-galactosidase gene which can be 
complimented by a fragment coded for by M13 phage. If this fragment in M13 is intact 
(i.e. no insert) then cells carrying this phage will produce blue plaques in the presence of 
the inducer IPTG and the dye indicator x-gal. If DNA (to be mutated) has been 
successfully inserted into M l3 then colourless plaques will result. The F  plasmid 
necessary for pili formation via which M13 phage enters the cell is selected for as it 
allows growth in the absence of proline.
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MVI190 cells were streaked onto a glucose-minimal plate (77mM KH2P04, 
25mM K2HP04, 8mM NaCl, 19mM NH4Cl,lmM MgS04.7H20, 0.001% thiamine, 
0.2% glucose, 1.5% bactoagar) and grown at 37°C until colonies appear. This selects 
for cells containing the F  plasmid. A colony was used to inoculate 10 ml L broth and 
grown overnight. 250ml L broth was inoculated with enough overnight culture to give 
an OD60o 0-1 and grown to an OD 0.8-0.9. The cells were then pelleted at 5000 rpm for 
5 minutes at 4°C and resuspended in 50ml ice-cold lOOmM MgCl2 and left on ice for 30 
minutes. The cells were again pelleted and resuspended gently in 10ml ice-cold lOOmM 
CaCl2. A further 100ml CaCl2 was added and incubated on ice for 30-90 minutes. The 
cells were pelleted and resuspended in 12.5ml 85mM CaCl2, 15 % glycerol. The cells 
were aliquoted into 0.5mls and frozen in a dry ice/ethanol bath and kept at -70°C.
0.3ml competent MVI190 cells were transformed with 1-1 Ong ligation mixture on 
ice for 30-90 minutes. The cells were heat shocked at 42°C for 3 minutes and returned 
to ice. 10 or 50pl of transformed cells were added to 0.3 ml MV1190 overnight culture. 
50pl 2% X-gal and 20pl lOOmM IPTG were added to 2.5ml molten top agar (medium 
containing 0.7% bactoagar). This was cooled, added to the cells and immediately poured 
onto H agar plates (1% bactotryptone, 8mM NaCl, 1.5% bactoagar). The top agar was 
allowed to solidify and inverted overnight at 37°C. Clear plaques were picked and 
placed into 1ml TE and kept at 4°C.
Stocks of recombinant phage were prepared as described in Maniatis et al, 1989. 
Briefly, 50pl of MVI190 overnight culture was added to 2ml L broth. lOOpl of phage 
suspension was added and incubated for 5-6 hours at 37°C. 1ml was pelleted at 12,000g 
for 5 minutes and the supernatant containing the phage was stored at 4°C. The 
remaining culture was used to make a DNA miniprep from phage infected cells as 
described in Maniatis et al, 1989 and the presence of a correct insert verified by digestion 
as described in section 2.2.4.5.
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c) Titering phage.
The above M13 phage was titered on MV1190 cells. A colony of MV1190 cells 
was picked from a glucose minimal plate and used to inoculate 20ml L broth. This was 
grown overnight at 37°C. 3ml molten top agar was aliquoted into sterile tubes and kept 
at 55°C. The above phage stock was diluted in 4 serial, 100-fold dilutions in L broth. 
0.2ml of the MV1190 overnight culture was then added to lOOpl of the last 3 dilutions 
and incubated at room temperature for 5 minutes. One tube of top agar was mixed with 
each phage/culture mix and poured immediately onto an L broth agar plate. This was 
allowed to harden and then incubated at 37°C overnight. The number of plaques per 
plate were counted and the titer calculated using the formula:
titer = (no. plaques x 10 x dilution factor) pfu/ml.
d) Growth of Uracil-containing phage.
E.coli CJ236 has a dut-1, ung-1 phenotype which results in occasional uracils 
being substituted for thymine in all DNA synthesised in the bacterium. The F  plasmid 
which enables pili formation and phage infection was selected for by growing in the 
presence of chloramphenicol.
50ml 2xYT (1.6% bactotryptone, 1% yeast extract, 8mM NaCl) medium plus 
30pg/ml chloramphenicol was inoculated with 1ml CJ236 overnight culture and grown 
until ODgoo was 0.3 which corresponds to 1x10s cfu/ml. The titered phage was added 
to a multiplicity of infection of 0.2 and the culture further incubated at 37°C for 4-6 
hours. The cells were pelleted at 17,000g for 15 minutes. 150pg RNase A was added to 
the supernatant, containing the uracil containing phage, and incubated at room 
temperature for 30 minutes. 0.25x volume of 3.5M Nt^Ac, 20% PEG 8000 was added 
to the supernatant and held on ice for 30 minutes. The precipitate was collected by 
centrifugation at 17,000g for 15 minutes at 4°C. The pellet was drained and resuspended 
in 200pl high salt buffer (300mM NaCl, lOOmM Tris pH8.0, ImM EDTA). This was
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incubated for 30 minutes on ice, centrifuged briefly and the supernatant stored at 4°C. 
The efficiency of infection of the phage on CJ236 cells was calculated by titering the 
uracil-containing phage stock on CJ236 and MV1190 as described in part c) of this 
section. As uracil-containing phage are inactive on MVI190, the titer on MVI190 was 
104 or less lower than that on GJ236 cells indicating successful uracil incorporation into 
the M13 phage DNA.
Single-stranded DNA was extracted from the phage by phenol/chloroform 
extraction and precipitation with O.lx volume 7.8M NH4AC and 2.5x volume ethanol at 
-70°C for 30 minutes.The DNA was pelleted by centrifugation, washed and re-dissolved 
in TE.
e) Synthesis of mutant strand.
The oligonucleotide containing the required mutation was firstly phosphorylated by 
incubating 200pmol oligonucleotide with lOOmM Tris pH 8.0, 0.2M MgCl2, 0.1M DTT, 
ImM ATP, 4.5 units T4 polynucleotide kinase and incubating at 37°C for 45 minutes. 
The reaction was stopped by heating to 65°C for 10 minutes.
2-3pmol oligonucleotide was annealed to 200ng uracil-containing DNA in 20mM 
Tris-HCl pH7.4,2mM MgC^, and 50mM NaCl. The reaction was heated at 70°C for 5 
minutes, cooled slowly to 30°C, then placed on ice.
The complementary DNA strand was synthesised by adding 0.4mM of each of 
dATP, dTTP, dCTP, dGTP, 0.75mM ATP, 17.5mM Tris-HCl pH7.4, 3.75mM MgCl2, 
21.5mM DTT, 2-5 units T4 DNA ligase and 0.5 units T7 DNA polymerase to the above 
and leaving on ice for a further 5 minutes. The reaction was continued at 25°C for 5 
minutes followed by 37°C for 30 minutes and stopped by adding 90pl lOmM Tris pH8.0, 
lOmM EDTA and freezing.
The mutant phage DNA was then transformed into MVI190 (which will only 
replicate the non-uracil containing template i.e. mutant sequence) as described in part 
b) of this section. Single-stranded DNA was prepared as in part d) and sequenced as 
described in section 2.2.4.12. to identify phage carrying the required mutation.
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2.2.5. Cytogenetics
2.2.5.1. Preparation of metaphase chromosome spreads from human 
SCC for FISH
Glass slides were pre-soaked in a solution of 3% conc. HC1 in 70% methanol:
30% H2O for a minimum of 1 hour but not more than 24 hours. Slides were then rinsed 
in distilled water and stored at 4°C until required.
0.03pg/ml colcemid was added to 50% confluent monolayers of SCC cell lines in 
5cm dishes and incubated for 2.5-3 hours. The cells were then trypsinised and pelleted at 
lOOOrpm for 5 minutes. The pellet was flicked up and 1.5ml hypotonic solution (0.075M 
KC1 pre-warmed to 37°C) was added drop-wise, using a pasteur pipette, with constant 
agitation. A further 5ml was added, the tube inverted and incubated at 37°C for 18 to 20 
minutes. The swelling was stopped by adding 10 drops of freshly prepared Camoy’s 
fixative (3:1 methanol: glacial acetic acid), inverting to mix and pelleting the cells as 
above. The pellet was again gently flicked up and resuspended in 1.5ml freshly prepared 
fixative with constant agitation to prevent clumping. A further 5ml fixative was added, 
mixed by inverting and incubated at room temperature for 10 minutes. The cells were 
again pelleted and resuspended in fixative as above and incubated for 30 minutes at room 
temperature. The cells were pelleted and resuspended in sufficient fixative to give 
correct density for dropping slides.
50(0.1 aliquots of the above metaphase preparations were dropped onto the prepared 
drained slides. The slides were allowed to air dry before checking the spreads.
Slides used for FISH analysis were aged for 1-2 weeks before use. This was found 
to lower background.
2.2.5.2. Fluorescence In situ hybridisation (FISH).
The slides carrying the chromosome spreads were fixed in freshly prepared 
Camoy’s fixative for 1 hour and rinsed in 2x SSC. They were then treated with
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lOOpg/ml RNase in 2x SSC for 1 hour at 37°C and rinsed in 2x SSC. Protein was 
digested by incubating the slides in 0.01% pepsin in 0.01 M HC1 for 10 minutes at 37°C, 
then rinsed in PBS. The spreads were fixed again by placing in Streck tissue fixative for 
10 minutes at room temperature. The slides were then rinsed in PBS and dehydrated 
twice in 70% ethanol for 2 minutes and twice in 100% ethanol for 2 minutes and allowed 
to air dry.
The chromosomes were denatured on the slides in 70% formamide in 2x SSC at 70 
°C for 5 minutes. The slides were then washed in a large volume of 70% ethanol and 
dehydrated in 70% ethanol and 100% ethanol as before.
The p53 cosmid probe (p5106-DIG) was denatured immediately before use, at 37° 
C for 5 minutes. The chromosome 17 centromere probe (aCHAD 9) was diluted 1:25 
and denatured at 70°C for 5 minutes. 10pl of each probe was dropped onto the spreads 
and covered with a coverslip. Cowgum was used to seal around the edges of each 
coverslip and the slides were placed in a dark, humidified box at 37°C overnight.
The coverslips were removed in 2x SSC and the slides washed twice in 50% 
formamide, lx SSC at 42°C for 20 minutes. The slides were then washed in 2xSSC at 
42°C for 20 minutes. The probe was detected by firstly blocking in PN-TB (0.1M 
NaH2PC>4, 0.1M Na2HPC>4, 0.05% Tween) buffer for 15 minutes at room temperature. 
lOOpl primary antibody (sheep anti-digoxigenin, diluted 1:200 in PN-TB) was placed 
onto each slide and covered with parafilm. The slides were incubated for 1 hour, in the 
dark, at room temperature. The slides were then washed for 10 minutes in PN-TB at 
room temperature. The secondary antibody, F1TC conjugated donkey anti-sheep, was 
diluted 1:500 in PN-TB and lOOpl placed on each slide as described above. The slides 
were again incubated for 1 hour at room temperature in the dark. The slides were finally 
washed in PN-TB for 20 minutes at room temperature, dehydrated in 70% and 100% 
ethanol as before and mounted in antifade medium (Vectashield).
Hybridisations were analysed using a Biorad confocal microscope MRC600 with a 
krypton argon laser.
96
Chapter 3
Genetic analysis of SCC12B and SCC12F
3.1. Characterisation of SCC12F and SCC12B.
SCC12B and SCC12F were originally derived from the same tumour but appear to 
differ in their ability to terminally differentiate and undergo controlled cell death when 
detached from the culture dish and also differ in their degree of tumorigenicity as 
discussed in section 1.1.2. The two cell lines were therefore analysed for genetic 
differences in order to try and explain their different phenotypes.
3.1.1. Chromosome 9.
Microsatellite analysis was carried out on both arms of chromosome 9 using a wide 
range of primers as detailed in table 3 (section 2.2.4.11). These microsatellites were 
investigated in SCC12F and SCC12B as they have previously been reported to show a 
high degree of LOH in SCC-HN (Loughran et al., 1994; Edington et al., 1995). There is 
also an 84% chance of LOH at 9p21 in both lines based on the fact that the chance of all 
six microsatellites in this region being non-informative is less than 16% (Loughran et al., 
1994; Latif etal., 1992).
Loss of heterozygosity (LOH) at a certain locus is usually scored by comparing the 
number of allele bands between tumour DNA and normal DNA from the same individual. 
In this case normal DNA was not available for analysis but it was sufficient to compare 
SCC12F with SCC12B to highlight any differences in LOH between the two cell lines. 
Examples of PCR of microsatellite allele bands GSN and D9S157 are illustrated in figure 
3.1 and the complete data is summarised in figure 3.2. Clones 19 is a single cell clone of 
SCC12F (see section 5.1.1 for further details). Swiss 3T3 fibroblast DNA was included 
as a control in order to eliminate any microsatellite amplification due to contamination of 
the cell line DNA with feeder DNA. No microsatellite amplification from the 3T3 DNA 
was observed at any loci. Where two bands were visible in all cell lines, this was marked 
as informative and no loss of heterozygosity. If one allele band had disappeared but was 
clearly visible in the other cell lines then this was recorded as loss of heterozygosity. If 
only one band was apparent in all cell lines then these were scored as either
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Figure 3.1
Microsatellite analysis of chromosome 9
Microsatellite amplification at two loci, GSN (top) and D9S157 (bottom) on 
chromosome 9 are shown for examples. The remaining microsatellite data is summarised 
in figure 3.2.
Cell lines SCC12B, SCC12F and two clones of SCC12F clone 19 and clone 24 are 
compared. 3T3 DNA was incorporated to eliminate the possibility of contamination 
from feeder cells. No microsatellite amplification from 3T3 DNA was observed at any 
loci.
GSN (top) Amplified microsatellite DNA was electrophoresed on a 9% polyacrylamide 
gel and the product size was approximately 89-117bp. The microsatellite band is shown 
by the lower arrow and the shadow band above.
D9S157 (bottom) Amplified microsatellite DNA was electrophoresed on a 10% gel and 
the product size was 133-157bp. The microsatellite and shadow bands are again shown 
by the arrows.
Both loci show amplification of only one allele band in all four lanes.
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noninformative or loss in all cases but as no normal DNA was available to make 
comparisons this result was inconclusive. Results are expressed as amplification of one 
allele or two alleles (figure 3.2) and SCC12F, SCC12B and clone 19 were compared.
The "shadow" bands (shown by the arrows on figure 3.1) appearing at larger 
increments are common in PCR of microsatellites. It is unclear as to what they 
represent or how they can be eliminated, but it has been suggested that where there is a 
vast excess of primers, the shadows are caused by amplified, partially denatured product 
with extra primer bound at the denatured ends (D.Black, personal communication).
As summarised in figure 3.2, no differences in the amplification of microsatellites 
investigated on chromosome 9 between SCC12B, SCC12F and clones 19 was apparent.
3.1.2. Chromosome 3p
Microsatellite analysis was also carried out on the short arm of chromosome 3 
using the primers as detailed in table 3 (section 2.2.4.11). These loci have previously 
been shown to exhibit a high degree of LOH in SCC-HN (Latif et a l , 1992; Edington et 
al., 1995) and therefore were good candidates on which to find differences in LOH in 
SCC12B and SCC12F.
An illustration of amplified microsatellite allele bands obtained from primers 
D31067 and D31038 are shown in figure 3.3 and the complete micosatellite data for 
chromosome 3p is reported in figure 3.4. Results were scored as for chromosome 9 
described in section 3.1.1.
No differences in the microsatellite amplification pattern on the short arm of 
chromosome 3 were observed between SCC12B, SCC12F and clones 19.
3.1.3. Cyclin D1
Cyclin D1 protein levels were compared between SCC12B, SCC12F and clone 19 
by western analysis. Results are shown in figure 3.5. BICR 6 was used as a positive 
control as it has been shown to overexpress cyclin D1 ( Nikolic et al, submitted for
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Figure 3.3.
Microsatellite analysis of chromosome 3
Microsatellite amplification at two loci, D3S1067 (top) andD3S1038 (bottom), on 
chromosome 3 are shown for examples. The remaining data is summarised in figure 3.4
Cell lines SCC12B, SCC12F and two clones of SCC12F clone 19 and clone 24 are 
compared. 3T3 DNA was incorporated to eliminate the possibility of contamination 
from feeder cells. No microsatellite amplification from 3T3 DNA was observed at any 
loci.
D3S1067 (top) Amplified microsatellite DNA was electrophoresed on a 10% 
polyacrylamide gel and the product size was approximately 95bp. The microsatellite and 
shadow band are shown by the arrows.
This microsatellite showed amplification of only one allele band in all four cell lines.
D3S1038 (bottom) Amplified microsatellite DNA was electrophoresed on a 10% 
polyacrylamide gel and the product size was approximately 115bp. The microsatellite 
and shadow bands are shown by the arrows.
All cell lines were heterozygous at this microsatellite showing amplification of both allele 
bands in all four cell lines.
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Figure 3.3 Microsatellite analysis of chromosome 3
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publication). Human cyclin D1 was seen as a band at approximately 34kDa and a 
mouse specific peptide was seen as a faint band approximately lOOkDa. This lOOkDa 
band was used as an indicator of the extent of contamination of mouse 3T3 feeders in the 
protein extract, and as can be seen from the western this contamination was very low.
The western blot shows that there is no difference in the levels of cyclin D1 protein 
expression between cell lines SCC12B, SCC12F and clone 19.
3.2 Analysis of p53 in SCC12B and SCC12F
1 The p53 tumour suppressor gene is frequently mutated m a wide variety ot cancers 
(discussed in section 1.4.3.1.) and has been shown to be important in the progression of 
tumours in the oral cavity (Gusterson et al., 1991; Bums et al., 1993; Bums et al., 1994a 
and b). It is therefore of interest to analyse and compare the p53 status in SCC12F and 
SCC12B in order to assess the role that p53 plays in the progression of this particular 
tumour.
The level of p53 protein is very low in normal cells due to its short half-life and is 
therefore difficult to detect by conventional protein detection methods such as western 
blotting and immunoprecipitation. Mutation of p53 however leads to a highly stabilised 
protein with a much increased half-life that is readily detected by these methods. The 
detection of high levels of p53 is therefore used as an early indication that the protein 
may have acquired a mutation and indeed in SCC-HN overexpression of the protein has 
been shown to always correlate with a p53 missense mutation or an in-frame deletion 
(Bums etal., 1993; Bums etal., 1994b).
3.2.1. p53 protein levels
p53 protein levels were analysed in SCC12B, SCC12F and single-cell clones of 
SCC12F clone 19 and clone 24 as shown in figure 3.6. SCC4 was used as a positive 
control as it has been shown to have a stabilised p53 protein and a point mutation at 
codon 151 (Bums etal., 1993). HFF9 cells (human foetal fibroblasts) express wild-type
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F ig u r e  3 .5  W e s te r n  blot a n a ly s is  o f  C y c lin  D1 in S C C  cell lines
50ug of protein extracts were electrophoresed through a 107c denaturing 
polyacrylamide gel and blotted, as described in materials and methods.
The rabbit polyclonal antibody (287-3) was used at a 1:500 dilution.
BICR 6 cell line overexpresses human p34 cyclin D1 and wasused as a positive 
control. Arrows point to a murine specific peptide ~ lOOkD and the 
cyclin D1 specific 34kD protein.
F i g u r e  3 .6  W e s t e r n  b lo t  a n a l y s i s  o f  p 5 3  in  S C C  c e l l  l in e s
250ug of protein extracts were electrophoresed through a 107c denaturing 
polyacrylamide gel.as described in materials and methods. The antibody PAbl 801 
was used at a final concentration of lug/ml. SCC4 expresses mutant p53 containing 
a mutation at codon 151. HFF9 cells express wild-type p53 which can 
hardly be detected. Arrow points to p53 protein.
p53 therefore giving a very faint p53 signal in this assay. This cell line also enabled the 
p53 protein band to be identified as the lower of the two bands shown in figure 3.6 
migrating at approximately 53kDa and often seen as a doublet (Harlow et al, 1985).
Interestingly, SCC12B appears to have very high levels of p53 compared with 
SCC12F. Clones of SCC12F have variable levels of p53 protein (see also figure 5.1) and 
clone 19 was used as a target cell in subsequent experiments (see section 5.1.).
3.2.2 Identification of a p53 mutation in SCCI2B and SCC12F
Detection of high levels of p53 protein indicates the presence of a stabilised p53 
protein and suggests the possibility of a p53 mutation. SCC12B and SCC12F appear to 
have different levels of p53 protein (as shown in the above section) and were therefore 
sequenced for a p53 mutation. Total RNA was reverse transcribed into cDNA and 
various fragments of p53 were amplified by PCR using the p53 specific primers which 
are detailed in table 1. The location of the PCR primers and also the sequencing primers 
within the p53 cDNA are illustrated in figure 2.1. The complete coding sequence, 
codons 1-393 of p53 cDNA was sequenced in both cell lines. SCC12B was found to 
contain a novel p53 mutation at codon 216, a T—»G transversion causing a valine to be 
substituted for a glycine, as shown in figure 3.7. Interestingly, the mutation appears to 
be a heterozygous one with the wild-type p53 allele unusually still being expressed. 
SCC12F expresses much less p53 protein (figure 3.6) and accordingly appears to express 
very little p53216 mutant transcript as shown by the very faint additional G base 
highlighted by the arrow on the sequence in figure 3.7. SCC12F appears to mostly 
express the wild-type p53 allele. The normal wild-type sequence at codon 216 from 
BICR 3 (which has been shown to have an alternative mutation at codon 282 (Bums et 
al, 1993) is shown in figure 3.7 for comparison.
Exon 6 amplified DNA from both cell lines was sequenced directly with primer 6U 
(table 2) and identical results were obtained as from RNA |
Whilst searching for a mutation in p53 a polymorphism was identified at codon 72 
exchanging a proline for an arginine in both cell lines. Differences in the sequence of
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codon 72 have been observed by other investigators analysing cDNA and genomic DNA 
from various sources (Buchman et al, 1988; Lamb and Crawford, 1986). This amino acid 
change has been shown to cause a difference in protein mobility on SDS-polyaciylamide 
gels. It is a fairly frequent polymorphism and both forms of p53 have been shown to be 
functional. The presence of this polymorphism in both cell lines is further proof that 
SCC12F and SCC12B originated from the same tumour.
3.2.3. p53 gene dosage in SCC12F and SCC12B
Both western blot analysis and sequencing of p53 as shown previously, showed 
that SCC12F and SCC12B express different dosages of wild-type and mutant p53216 
protein. The dosage of each were quantified further by dot blot analysis probing both 
cDNA amplified with primers K and G and DNA amplified with 6U and 6D. Equal 
amounts of amplified cDNA or DNA (as judged by agarose gel electrophoresis) were 
used for each cell line and 2 fold dilutions were added to the filter vertically. Normal 
human keratinocytes (HEK) was used as a control for background hybridisation.
The cDNA dot blot is shown in figure 3.8a. The density of each spot was 
measured by molecular dynamics laser densitometry using PDI image analysis software 
and is summarised in figure 3.8b. The dot blot confirms that SCC12B expresses more 
mutant p53 transcript than SCC12F and the PDI measurements suggests that there is a 
two fold difference if the density of each spot at varying dilutions are compared between 
the two cell lines. The background hybridisation is very low as shown by the lack of 
hybridisation of the mutant probe to HEK cDNA.
The blot probed with the wild-type oligonucleotide shows that SCC12F and 
SCC12B appear to express lower levels of wild-type p53 than HEK cells. This is not 
surprising in the case of SCC12B which has been shown to express mutant and wild-type 
sequences and it is therefore likely that the level of wild-type p53 would be lower than in 
normal HEK cells. However sequence analysis suggests that SCC12F expresses mostly 
wild-type DNA and RNA. The difference in the wild-type spot intensities on the cDNA 
dot blot in figure 3.8 and also on the DNA dot blot in figure 3.9 between SCC12F and
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Figure 3.8a
cDNA dot blot analysis
Total RNA from HEK, SCC12B and SCC12F was reverse transcribed and amplified 
by PCR using primers K—»G. Equal amounts of DNA were hybridised to each filter 
with two fold serial dilutions added vertically. Either wild-type p53 (right) or p53216 
mutant (left) oligonucleotide was used as a probe and any non-specific binding was 
removed by washing in TMAC at 61 °C as described in section 2.2.4.14.
Figure 3.8b
Densitometry measurements
The density of each spot in the dot blots in figure 3.8a above were measured by 
molecular dynamics laser densitometry using PDI image analysis software. Each 
measurement illustrated in the table corresponds to the dot in the identical position on 
the blots in figure 3.8a. Density is measured in pixel density units (ODxMM2) which 
is a function of spot intensity and the number of pixels covered. Only those dots that 
can be seen by eye are included in the tables.
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Figure 3.8a
216cDNA dot blot probed with wild-type or p53 mutant oligonucleotides.
216p53 mutant probe wild-type p53 probe
Figure 3.8b Densitometry measurements
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Figure 3.9a
DNA dot blot analysis
Exon 6 of p53 DNA was amplified using primers 6U and 6D from HEK, SCC12B, 
SCC12F and a clone of SCC12F, clone 19. Equal amounts of DNA were hybridised 
to each filter with two fold serial dilutions added vertically. Either wild-type p53 
(left) or p53216 mutant (right) oligonucleotide was used as a probe and any non­
specific binding was removed by washing in TMAC at 61°C as described in section 
2.2.4.14.
Figure 3.9b
Densitometry measurements
The density of each spot in the dot blots in figure 3.9a above were measured by 
molecular dynamics laser densitometry using PDI image analysis software. Each 
measurement in the tables corresponds to the dot in the identical position on the blots 
in figure 3.9a. Density is measured in pixel density units (ODxMM2) which is a 
function of spot intensity and the number of pixels covered. Only those dots that 
could be seen by eye are included in the tables.
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Figure 3.9a
216
DiNA dot blot probed with wild-type or p53 mutant oligonucleotide.
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HEK are therefore hard to explain. It may be that SCC12F does have less wild-type 
sequence as a result of aneuploidy or it may be simply that HEK DNA and RNA is more 
easily and cleanly amplified than tumour DNA. More importantly,comparison of the 
hybridisation of the wild-type probe to SCC12F and SCC12B (figure 3.8a) suggests that 
SCC12F may have a two fold increase of wild-type transcript as compared to SCC12B. 
This was repeated and the results confirmed.
The dot blot was repeated using DNA as shown in figure 3.9a and the density 
measurements summarised in figure 3.9b. Although this blot was difficult to reproduce 
identically, it does again show that SCC12B contains more mutant p53 than SCC12F. 
The blot probed with wild-type p53 oligonucleotide does not indicate any difference 
between the level of wild-type p53 in the two cell lines unlike the cDNA dot blot in 
figure 3.8a. It does however show that a single cell clone of SCC12F, clone 19, contains 
more wild-type p53 than SCC12B and SCC12F. Hybridisation of the p53216 mutant p53 
oligonucleotide to DNA from each cell line confirms that SCC12B also contains more 
mutant p53 DNA than any other cell line.
Dot blot analysis of SCC12F and SCC12B at both the DNA and RNA levels 
together with the sequencing data has shown therefore that SCC12B expresses more 
mutant p53216 than SCC12F, and the densitometry measurements suggest this to be by a 
2:1 ratio respectively. Also SCC12F and clones of SCC12F may express more wild-type 
p53 than SCC12B.
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3.2.4. Analysis of chromosome 17 number in SCC12F and SCC12B by
fluorescent in situ hybridisation (FISH).
Taken together the analysis of p53 by western blot, sequencing and dot blot in 
SCC12B and SCC12F have indicated a difference in the wild-type to mutant p53216 
dosage between the two cell lines. It is therefore important to establish the number of 
p53 genes and as the p53 gene maps to chromosome 17pl3.1, the number of copies of 
chromosome 17 in these two cell lines, so that a clearer picture of the p53 status in these 
two cell lines can be established.
The number of chromosome 17 copies in SCC12F, SCC12B and clone 19 was 
analysed by FISH using a chromosome 17 centromere probe as shown in figure 3.10. 
Fluorescence was analysed on a Bio-rad MRC-600 laser scanning confocal microscope 
equipped with a krypton/argon ion laser. Hybridisations of the probe were visualised 
with FITC (pseudocoloured green) using 488/568nm line excitation and dual channel 
522 and 585nm emission filters.
Metaphase chromosomes from normal human blood lymphocytes were used as 
a control for hybridisation frequency. Two signals were visualised on most normal 
chromosome spreads as shown in figure 3.10 and an average hybridisation frequency (i.e. 
average number of signals / spread) of 1.93 was achieved. In comparison, three signals 
were observed on the metaphase spreads of clone 19, SCC12B and SCC12F as indicated 
by the arrows. These signals were localised to the centre of each chromosome and only 
one signal was obtained per chromosome as expected with a centromeric probe. The 
hybridisation frequencies for each cell line ranged between 2.9 and 3.1. and no gross 
structural rearrangements of chromosome 17 was observed.
Clone 19, SCC12B and SCC12F therefore all carry three copies of chromosome
17.
113
3.2.4. Analysis of chromosome 17 number in SCC12F and SCC12B by
fluorescent in situ hybridisation (FISH).
Taken together the analysis of p53 by western blot, sequencing and dot blot in 
SCC12B and SCC12F have indicated a difference in the wild-type to mutant p53216 
dosage between the two cell lines. It is therefore important to establish the number of 
p53 genes and as the p53 gene maps to chromosome 17pl3.1, the number of copies of 
chromosome 17 in these two cell lines, so that a clearer picture of the p53 status in these 
two cell lines can be established.
The number of chromosome 17 copies in SCC12F, SCC12B and clone 19 was 
analysed by FISH using a chromosome 17 centromere probe as shown in figure 3.10. 
Fluorescence was analysed on a Bio-rad MRC-600 laser scanning confocal microscope 
equipped with a kiypton/argon ion laser. Hybridisations of the probe were visualised 
with FITC (pseudocoloured green) using 488/568nm line excitation and dual channel 
522 and 585nm emission filters.
Metaphase chromosomes from normal human blood lymphocytes were used as 
a control for hybridisation frequency. Two signals were visualised on most normal 
chromosome spreads as shown in figure 3.10 and an average hybridisation frequency (i.e. 
average number of signals / spread) of 1.93 was achieved. In comparison, three signals 
were observed on the metaphase spreads of clone 19, SCC12B and SCC12F as indicated 
by the arrows. These signals were localised to the centre of each chromosome and only 
one signal was obtained per chromosome as expected with a centromeric probe. The 
hybridisation frequencies for each cell line ranged between 2.9 and 3.1. and no gross 
structural rearrangements of chromosome 17 was observed.
Clone 19, SCC12B and SCC12F therefore all carry three copies of chromosome
17.
113
Figure 3.10 FISH analysis of chromosome 17
Lymphocytes Clone 19
' - ' T V
V &
SCC12B SCC12F
Chromosome 17 number was analysed in Clone 19. SCC12B andSCC12F using the 
centromeric probe alpha-CHAD 9. Metaphase spreads are shown for each cell line. 
Chromosomes are counter stained red and the hybridisations are shown in green.
3.2.5. Analysis of p53 gene amplification in SCC12F and SCC12B by
fluorescent in situ hybridisation (FISH).
As the p53 gene is located on chromosome 17p and we have observed an 
amplification of chromosome 17 in clone 19, SCC12F and SCC12B as well as a 
difference in the mutant to wild-type p53 gene dosage it was of interest to analyse the 
p53 gene copy number in these cell lines and to see if this correlates with the numbers of 
chromosome 17
FISH was carried out as described in section 2.2.5. and the fluorescence was 
observed as described in section 3.2.4. Metaphase spreads from normal human 
lymphocytes were again used as a control and as shown in figure 3.11. As expected four 
signals were observed, one on each chromatid consistant with the presence of two copies 
of the p53 gene. The observed hybridisation frequency was again 1.9. Six signals were 
however visualised on each metaphase spread from Clone 19, SCC12F and SCC12B as 
shown in figure 3.11. The hybridisation frequency ranged from 2.8-3.0 for each cell line. 
Two signals were visualised per chromosome and these were located at the ends of the 
short arms of the chromosomes consistent with the position of the p53 gene.
Therefore clone 19, SCC12F and SCC12B all carry three copies of the p53 
gene and although double hybridisations were not carried out it is assumed that as there 
are also three copies of chromosome 17 that each p53 gene lies on a the short arm of 
chromosome l7andhas not been translocated to another chromosome.
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Figure 3.11 Detection of p53 gene copies by FISH.
Lymphocytes Clone 19
. 3 R y %
SCC12B SCC12F
p53 copy number was analysed in clone 19. SCC12F and SCC12B using the p53 
probe p 5 106-DIG. Metaphase spreads are shown for each cell line. 
Chromosomes are counterstained red. and p53 hybridisations green.
Chapter 4 
Characterisation of p53216 mutant.
2164.1 Characterisation of the p53 Val —>Gly mutant.
4.1.1. Synthesis of recombinant p5 3 mutants.
p53 mutants, p53216 val—>gly and P53248 arg -»trp were synthesised using the 
Biorad M13 mutagenesis kit as described in section 2.2.4.15. Wild-type p53 removed 
from the vector pC53-SN3 was used as the template and was placed into M13mpl8 for 
mutagenesis. Once synthesised each p53 mutant was completely sequenced to check 
that only the required mutation had been incorporated. To further ensure any phenotype 
produced by the p53216 mutant was actually due to the acquisition of this mutation alone 
and not by some other spontaneous mutation which frequently occurs in culture, two 
p53216 mutant clones were selected and used in subsequent experiments, namely 216 (1) 
and 216 (2). The mutants were returned to the pCMV-Neo-Bam vector where the p53 
cDNA is under the transcriptional control of the cytomegalovirus (CMV) promoter 
enhancer and the neomycin resistance gene is under the control of the simian virus 40 
(SV40) promoter enhancer.
2164.1.2. Loss of growth suppressive function of p53 mutant.
The introduction of wild-type p53 into a cell causes the arrest of cellular 
proliferation in G1 ( Baker et al., 1990; Casey et al., 1991; Diller et al., 1990; Mercer et 
al., 1990). Indeed as discussed in section I.4.3.6., one of the known functions of wild- 
type p53 is to induce a G1 arrest after DNA damage to allow the cell to undergo any 
necessary repair before proceeding further through the cell cycle. Escape from this cell 
cycle checkpoint is an important step in the progression of oncogenesis, and many 
different types of tumours have been shown to inactivate p53 by acquiring a p53 
mutation in one allele followed by loss of the other wild-type p53 allele during the 
progression of the cancer. In order to investigate whether the p53216 mutant observed in 
SCC12B is an important player in the progression of this tumour it is important to
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Figure 4.1 Expression o f p53 m utant constructs in Saos-2 cells
Saos-2 cells were transfected with p53~16 val— gly (a and b). wild-type 
p53 (c and d) and CMV vector alone (e and f) and stained with PAblSOl 
to show p53 expression pattern. Phase contrast (left) and green filter (right) 
photographs are shown. Arrows indicate nuclear staining in b. and 
cytoplasmic staining in d.
Bar = lOum —
establish that this mutant has lost its ability to suppress cell growth and is not a silent 
mutation or a polymorphism.
Saos-2 is a human osteosarcoma cell line with no endogenous p53 due to the 
deletion of both p53 alleles. Previous experiments have shown that Saos-2 cells cannot 
tolerate the expression of wild-type p53 (Diller et tf/,1990) and other investigators 
(Frebourg et al, 1992; Chen et al, 1990) have used Saos-2 cells to reveal various 
properties of p53 mutants. This therefore provided an ideal target on which to test the
p i  /:
growth suppressive ability of the p53 mutant. It also allowed the expression of p53 
from the CMV promoter to be analysed before its use in subsequent experiments.
The p53216 val—>gly mutant was transfected into Saos-2 cells along with 
p53248arg-»trp, p53143ala—m l  mutant (pC53-SCX3), wild-type p53 (pC53-SN3) and 
the vector containing no p53 insert (pCMV-Neo) as described in section 2.2.1.4.
Phase contrast photographs of the expression of each p53 protein in Saos-2 cells 
is shown in figure 4.1. Figure 4.1a shows the expression of p53216 protein. This mutant 
protein is expressed at high levels in the nucleus of the cells as shown by the arrows. 
Visualising the staining through a green filter enhances this nuclear expression pattern as 
shown in figure 4.1b. Expression of p53248 and p53148 were identical to figure 4.1a and 
b (data not shown). No p53 protein expression was seen in cells transfected with vector 
alone ( figure 4.1e and f) as expected. Slight background staining appears when 
visualised through a green filter (figure 4.If). Few colonies were expected from cells 
transfected with wild-type p53 due to its growth suppressive properties (see also figure 
4.2). Those that arose mostly showed abnormal expression of the p53 protein in the 
cytoplasm (figure 4.1c) which is seen clearer in the photograph taken with a green filter 
(4.Id) and identified as cytoplasmic by comparison with the nuclear pattern seen in figure 
4.1b. The ability of these colonies to survive the expression of wild-type p53 and its 
abnormal cytoplasmic expression suggests that the protein is inactive and although the 
protein in these cells was not sequenced it is likely that they have accummulated a 
mutation which has prevented nuclear targetting.
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Figure 4.2
Expression of various p53 mutants in Saos-2 cells.
□  % cytoplasmic staining 
■  % nuclear staining
2 1 6 ( 1 )  2 4 8  143 w ild -ty p e  vec to r
p53 construct
Various p53 constructs were transfected into Saos-2 cells as described in methods 
section 2.2.1.4. Transfected cells were plated at 4xl05 cells /10cm dish.
Colonies were selected with 500ug/ml G418 and were visible within 3 weeks.
The percentage of total cells plated that gave rise to resistant colonies for each 
construct was 216(1) 0.4%; 248 0.6%; 143 0.9%; wild-type 0.3% 
and vector 0.6%.
Whole plates were stained for p53 expression using PAbl801.
Positively stained cells were counted under a light microscope for p53 expression 
and it was noted whether this expression was the usual nuclear pattern or whether 
expression was mostly cytoplasmic, indicating a non-functional protein. 
p53 constructs used were : 216 gly - val, 248 arg - trp, 143 ala - val or wild-type 
p53 inserted into the pCMV-Neo vector or vector alone.
Saos-2 colonies positive for p53 staining were counted in each transfection and 
the positionof the protein expression, either nuclear or cytoplasmic, was noted. Results 
are shown in the graph in figure 4.2. 66-70% of Saos-2 cells transfected with either the 
p53216, p53248 or p53143 mutants tolerated the expression of the mutant p53 protein and 
this expression was almost entirely nuclear (shown by the solid shading in figure 4.2). In 
comparison only 11% of the Saos-2 cells transfected expressed wild-type p53 and of 
these, 8% expressed the p53 protein abnormally in their cytoplasm. This therefore shows 
that the p53216 mutant identified in SCC12B as well as has P53248 and p53143 mutants 
have lost their growth suppressive properties and cells are able to tolerate the expression 
of these mutant proteins. The p53216 mutant therefore actively contributes to the 
oncogenic phenotype of SCC12B by preventing the cells from growth arresting.
4.1.3. Saturation density of Saos-2 cells expressing mutant p53 .
As determined in the previous section, the mutant p53216 val-»gly mutant has 
lost its ability to suppress cellular growth. It is not clear from this however whether this 
mutant has purely lost its wild-type function or whether it can also promote growth on 
an oncogenic background. Several groups have shown that some p53 mutants have 
gained a function (Dittmer et al, 1993 and Chen et al, 1990) enabling them to promote 
the oncogenic phenotype of the cell.
Saos-2 cells transfected with either p53216 ,p53248 or p53143 mutants were 
seeded at a density of lx l 0^ cells/5cm dish. Cells were trypsinised in duplicate at 
various time points and cell numbers recorded as shown in figure 4.3. The experiment 
was repeated twice, and both experiments are illustrated (figure 4.3 a and b). Each cell 
line expressing mutant p53 showed no difference in cell growth when compared to Saos- 
2 cells expressing the vector alone.|In fact Saos-2 parental cells showed a slightly higher 
growth rate (figure 4.3b) than the cell lines expressing the mutant p53 constructs but this 
was probably due to G418 selection procedures. Therefore none of the p53 mutants 
tested, including p53216, increased the saturation density or gave a growth advantage to 
the parental Saos-2 cells.
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Figure 4.3.
Saturation density of Saos-2 cells expressing mutant 
p53 constructs.
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Saos-2 cells were transfected with p53 mutants 216 val -> gly, 143 ala -> val,
248 arg trp or vector alone (CMV4). Equal numbers (1x10s) were seeded 
into a 5cm dish and removed and counted at the times indicated. Each cell 
count is the mean number from duplicate plates.
It seems therefore that the p53216 mutant present in SCC12B and SCC12F 
contributes to tumour progression by losing its wild-type growth suppressive properties. 
It does not however seem to have gained an oncogenic function and does not give the 
cells in which it is expressed an increased growth advantage over neighbouring cells at 
least in Saos-2 cells.
4.1.3. Conformation of the p53 mutant.
The p53 protein in SCC12B and SCC12F was immunoprecipitated using various
antibodies as shown in figure 4.4. PAbl620 (Milner et al, 1987) recognises an epitope
mapping towards the N-terminus and reacts with p53 in a wild-type conformation only.
The antibody PAb240 (Garmon et al, 1990; Stephen and Lane, 1992) recognises the
epitope between amino acids 212-217 within the hydrophobic core of the protein. It
therefore only complexes with p53 in a denatured or "mutant" conformation. DO-1
(Vojtesek et al, 1992) is a monoclonal antibody that reacts with all varieties of p53.
SVK14 is an SV40 transformed keratinocyte cell line where the wild-type p53 is bound
and stabilised by the SV40 large T antigen and is therefore readily detectable.. This cell
line was used as a control as the p53 protein is precipitated by PAbl620 but not by
PAb240. SCC4 has a p53 mutation at codon 151 (Bums et al., 1993) which produces a
stabilised p53 protein that reacts with PAb240 but not PAbl620.
SCC12B expresses a large amount of p53 protein as already shown by western
analysis (figure 3.6) and confirmed by the amount of protein shown to immunoprecipitate
with DO-1 (figure 4.4). All the p53 protein expressed in SCC12B appears to react with
PAbl620 and not with PAb240. Figure 4.4 also confirms that SCC12F has less p53
protein than SCC12B as shown by comparing the quantity of protein bound to DO-1.
The small amount of protein detected in SCC12F is also only reactive with PAbl620 and
216not PAb240. This therefore suggests that the p53 mutant protein has a wild-type 
conformation. This is unusual as most p53 mutants have a PAb240 reactivity and it 
prevents any further analysis of the relative dosages of wild-type and mutant p53 protein 
expressed in the two cell lines by immunoprecipitation.
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Figure 4.4 Immunoprecipitation of p53 from SCC12B and SCC12F
  SCC12B   S C C 12F----- 1
p53 antibody
* < -----  p53
IsG
SVK14 SCC4
p53 antibody
< -----  p53
< —  IgG
lOOug pre-cleared protein extract from each ceU line was incubated overnight at -V C w ith p53 
antibody as labelled. The antibody/protein complex was pelleted with protein G plus agarose 
beads, washed and eleetrophoresed by SDS-PAGE on a 12l7i gel. p53 protein was transferred 
onto immobilin P nitrocellulose and detected using p53 rabbit antibody CM-1 (1:250 dilution) 
and anti-rabbit Ig HRP antibody (1:5000). The filter was immersed in ECL reagent and the 
film exposed for 1 minute.
DO-1 recognises both mutant and wild-type p53. PAM620 recognises only wild-tvpe and 
PAb240 recognises only mutant p53.
Chapter 5
The effect of increased mutant p532l6 dosage 
keratinocyte differentiation
5.1. Expression of p53216 mutant in clone 19
5.1.1. Derivation of the target cell line, clone 19.
In order to analyse the effect of increasing the mutant to wild-type p53 gene 
dosage on malignant phenotype an appropriate target cell was needed. Whilst analysing 
the p53 protein levels in SCC12F and SCC12B it was noticed that expression in SCC12F 
appeared to be heterogeneous. Single cell clones were isolated from this cell line and 
examined for their p53 protein expression level as shown in figure 5.1. As this blot 
shows, different clones express varying levels of p53 protein. BICR3 was used as a 
positive control as it has been shown to have a p53 mutation at codon 282 resulting in a 
highly stable p53 protein (Bums et al, 1993).
A clone expressing low levels of p53 protein (clone 19), as shown in figure 5.1 
and also in figure 3.6 was chosen as a target cell in which to alter the wild-type to mutant 
p53216 gene dosage. Due to the very low level of p53 protein in this clone it presumably 
expresses very little stabilised mutant p53 protein and therefore has a more normal p53 
phenotype than SCC12B. This was confirmed by DNA dot blot analysis in figure 3.9 
where clone 19 appears to have more wild-type p53 DNA than SCC12B.
Immunoprecipitation analysis of p53 protein was carried out on clone 19 as 
shown in figure 5.2. No p53 protein signal was seen after the usual 30 second exposure 
to ECL agreeing with the above observation that clone 19 has very low levels of p53 
protein. However if the film was left in contact with the blot for 20 minutes (figure 5.2) 
which completely overexposed signals from the control cell lines, a signal was obtained 
with the DO-1 antibody and PAbl620 but not with PAb240. This confirmed the 
observation that the p53 protein in clone 19 of SCC12F as with SCC12B has a wild- 
type, PAbl620 reactive conformation. It therefore cannot be revealed by this method 
whether the protein in clone 19 has a wild-type or mutant sequence but it is more likely 
that the protein is wild-type as it is not stabilised and is present at very low levels in the 
cell requiring a long exposure time to be visible unlike the highly stabilised mutant p53 
protein in SCC12B.
Figure  5.1
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Single cell clones of SCC12F were isolated. 2>0ug protein extract 
from each clone was eleetrophoresed through a 127c denaturing polyacrylamide 
gel. as described in materials and methods. p53 protein was detected with 
the antibody PAbl 801 at a Final concentration of lug/ml.
BICR3 was a positive control for p53 expression.
Figure 5.2 Im m unoprecip ita tion  of p53 protein in clone 19
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lOOug pre-cleared protein extract from each cell line was incubated at 4°C with 
p53 antibody as labelled. The antibody/protein complex was pelleted with protein 
G plus agarose beads, washed and electrophoresed by SDS-PAGE through a 
12$ gel. Protein was transferred onto immobilin P nitrocellulose and detected 
using p53 rabbit antibody CM-H 1:250 dilution) and anti-rabbit Ig HRP antibody 
(1:5000 dilution). The filter was immersed in ECL reagent and the film exposed for 
30 seconds (top) or 20 minutes (bottom).
DO-1 antibody binds to both wild-type and mutant forms of p53. PAb 1620 binds only 
to wild-type p53 and PAb240 binds only to mutant p53..
Although clone 19 expresses low levels of p53 protein, it still appears to contain 
three copies of the p53 gene as detected with FISH analysis (see figure3.11, section 
3.2.5.) and three copies of chromosome 17 (figure 3.10, section 3.2.4) identical to 
SCC12B and SCC12F. It therefore does not appear to be the number of p53 gene 
copies that differs between each cell line, but the dosages of mutant to wild-type p53 
genes.
Clone 19 therefore is a more relevant target cell in which to manipulate the 
dosages of wild-type and mutant p53 than a null p53 cell as it retains a related genetic 
background to SCC12B and the effects of increased mutant p53216 protein on malignant 
phenotype in this cancer will be easier to interpret .
5.1.2. Introduction of mutant p53216 into clone 19.
p53216 val—>gly mutant was synthesised as described in section 2.2.4.15 and 
4.1.1. In order to ensure no other spontaneous mutations arise in culture giving spurious 
results, two p53216 mutants were used in the following experiments, namely 216(1) and 
216(2).
Wild-type and mutant DNA was transfected into clone 19 as described in section 
2.2.1.4. Resistant colonies were picked, expanded and stained for p53 expression. No 
resistant colonies overexpressing p53 were obtained from cells transfected with wild-type 
p53. Large numbers of colonies were obtained by transfection of clone 19 with 216(1) 
and 216(2), 14 resistant colonies arose from lxlO6 transfected cells and 12 colonies from 
7.5x105 cells respectively. Fewer resistant colonies were obtained from the vector alone, 
6 colonies from 1.5xl06 transfected cells.
High levels of p53 protein expression was obtained from the expression vector as 
shown by western analysis in figure 5.3. Two transfectants 19 216(2) 3 and 19 216(1) B 
are shown as examples. Transfectant 19 216(2) 3 shows a similar p5 3 expression level
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Figure 5.3
L e v e l s  o f  p 5 3  p r o t e i n  in  t r a n s f e c t a n t s  o f  c l o n e  19  e x p r e s s i n g  
C M V - p 5 3 216
50ug protein extract from each cell line was eleetrophoresed through 
a 12Vc denaturing polyacrylamide gel. as described in materials and methods. 
P53 protein was detected with the antibody PAb 1801 at a final concentration 
of lug/ml.
19 (216)1 B and 19 (216)2 3 were produced from clone 19 transfected with 
mutant p53 216(1) or 216(2) respectively.
19 CMV8. CMV12 and C M V 13 are clone 19 transfected with CMV vector 
alone.
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(data not shown). No stabilised p53 protein was shown as expected in three clones 
transfected with the vector only (19 CMV8,19 CMV12 and 19 CMV13).
The conformation of the mutant p53216 was analysed in the transfectants by 
immunoprecipitation (figure 5.4) to compare it with that analysed in SCC12B and 
SCC12F (figure 4.4, section 4.1.3). Large amounts of p53 protein in the two 
transfectants 19 216(1) B (figure 5.4) and 19 216(2) 3 (data not shown) react with 
antibody DO-1 that recognises both wild-type and mutant conformations. The majority 
of this mutant p53 protein is reactive with PAbl620 as is the p53 protein in SCC12B and 
SCC12F. However there appears to also be some reactivity with PAb240 (which reacts 
with only p53 in a mutant conformation) in the transfectants which was not apparent in 
SCC12B, SCC12F or clone 19 (figures 4.4 and 5.2). This reactivity in clone 19 
transfectants may be due to the high levels of mutant p53216 expression resulting in some 
becoming denatured during the experiment. The same controls were used as before, 
SVK14 containing SV40 large T antigen bound wild-type p53 and SCC4 containing 
mutant p53151 (Bums et al., 1993). There also appears to be some cross-reactivity with 
PAb240 in the control SVK14. This reactivity of normally PAbl620 reactive p53 with 
PAb240 may be due to slight degradation of the protein in cases where it is at extremely 
high levels in the cell or perhaps slightly different conditions which vary between 
experiments may lead to a low level of protein denaturation.
To analyse the cellular expression of the p53216 mutant in transfected cell lines, 
cells were seeded onto chamber slides and stained for p53 with PAbl801 as described in 
section 2.2.2.1. and shown in figure 5.5. The position of the staining was enhanced by 
using a green filter (figure 5.5 right) and can be seen to be nuclear in 19 216 (2) 3 (a and 
b) and 19 216 (1) B (c and d). Only slight p53 staining was visible in 19 CMVI3 
expressing the vector alone as expected.
When visualised under the microscope the majority of the transfected cells (figure 
55 a-d) stained for p53 protein. However where the cells differentiated to produce foci 
in culture the staining appeared to be more suprabasal. As the basal cells are the only 
proliferating cells in the epidermis, it would be expected that an increase in mutant p53 
would only have an effect if expressed in these cells and not later when the cells have
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Figure 5.5 Clone 19 transfected with p53 ",6 mutant constructs.
Clone 19 was transfected with p53“16 mutant constructs and stained 
for p53 protein using PAbl801 as described in materials and methods. 
Phase constrast (left) and green filter (right) photographs are shown. 
Clone 19 216(2) 3 is shown in a and b, clone 19 216(1) B in c and d. 
and vector alone 19 CMV 13 in e and f.
Arrows show expression of p53 protein. Bar =10um
Figure 5.6 Raft cu lture o f clone 19 216(1) B stained  with 
haem atoxylin  and eosin.
•granular layer
collagen matrix
Clone 19 216(1 )B was grown on a raft culture and stained with 
haematoxylin and eosin to show stratification, as described in materials 
and methods. Cellular layers are as shown.
Bar = lOum s
Figure 5.7 Raft culture of clone 19 216( 1 )B stained for p53 protein.
Clone 19 216( 1 )B was grown on a raft culture and stained for p53 protein 
with PAM 801 (a and b) as described in materials and methods. P53 protein 
is expressed in all layers of the raft culture as indicated by the arrows.
Clone 19 CMV 13 showed no p53 protein expression as expected (c and d). 
Phase contrast (left) and green filter (right) photographs are shown.
Bar = lOum ■
already been committed to terminal differentiation. In order to check the spatial 
expression from the CMV vector, cells were grown on raft cultures (Kopan et al., 1987) 
either completely submerged in medium or only fed from the bottom of the raft.
Cryostat sections of each raft culture were stained with haematoxylin and eosin to 
enhance cellular morphology (figure 5.6) and show stratification. The raft sections were 
also stained with involucrin and staining was restricted to the suprabasal layers as 
expected! The basal cells were present and remained unstained As
shown in figure 5.7 when stained with the p53 antibody PAbl801 the expression of p53 
protein from the CMV promoter appears to be in all layers of the raft culture and not 
confined to the upper layers as first thought. The CMV promoter was therefore suitable 
to drive the expression of mutant p53216 protein to all layers of the stratified 
keratinocyte cultures.
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5.2. The effect of p53216 mutant dosage on the progression of 
S C C .
5.2.1. Morphology of cell lines.
Phase contrast photographs of each cell line used in experiments described in this 
thesis are shown in figure 5.8. HEK cells showed the normal polygonal shaped cells and 
were grown in serum containing medium in the presence of 3T3 feeders as described in 
section 2.1.1. Similar culture conditions were used for all other cell lines, i.e. DMEM 
supplemented with 10% serum and hydrocortisone. Clone 19, a low expressing p53 
clone of SCC12F, grew very slowly in these culture conditions. Optimal conditions in 
which to grow this cell line were not defined and culture conditions were kept identical 
to other cell lines for control purposes. Like HEK cells, clone 19 preferred to be kept at 
a high cell density, losing cloning efficiency if the cells were extensively split. Clone 19 
also maintained the characteristic cobblestone morphology of normal keratinocytes as did 
SCC12F (figure 5.8 B and D). The morphology of SCC12F and SCC12B have been 
previously described elsewhere (Dawson et al., 1990; Jaffe et al., 1992). SCC12B 
appear much flatter than SCC12F (figure 5.8C) or clone 19 and appeared to have an 
increased growth rate. SCC12B is able to grow in the presence of reduced serum (Jaffe 
et al., 1992 and data not shown). 19 CMV 13 and 19 CMV8 (G and H), clones of clone 
19 expressing the CMV vector alone showed no obvious differences from clone 19. 
Clones transfected with mutant p53216 (19 216(1) B and 19 216(2) 3 figure 5.8 E and F) 
however yielded cell lines that showed increased growth rates and reduced iserum 
dependence i . Both of these cell lines also appeared to have more
compact cell growth and seemed to be less contact inhibited than other cells.
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5.2.2. Expression of involucrin.
Involucrin expression was analysed on all the cell lines shown in figure 5.8 after 
suspension culture for 0 and 3 days (as described in section 2.2.1.5 and section 2.2.2.2). 
Cell density was controlled for by growing cells at both high density (2xl06cells/5cm 
dish) and low density (3x105 cells /5cm dish) before being placed in suspension culture.
Figure 5.9 shows the staining pattern of normal HEK cells expressing involucrin 
after 3 days in suspension. All other cell lines showed a similar staining pattern (data not 
shown) in the proportion of cells that stained (figure 5.10 and 5.11). It has previously 
been reported that involucrin expression correlates with cell size (Watt and Green,
1981), the larger cells being more differentiated and therefore expressing more involucrin 
protein (as discussed in section 1.1.3). The large dark red cells highlighted by the arrows 
were scored positive and any other cells were scored negative for involucrin expression.
After culturing at high density 37% of normal HEK's expressed involucrin and 
this increased to 64% after 3 days in suspension culture (figure 5.10a and b). A similar 
trend was followed by all other cell lines. A slightly lower 20-30% of these cells 
expressed involucrin at day 0, and this increased to 50-60% after day 3. 19 CMV13 
appeared to have a much higher involucrin expression after day 3 but this was based on 
only one experiment (hence the absence of a standard deviation value).
No affect on involucrin expression was therefore apparent when the mutant 
p53216 levels were increased and these cells were grown at high density.
An affect became clearer when the cell lines were grown at lower density before 
being placed in suspension (figure 5.11a and b). 5-28% of cells in all cell lines expressed 
involucrin at day 0. Involucrin expression then increased in most cell lines after 3 days in 
suspension (figure 5.11b). The largest increase was in clone 19 where expression 
increased from 14% to 57%. Control cell lines 19 CMV8 and 19 CMV13 showed a 
similar increase. However, cell lines 19 216(1) B and 19 216(2) 3 showed only a very 
slight increase (-3%) in involucrin expression after 3 days in suspension culture
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Figure 5.9
Phase contrast photograph shows involucrin staining of HEK cells 
3 days after suspension culture. All other cell lines showed a similar 
staining pattern and the proportion of cells stained are shown in 
figure 5.10 and 5.11. The dark red cells (examples are highlighted 
by the arrows) were scored as positive.
Bar = lOuM ■
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Figure 5.10
Involucrin expression in cells induced to differentiation by suspension 
culture.
High density
Cells were seeded at 2xl06/5cm dish and cultured for 4 days. Cells were then 
trypsinised and either stained for involucrin immediately (day 0) or placed in 
suspension culture at 105 cells/ml for 3 days. These cells were washed from 
methylcellulose and then stained for involucrin.
Cells were scored positive or negative and expressed as a percentage of the total cells 
counted.
Experiments were repeated 2-4 times and the average value for each cell line was 
calculated and plotted as shown ± standard deviation
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Figure 5.11
Involucrin expression in cells induced to differentiation by suspension 
culture.
Low density
Cells were seeded at 3xl05/5cm dish and cultured for 4 days. Cells were then 
trypsinised and either stained for involucrin immediately (day 0) or placed in 
suspension culture at 105 cells/ml for 3 days. These cells were washed from 
methylcellulose and then stained for involucrin.
Cells were scored positive or negative and expressed as a percentage of the total cells 
counted.
Experiments were repeated 2-4 times and the average value for each cell line 
calculated and plotted as shown ±.standard deviation, 
n/a means not counted due to contamination.
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Therefore, increasing the levels of mutant p53216 protein in clone 191 appears to 
inhibit the ability of these cells to express involucrin in response to suspension induced 
terminal differentiation, if these cells are cultured at low density.
5.2.3. Resistance of cell lines to suspension induced cell death.
The colony forming efficiency of each cell line was measured without being 
placed in suspension culture (day 0) and after 24 hours in suspension culture (24 hours) 
as described in section 2.2.1.7. Cell density was controlled for by plating cells at both 
high density (2xl06cells/5cm dish) and low density (3x105 cells /5cm dish) before being 
placed in suspension culture. The resistance of cells to suspension induced cell death 
was plotted for each cell line (figure 5.12 and 5.13) and this was expressed as the number 
of colonies formed after 24 hours in suspension as a percentage of the number of 
colonies obtained at day 0. Cloning efficiencies without suspension culture are given in 
the corresponding figure legends and are expressd as a percentage of the total cells 
plated.
The survival of clone 19, SCC12F and SCC12B were compared to 19 (216)1 B 
as shown in figure 5.12. At both low and high density clone 19 and SCC12F had a much 
lower colony forming efficiency than SCC12B and 19 (216)1 B. SCC12B still retained a 
40% colony survival after 24 hours in suspension culture, a similar figure as obtained by 
Parkinson et al, 1983. The cloning efficiencies of SCC12F and SCC12B were much 
lower than clone 19 and 19 (216)1 B as shown by the percentage number of colonies at 
day 0 as detailed in figure 5.12 legend. This was probably due to the fact that the 
SCC12B and SCC12F cells used were of a much lower pass than the other two cell lines 
and this could also explain the larger standard deviation for values obtained from 
SCC12B.
SCC12F, clone 19, and two clones of 19 expressing the vector alone (19 CMV13 
and 19 CMV8) had similar survival patterns and their survival was lower than 19 
(216)1 B and 19 (216)2 3 (figure 5.13). At high density, colony survival ranged from 
with between 41% (19 CMV8) to 18% (SCC12F). At lower density similar results were
144
Figure 5.12
Colony survival after suspension induced cell death. 
Experiment 1
Cells were seeded at either 2xl06/5cm dish (high density) or 3xl05/5cm dish (low 
density) and incubated for 4 days. Cells were then either plated at 500 cells /T25 flask 
or placed in suspension culture for 24 hours. These cells were then washed from the 
methylcellulose and plated at 103/T25 flask. Cells were incubated at 37°C until 
colonies were easily visible and then stained with 1% rhodamine and counted.
Colony numbers were recorded per 500 cells plated.
Experiments were repeated at least 3 times and the average number of colonies per 
time point for each cell line recorded
Percentage colony survival is plotted for each cell line i.e. the number of colonies 
counted after 24 hours in methylcellulose as a percentage of the number of colonies 
counted without suspension culture (day 0), ± standard deviation.
Colony survival at day 0 recorded as a percentage of total cells plated for each cell 
line are:
High density
Clone 19 19.9%, SCC12F 9.1%, SCC12B 5%, 19 (216)1 B 29.6%
Low density
Clone 19 33.2%, SCC12F 8.5%, SCC12B 10.8%, 19(216)1 B 26.4%
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obtained with a survival range form 48% (19 CMV8) to 24% (clone 19). As expected 
normal HEK cells had very low resistance to suspension induced cell death with very few 
colonies being formed after 24 hours in suspension.
The cell lines expressing large amounts of mutant p53 (19 (216)1 B and 19 
(216)2 3) were shown to have aj higher resistance to suspension induced cell death 
(figure 5.12 and 5.13). Also colonies arose from these cell lines more quickly than other 
cell lines and appeared larger and healthier. Colonies were often stained upto five days 
before any other cell line to prevent the colonies merging. At high density 49% and 61% 
colonies survived after 24 hours respectively. At low density this survival increased to 
73% and 70% respectively.
These results therefore suggest that 19 (216)1 B and 19 (216)2 3, which express 
high levels of mutant p53216, have a higher colony forming ability and therefore a greater 
resistance to suspension induced cell death than cell lines that have lower levels of 
mutant p53. This resistance is enhanced by growing the cells at lower density where 
survival is approximately double that of the other cell lines.
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Figure 5.13
Colony survival after suspension induced cell death.
Cells were seeded at either 2xl06/5cm dish (high density) or 3xl05/5cm dish (low 
density) and incubated for 4 days. Cells were then either plated at 500 cells /T25 flask 
or placed in suspension culture for 24 hours. These cells were then washed from the 
methylcellulose and plated at 103/T25 flask. Cells were incubated at 37°C until 
colonies were easily visible and then stained with 1% rhodamine and counted.
Colony numbers were recorded per 500 cells plated.
Experiments were repeated at least 3 times and the average number of colonies per 
time point for each cell line recorded
Percentage colony survival is plotted for each cell line i.e. the number of colonies 
counted after 24 hours in methylcellulose as a percentage of the number of colonies 
counted without suspension culture (day 0), ± standard deviation.
Colony survival at day 0 recorded as a percentage of total cells plated for each cell 
line are:
High density
HEK 8.2%, Clone 19 41.6%, 19 CMV8 38.1%, 19 CMVI3 51.5%,
SCC12F 37%, 19 (216)1 B 47%, 19 (216)2, 3 50.7%.
Low density
HEK 2.3%, Clone 19 47.1%, 19 CMV8 45.4%, 19 CMV13 73.9%,
SCC12F 36.8%, 19 (216)1 B 46.2%, 19 (216)2,3 58.3%.
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5.2.4. Formation of comified envelopes.
Comified envelopes are first visible in cells of the granular layer (Sun and Green, 
1976). Such comified envelopes are formed as the cells become permeable to trypan 
blue (Green, 1977) by the crosslinking of several proteins by the calcium dependent 
cellular enzyme transglutaminase (Rice and Green, 1979). Comified envelopes can easily 
be isolated by their insolublility to detergents and reducing agents (Sim and Green,
1976). HEK cells can be induced to terminally differentiate byjculturingthem in 
methylcellulose. Such cells have been shown to form insoluble comified envelopes 
almost immediately and 50% of these cells form comified envelopes by day 5 (Green,
1977).
The ability of SCC12F, SCC12B, clone 19 and clone 19 transfected with high 
levels of mutant p53216 to form envelopes was investigated. Comified envelopes were 
counted after cells had been cultured in methylcellulose for 5 days as described in section 
2.2.1.6. Cell density was controlled for by plating cells at both high density 
(2xl06cells/5cm dish) and low density (3x105 cells /5cm dish) before being placed in 
suspension culture.
Envelopes were obtained by their resistance to treatment with 5% SDS/1% [3 
mercaptoethanol and boiling at 100°C and an example of their appearance is shown in 
figure 5.14, one of many being highlighted by an arrow. They are often very large 
rounded and transparent structures and can be seen by focussing through several planes 
using the phase contrast of a light microscope. Electron micrograph studies of the 
envelope have previously been reported (Green, 1977).
SCC12B and 19 (216)1 B develop very few comified envelopes after 5 days in 
suspension culture (figure 5.15) when grown at both high and low density. SCC12F 
develops slightly more envelopes but still very few relative to clone 19.
This is again shown in figure 5.16 where SCC12B, 19 (216)1 B, 19 (216)2 3 and 
19 (216)2 1 which all express large amounts of mutant p53216 are deficient in forming 
comified envelopes after 5 days in suspension culture. These cell lines appear to form 
slightly higher numbers of envelopes when grown at high density than at low density
150
(figure 5.16) but in comparison to controls these numbers are still very low. In this 
experiment too, clone 19, SCC12F and 19 CMV8 and 19 CMV13 which express the 
vector alone, all develop higher numbers of comified envelopes than the cell lines 
expressing more mutant p53 but lower numbers than normal cells. Their ability to form 
envelopes was also higher when grown at high density than when grown at a lower 
density. Normal HEK cells, as expected, develop large numbers of envelopes after 
suspension induced terminal differentiation (figure 5.16).
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Figure 5.14
Phase contrast photograph showing the structure of comified envelopes 
obtained from HEK cells 5 days after suspension culture. One of many 
is highlighted by the arrow. Numbers of comified envelopes formed 
in each cell line are shown in figure 5.15 and 5.16.
Bar = lOuM "  —
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Figure 5.15
Comified envelope formation after suspension culture. 
Experiment 1
Cells were seeded at either 2xl06/5cm dish (high density) or 3xl05/5cm dish (low 
density) and incubated for 4 days at 37°C. Cells were then suspended in 
methylcellulose at 105/ml for 5 days . Cells were then washed and resuspended at 
3xl05/ml in 5% SDS/1% |3 mercaptoethanol and solubilised by boiling for 5 minutes. 
Comified envelopes were counted using a haemocytometer under a light microscope. 
Numbers are plotted per 104/ml and are the average values obtained from at least 4 
experiments. Standard deviations ± are also plotted
Percentage of cells which had formed comified envelopes at day 0 before suspension 
culture are:
High density
Clone 19 0.2%, SCC12F 0.33%, SCC12B 0.33%, 19 (216)1 B 0.67%.
Low density
Clone 19 0.9%, SCC12F 0.67%, SCC12B 0.1%, 19 (216)1 B 0.2%.
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Figure 5.16
Comified envelope formation induced by suspension culture. 
Experiment 2
Cells were seeded at either 2xl06/5cm dish (high density) or 3xl05/5cm dish (low 
density) and incubated for 4 days at 37°C. Cells were then suspended in 
methylcellulose at 105/ml for 5 days . Cells were then washed and resuspended at 
3xl05/ml in 5% SDS/ 1% |3 mercaptoethanol and solubilised by boiling for 5 minutes. 
Comified envelopes were counted using a haemocytometer under a light microscope. 
Numbers are plotted per 104/ml and are the average values obtained from at least 4 
experiments. Standard deviations ± are also plotted
Percentage of cells which had formed comified envelopes at day 0 before suspension 
culture are:
High density
HEK 2.3%, Clone 19 1.3%, 19 CMV8 0.67%, 19 CMV13 1.3%,
SCC12F 1%, SCC12B 1%, 19 (216)1 B 1.3%, 19(216)2 3 1%.
Low density
HEK 1.3%, Clone 19 0.67%, 19 CMV8 0.33%, 19 CMV13 0.33%, 
19CMV12 0.33%, SCC12F 0, SCC12B 0.33%, 19 (216)1 B 0.33%, 
19 (216)2 3 0.33%, 19 (216)2 1 0.33%.
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5.2.5. Morphology of cells after suspension culture.
Cells after 0,1, 3 and 5 days in suspension were stained withj acridine orange 
which binds to DNA, highlighting the position and size of the nucleus. Photographs 
showing the nuclear morphology after 24 hours and 5 days in suspension of clone 19 and 
19 216 (1) B are shown in figure 5.17. SCC12F and clone 19 cells transfected with the 
CMV vector alone showed a similar pattern as for clone 19 (figure 5.17 a and b). Other 
cell lines expressing high levels of mutant p53 (19 216(2) 3 and SCC12B) showed a 
similar staining as for 19 216(1) B (figure 5.17 c and d). As part of the terminal 
differentiation pathway keratinocytes have been shown to degrade their nuclear DNA in 
a manner characteristic of apoptosis (McCall and Cohen, 1991; Meredith et al. , 1993) 
and sometimes termed anoikis (Frisch and Francis, 1994). Nuclear digestion does not 
occur until a few days after the cells have become permeable and formed a comified 
envelope (Green, 1977) in the upper granular layer. Squames are often released from 
stratified colonies into the medium before their nuclei have been digested. It has 
previously been reported that 35% of HEK cells cultured in methylcellulose for 5 days 
have lost their nucleus (Green, 1977). The chromatin becomes condensed and 
marginated as can be seen in clone 19 figure 5.17b. During these morphological changes 
the DNA is fragmented into 200bp units by a calcium dependent endonuclease (McCall 
and Cohen, 1991) which can be visualised as a DNA ladder on an agarose gel (Meredith 
et al., 1993; Frisch and Francis, 1994). Cell lines expressing high levels of mutant p53 
(19 216(1) B) did not show any nuclear shrinking after 5 days in suspension (figure 
5.17d). No nuclear shrinking was apparent in other clones expressing mutant p53 either 
(data not shown). From these preliminary results it appears therefore that mutant p53 
has inhibited the ability of cells to destroy their nucleus, another feature of the terminal 
differentiation pathway.
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Figure 5.17 Acrydine orange staining of ceils after suspension culture
X
'
Clone 19
t *
24 hrs 5 days
19 216 (1) B
24 hrs 5 days
Clone 19 (a and b) and 19 216 (1) B (c and d) were placed in suspension  
culture for 24 hours (a and c) or 5 days (b and d). Cells were then stained  
with acrydine orange lOug/ml as described in materials and m ethods.  
Photographs show  exam ples of the typical m orphology o f these cells 
at the time points indicated.
Arrows shows nuclear condensation.
Bar = lOuM
5.2.6. Tumorigenicity of cell lines in nude mice.
Tumorigenicity data from two separate experiments are shown in figure 5.18 and 
5.19. Cells were injected at two different doses, 5xl06 or 1.6xl06 / mice in either flank 
of four week old nude mice The lower dose rarely gave rise to tumours, but tumours 
were formed from some cell lines when the larger cell dose was administered. Cysts 
were commonly formed immediately after injection but these slowly regressed.
SCC12F and clone 19 did not give rise to persistent tumours in either 
experiment. Mice injected with higher doses of both cell lines developed slowly 
regressing tumours and by the end of both experiments these had completely regressed in 
SCC12F and only one small cyst remained from the injection of clone 19.
Control cell lines, 19 CMV8 and 19 CMV13 expressing the CMV vector alone, 
produced a similar result to clone 19. No persistent tumours were produced by these cell 
lines (figure 5.19).
Contradictory to published results (Parkinson et al., 1984; Jaffe et al. , 1992) in 
our hands SCC12B did not form persistent tumours (figure 5.18). A relatively large 
tumour developed 2 weeks after the injection of 5xl06 cells/mouse but this slowly 
regressed throughout the period of the experiment.
Similarly cell lines 19 216(1) B and 19 216(2) 3, both expressing high levels of mutant 
p53216 protein showed a low tumorigenic potential. 19 216(2) 3 was totally non- 
tumorigenic at both cell doses and in both experiments. 19 216(1) B however was 
tumorigenic but only when injected at 5 xlO6 cells/mouse. This cell line produced large 
cysts at the beginning of each experiment at both doses but throughout the duration of 
the experiment these slowly regressed. Only one tumour remained in one of each of the 
the three mice (figure 5.18 and 5.19) reaching our criteria for tumorigenicity i.e. a 
tumour remaining on the mouse for 3 months and reaching 1cm3 in size. The tumour 
from 19 216 (1) B reached 1cm3 in both experiments with a latent period of 63-66 days. 
A third clone, (19 216 (1) 2) overexpressing mutant p53216 was also tested once for 
tumorigenicity and was found to be non-tumorigenic|
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Figure 5.18 
Tumorigenicity of cell lines injected into nude mice.
Experiment 1
Time after injection
Cell line 2 weeks 4.5 weeks 8 weeks 9.5 weeks 11.5 weeks 19 weeks
SCC12F
5x106 cells 4x4mm
(3/3)
3x3mm
(3/3)
2x2mm
(3/3)
lxlmm
(3/3)
2x2mm 
(3x3) (0/3)
1.6x10^ cells
(0/3) (0/3) (0/3) (0/3) (0/3) (0/3)
Clone 19
5x106 cells 4x4mm
(3/3)
2x2mm,
(3/3)
1x1 mm 
(3/3)
3x3mm
(1/3)
3x3mm
(1/3)
2x2mm
(1/3)
1.6xl06 cells
(0/3) (0/3) (0/3) (0/3) (0/3) (0/3)
SCC12B
5xl06 cells 5x5 mm 
(3/3)
4x4mm
(3/3)
3x3mm
(3/3)
3 x3mm 
(3/3)
4x4mm
(3/3)
2x2mm
(1/3)
1.6xl06 cells
(0/3)
2x2mm 
(1/3)
lx l mm 
(1/3) (0/3) (0/3) (0/3)
19 216(1) B
5x106 cells 5x5mm
(3/3)
5x6mm 
(2/3)
9x10 mm 
(3/3)
10x10 mm 
*  (2/3)
11x13mm 
(2/3)
12x14mm
(1/3)
1.6xl06 cells 2x2mm 
(2/3)
3x3 mm 
(1/3)
lx l mm 
(3/3) (0/3)
2x2mm 
(2/3) (0/3)
19 216(2) 3
5x106 cells 5 x5mm 
(3/3)
4x4mm 
(1/3) (0/3) (0/3) (0/3) (0/3)
1.6xl06 cells
(0/3) (0/3) (0/3) (0/3) (0/3) (0/3)
5x106 and 1.6xl06 cells were injected subcutaneously into the right or left flank 
respectively of four week old nude mice.
Size of tumour is shown in italics and measured in mm
A total of three mice was used per cell line. Numbers of mice with tumours are shown in 
parentheses.
*  Latent period of tumour where tumour reached 1cm3 was 66 days after injection.
Figure 5.19 
Tumorigenicity of cell lines injected into nude mice.
Experiment 2
Time after injection
Cell line 1.5 weeks 3weeks 10.5weeks
Clonel9
5xl06 cells 2x2mm
(3/3)
2x2mm
(3/3)
2x2mm
(1/3)
1.6xl06 cells 2x2mm
(3/3)
lx l mm 
(2/3) (0/3)
19 CMV8
5xl06 cells 2x2mm
(3/3)
2x2mm
(3/3) (0/3)
1.6xl06 cells
(0/3) (0/3) (0/3)
19 CMV13
5xl06 cells 4x4mm
(3/3)
2x2mm 
(3/3) (0/3)
1.6xl06 cells
(0/3) (0/3) (0/3)
19 216(1) B
5xl06 cells 6x6 mm 
(3/3)
Ixlmm
(2/3)
10x10mm
*(1/3)
1.6xl06 cells 4x4mm 
(2/3)
6x6 mm 
(2/3) (0/3)
19 216(2) 3
5xl06 cells 2x2mm 
(3/3)
4x4mm 
(2/3) (0/3)
1.6xl06 cells 2x2mm
(3/3)
2x2mm
(2/3) (0/3)
5x106 and 1.6xl06 cells were injected subcutaneously into the right or left flank 
respectively of four week old nude mice.
Size of tumour is shown in italics and measured in mm
A total of three mice was used per cell line. Numbers of mice with tumours are shown in 
parentheses.
*  Latent period of tumour where tumour reached 1cm3 was 63 days after injection.
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Chapter 6 
Discussion
6.1 Genetic differences between SCC12B and SCC12F.
SCC12B and SCC12F represent two distinct cell populations within a single 
tumour (SCC12) at different stages of malignant progression (Rheinwald and Beckett, 
1981). As outlined in section 1.1.2. SCC12B is more tumorigenic and more resistant to 
terminal differentiation signals than the sister cell line SCC12F. Somatic cell hybrids 
derived by fusing SCC12B with SCC12F showed a much lower tumorigenic phenotype 
than the parental SCC12B cell line (Jaffe et al, 1992). This suggests that the malignant 
phenotype is recessive and SCC12F was able to donate a suppressor function to the 
hybrid. It was therefore reasonable to assume that SCC12F possessed a gene or genes, 
possibly a tumour suppressor gene, that had become inactivated in SCC12B preventing it 
either directly or indirectly from responding normally to terminal differentiation signals 
and aiding its progression to malignancy.
Several known genes or loci known to be important in SCC-HN development 
were compared between SCC12F and SCC12B in the hope of finding a genetic 
difference that could be responsible for their different phenotypes.
Comparison of cyclin D1 protein levels in SCC12B and SCC12F showed no 
noticeable difference between the two cell lines (section 3.1.3) and very little 
overexpression of the protein was observed when compared with other SCC cell lines. 
Also transfection of cyclin D1 into SCC12F did not increase its tumorigenic potential 
(M.Nikolic, personal communication). These observations suggest that although cyclin 
D1 amplification is frequently observed in a variety of tumours including SCC-HN (Jiang 
et al., 1992, Nikolic et al., submitted) it does not play an important role in the 
progression of this particular SCC-HN cancer.
Analysis of microsatellite sequences on chromosomes 9 and 3p did not reveal any 
differences in LOH between SCC12B and SCC12F either. These two chromosomes 
were chosen for analysis over any other as there is currently more data linking loci on 
these chromosomes with SCC development (section 1.4.1.1). Chromosome 3p has been 
shown to have frequent loss of heterozygosity in SCC-HN (Edington et al., 1995; and 
unpublished data). Previous analysis of chromosome 9 in SCC-HN has shown there to
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be an 84% chance of LOH at 9p21 in SCC-HN (Loughran et al., 1994). The majority of 
microsatellites used only showed amplification of one allele band in both cell lines. This 
was marked as non-informative, but as no normal DNA from the patient was available 
for comparison a loss could have occurred at that locus in both cell lines, possibly 
highlighting the position of a gene whose inactivation plays an important and early role in 
the development of this SCC. The data however does not answer the initial question by 
revealing any candidates on chromosomes 9 or 3p that could be responsible for the 
different phenotypes of these two cell lines.
On analysing the p53 tumor suppressor protein levels in SCC12B and SCC12F a 
difference in expression levels was observed. SCC12B appeared to express much higher 
levels of p53 protein than SCC12F (figure 3.6). Single clones of SCC12F could also be 
isolated that had varying levels of p53 protein supporting the hypothesis that SCC12F 
progression towards the more malignant phenotype seen in SCC12B is accompanied by 
the expression of high levels of p53 protein. Wild-type p53 has a relatively short half-life 
but this becomes increased when the protein is stabilised by a mutation. SCC12B was 
indeed found to express a novel p53 mutation at codon 216, a T-»G transversion, 
substituting a valine for a glycine (figure 3.7). Interestingly, the mutation appears to be a 
heterozygous one with the wild-type allele being retained. This is rare as the wild-type 
affect of p53 is dominant as shown by the induction of growth arrest by expressing wild- 
type p53 into cell lines carrying endogenous mutant p53 (Mercer et al., 1990; Baker et 
al., 1990; Casey et al., 1991) and usually both alleles are mutated as the cancer 
progresses for example in Li-Fraumeni patients (Srivistava et al., 1992b).
In line with the low level of p53 protein expression, little mutant protein was 
detected in SCC12F which appears to express mostly the wild-type allele (figure 3.7). 
This suggests that accumulation of this p53 mutation occurs later in the progression of 
this SCC. Although this particular mutation is novel and lies outside a conserved domain 
where most mutations are observed (figure 1.3), other mutations at this codon have been 
reported (Caron de Fromentel and Soussi, 1992) and therefore this part of the protein is 
a relevant site for mutagenesis.
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Codon 216 is positioned in the hydrophobic core of the p53 protein and is not 
involved directly in DNA binding (Clore et al., 1994). This region coincides with the 
epitope recognised by PAb240 (residues 212-217) (Stephen and Lane, 1992). This 
epitope however is cryptic and the protein has to be denatured or this region of the 
protein unfolded in order for the antibody to bind. This mutant p53 is unusual in that it 
is not recognised by PAb240 in immunoprecipitation experiments (figure 4.4). At first 
glance this may not be surprising as the mutation at codon 216 may disrupt the epitope 
and prevent the antibody from binding. Another mutation in a Burkitts lymphoma cell 
line (Farrell et al., 1991) was identified in the PAb240 epitope region at codon 213 
substituting an arginine for a glutamine. This mutation was also a heterozygous one and 
the protein had also lost reactivity with PAb240 presumably due to the disruption of the
p i  f iepitope. However the p53 mutant protein is still reactive with the antibody PAbl620 
which recognises the wild-type conformation suggesting that the mutation has not 
unfolded the protein and the PAb240 epitope is not revealed. Glycine and valine amino- 
acids are very similar in that they both have aliphathic side chains and are non-polar 
although glycine is less hydrophobic than valine. Glycine has a small side chain of a 
single hydrogen whilst valine is slightly more bulky with two methyl groups but this 
substitution would have few constraining effects on the protein. Immunoprecipitation 
studies suggest that a substitution of a glycine for a valine in this region does not alter 
the protein conformation and the mutant is a class I type as discussed in section 1.4.3.2. 
However, if this were a silent mutation then the protein would be expected to behave as 
a wild-type protein. This is clearly not the case as the protein is stabilised like most 
mutants and when transfected into Saos-2 cells (Frebourg et al., 1992) the mutant 
protein has lost its ability to suppress cellular growth (section 4.1.2). This mutation,then, 
whilst it has no effect on protein conformation, it does inactivate the growth suppressor 
function of p53.
Preliminary studies suggest that this mutant p53216 protein has not gained any 
non wild-type functions. Saos-2 cells expressing the mutant p53 do not show an increase 
in saturation density (section 4.1.3) (Chen et al., 1990) and therefore the mutant does 
not appear to promote an oncogenic phenotype by giving the cells a selective growth
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advantage. However additional transcriptional and DNA binding properties of the 
mutant cannot be ruled out and require further analysis (Bargonetti et a l , 1992; Scharer 
andlggo, 1992; Dittmer etal., 1993)
As both SCC12B and SCC12F have retained expression of the wild-type p53 it is 
possible that the difference in their phenotypes may be due to the dosage effects of the 
mutant p53 protein. Both cell lines were found to contain three copies of chromosome 
17 and three copies of the p53 gene confirming the karyotype carried out by Jaffe et al, 
1992, showing that both cell lines were triploid. Although double hybridisations were 
not carried out it can be concluded from these results that all three p53 genes lie on a 
chromosome 17 and the position of the signal (figure 3.11) indicates each gene lies on 
the short arm as expected. Dot blot analysis of the mutant and wild-type gene dosages in 
the two cell lines confirmed that SCC12B expressed much more, perhaps double the 
amount of mutant p53 DNA and RNA than SCC12F (section 3.2.3). Conversely, 
SCC12F and a clone of SCC12F (clone 19) were shown to express more wild-type p53 
than SCC12B. In conjunction with the known p53 copy number in both cell lines I 
suggest that SCC12B carries two mutant and one wild-type p53 genes and SCC12F and 
clones of SCC12F carry two wild-type and one mutant p53 genes. A third chromosome 
17 was acquired by both cell lines probably by chromosomal duplication or uneven 
segregation during mitosis and suggests that development of aneuploidy in this tumour is 
an early event. The acquirement of a second p53 mutation by SCC12F during 
progression towards SCC12B is unlikely to occur by a second independent point 
mutation as the probability that the same mutation would be acquired is very small. 
However gaining a second identical mutation could occur by non-disjunction at mitosis 
leading to a loss of one of the wild-type chromosomes, followed by duplication of the 
mutant chromosome, or alternatively by mitotic recombination between a mutant 
chromosome and a wild-type one.
The presence of both mutant and wild-type p53 in a neoplastic cell suggests that 
the mutant has inactivated the wild-type protein in a dominant-negative manner. Usually 
a dominant-negative protein would bind and also sequester the wild-type protein (Milner 
and Medcalf, 1991). In this case the p53216 mutant retains reactivity with the PAbl620
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and therefore it is difficult to ascertain how much of the immunoprecipitated protein is 
wild-type. Heterozygous mutations are a characteristic of the Li-Fraumeni syndrome but 
the normal cells rarely accumulate p53 protein when the mutation is in this heterozygous 
state (Bhatia et al., 1993; Srivistava et al., 1992b). When the wild-type p53 is lost 
during tumour progression the mutant protein then accumulates. Therefore stabilisation 
of p53 protein in the presence of a heterozygous mutation as in SCC12B signifies that 
the mutation is dominant. The higher levels of mutant p53 in SCC12B as compared to 
SCC12F suggests that the dose of the mutant in relation to the wild-type protein is 
critical in the phenotype displayed. This thesis shows that increasing the levels of mutant 
p53 in a clone of SCC12F (clone 19) did yield a phenotype similar to SCC12B 
(discussed further in the next section). The p53 mutant therefore shows a dose- 
dependant dominance over the endogenous wild-type p53, SCC12F and SCC12B being 
two examples of the phenotype gained at different mutant doses. It is postulated that as 
the mutant dose increases then the heterotetramers formed with the wild-type protein 
contain more mutant p53 molecules and therefore may reduce the wild-type proteins 
affinity to DNA and transcriptional activity. Sim et al. 1993 showed that to completely 
suppress cell growth by the wild-type p53 a ratio of 3 mutant to 1 wild-type molecule in 
the tetramer was needed. This therefore explains why SCC12B requires such a large 
expression of mutant p53 to express a neoplastic phenotype and why the mutant is 
inactive in displaying such a phenotype at smaller doses as in SCC12F. It has yet to be 
clarified if the mutant has itself additional activities once it has sequestered any wild-type 
p53 function.
6.2 Increased mutant p53216 blocks the ability of SCC12F to 
terminally differentiate.
In order to analyse the effect that mutant p53 dosage has on the cells ability to
f \terminally differentiate p53 was overexpressed in a clone of SCC12F, clone 19. Only 
small amounts of p53 protein were detected in this clone (figure 5.1) and hence it 
presumably expressed very little mutant p53 protein. This clone therefore represented a
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more normal phenotype than SCC12B yet still retained a related genetic background on 
which to manipulate the mutant p53 gene dosage. The use of normal keratinocytes as a 
target would have been hindered by their short lifespan in culture and the use of null or 
normal keratinocytes would not have taken into account any initiating event that had 
occurred prior to the acquisition of this mutant p53 which perhaps acts in concert with 
the mutant to yield the phenotype displayed by SCC12B. The use of clone 19 therefore 
is a very appropriate and relevant target cell for investigating the influence of genetic 
events on the progression of this SCC-HN.
The growth and morphology of the cell lines used in this thesis displayed subtle but 
important differences. Clone 19, a low expressing p53 clone of SCC12F, grew very 
slowly in the culture conditions used i.e. 10% serum. They also preferred to be kept at 
quite a high cell density, losing cloning efficiency if the cells were split harshly. The 
culture conditions for this cell line were not optimised but kept identical to the other cell 
lines for a standard throughout all the experiments. Clone 19 also maintained the 
characteristic cobble stone morphology of normal keratinocytes as did SCC12F (figure 
5.8). SCC12B however appeared much flatter and exhibited a slightly faster growth 
rate. As previously reported they were able to grow in the presence of reduced serum 
(Jaffe et al., 1992). Similarly transfection of clone 19 with mutant p53216 yielded cell 
lines that showed increased growth rates and reduced serum dependence
These cell lines (19 216(1)B and 19 216 (2) 3) also showed more compact cell 
growth and seemed to be less contact inhibited (figure 5.8). These observations 
therefore indicate a correlation between p53 mutant protein levels and morphological 
changes.
Analysis of the ability of the mutant p53 transfectants (19 216(1)B and 19 216 (2) 
3) to respond to suspension induced terminal differentiation revealed two independent 
signals which could influence the decision of the cell to differentiate. One signal 
appeared to be caused by mutant p53 which prevented or blocked the transfectants from 
differentiating, the second signal came from cellular crowding which stimulated the cells 
to differentiate and sometimes masked the inhibitory effect of mutant p53.
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If the cells were grown at high density before being placed in suspension no 
obvious effect of increased mutant p53 levels on involucrin synthesis was observed over 
the controls (figure 5.10). However if the cells were grown at a much lower density, 
reducing the extent of cellular contacts before being placed in suspension, a marked 
effect was observed in the ability of the cells to express involucrin (figure 5.11).
Cultured at low density, 19 216(1)B and 19 216 (2) 3 appeared to be blocked in their 
ability to express involucrin. The level of expression after three days in suspension was 
half that of the same cells grown at much higher density. At low density the expression 
of involucrin does not increase from day 0 to day 3 in these two cell lines compared to 
controls (figure 5.11). These results indicate that mutant p53 may prevent the ability 
of cells to express involucrin but this effect can be overridden by the effects of increased 
cellular crowding which stimulate involucrin expression. This stimulation of 
differentiation by crowding is also shown by comparing the extent of involucrin 
expression at day 0 in the low and high density experiments. Cells grown at low density 
(figure 5.11a) tend to express much less involucrin than those grown at higher density 
(figure 5.10a) suggesting that a stimulus induced by crowding is switching on 
differentiation in these cell lines even before thay are placed in suspension culture. It has 
been shown by others that the area of contact with the substratum and hence cell shape 
regulates proliferation and terminal differentiation of HEKs in culture (Watt et al., 1988). 
When spreading is restricted as in the case of cells cultured at high density, and hence the 
cells become slightly rounded, involucrin expression was stimulated and DNA synthesis 
inhibited (Watt et al., 1988). This effect of high density cultures is mimicked by 
suspension culture i.e. reducing contact with the substratum and forcing cells to alter 
their shape. The signalling pathway by which cells undergo terminal differentiation in 
response to cell density is not clear but is proposed to be mediated by receptors 
expressed on the keratinocyte cell surface. The two major classes of adhesive receptors 
expressed by keratinocytes are integrins (Hynes 1992) which mediate adhesion to the 
extracellular matrix (discussed in more detail in the next section), and cadherins which 
mediate cell-cell adhesion (Geiger and Ayalon, 1992). Integrin binding to the 
extracellular matrix has been implicated in cell signalling maintaining cell proliferation
(Adams and Watt, 1989). On commitment to terminal differentiation the ability of 
integrin receptors to bind ligand decreases (Adams and Watt, 1990) due to modulation 
of the receptors on the cell surface (Hotchin and Watt, 1992) and eventually expression 
of the integrin receptor is completely lost. The major cadherins expressed on 
keratinocytes are P cadherin (confined to the basal cells) and E cadherin and cell-cell 
adhesion mediated by these receptors in calcium dependent (Takeichi, 1991). Recent 
experiments have shown that in low calcium medium keratinocytes co-express integrins 
and terminal differentiation markers e.g. involucrin. On increasing the levels of calcium 
cells stratify and integrins are lost from the cell surface (Hodivala and Watt, 1994). 
Furthermore antibodies to P and E cadherin inhibited calcium induced stratification and 
loss of integrins (Hodivala and Watt, 1994). Therefore not only does decreased contact 
with the substratum and alteration of cell shape induce terminal differentiation of 
keratinocytes but also cell to cell adhesion mediated by cadherin interactions stimulates 
loss of integrin expression which is known to occur during terminal differentiation 
(Adams and Watt, 1989 and 1990).
Plating cells at high density may therefore have already committed or sensitised 
cells to any further differentiation stimulus and hence higher levels of involucrin are 
expressed after suspension culture in the high density experiment. It is clear however
p i  r
from the low density experiments that mutant p53 has an inhibitory effect on the 
production of involucrin but this inhibition can be overridden by a pathway independent 
of p53.
Increasing mutant p53 also had an inhibitory effect on the production of another 
marker of terminal differentiation, comified envelope formation. All cell lines expressing 
high levels of p53216 mutant i.e. 19 216(1)B, 19 216 (2) 3, 19 216 (2) 1 and SCC12B 
are unable to form comified envelopes after 5 days in suspension unlike all the controls 
(figure 5.15 and 5.16). This inability to form envelopes is observed when the cells are 
grown at both high density and low density. However at high density the numbers of 
envelopes counted were higher in all cell lines compared to low density experiments 
suggesting again that cellular crowding increases the proportion of terminally
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differentiating cells as discussed above. The differentiation signal exerted by cellular
crowding does not appear to have such a strong effect on comified envelope formation
fy \ f \as it does on involucrin synthesis. The inhibitory effect of mutant p53 on envelope 
formation can still be observed even when the cells are grown at high density before 
being placed in suspension. The difference in stimulation of both markers by cellular 
crowding is surprising as involucrin is the precursor protein of the envelope and 
therefore it would be expected that both would be expressed to the same degree in 
response to such a signal. However it is known that involucrin mRNA is expressed early 
in the basal compartment (Watt and Green, 1981) unlike the comified envelope which is 
formed much later in the granular layer (Sun and Green, 1976). As cells leave the basal 
layer, moving into the granular layer they become permeable (Green, 1977) and an 
insoluble comified envelope forms beneath the plasma membrane (Sun and Green, 1976). 
This envelope forms from the cross-linking of several proteins by the cellular enzyme 
transglutaminase (Rice and Green, 1977). One such precursor of the envelope is the 
soluble protein involucrin (Rice and Green, 1979; Watt and Green, 1981) which as 
previously discussed, is synthesised early in differentiation. Other membrane proteins 
however are also thought to be incorporated into the envelope (Simon and Green, 1984). 
Cells prevented from making contact with other cells by incubating them in semi-solid 
medium can also undergo differentiation developing detergent insoluble envelopes 
(Green, 1977) it therefore seems that cell to cell contact is not required for this aspect of 
terminal differentiation. Others have also shown that protein synthesis is also not 
required and inhibitors of protein synthesis actually stimulate envelope formation (Rice 
and Green, 1978) therefore the majority of cells at any time must have sufficient 
transglutaminase and precursor proteins to form envelopes. Transglutaminase activity 
has been identified in HEK cells (Goldsmith and Martin, 1975) and protein crosslinking 
can be induced by treatment with agents which affect cell membrane permeability and 
increase cellular calcium levels (Rice and Green, 1979). It is unclear whether the source 
of calcium increase that activates the transglutaminase is extracellular or intracellular but 
it is likely to come from the degradation of organelles such as mitochondria which 
release calcium into the cell, as cells incubated in calcium-free medium will ultimately
form cross-linked envelopes (Rice and Green, 1978). Studies of transglutaminase in 
SCC12B and SCC12F have shown that SCC12B has as much as a 50 fold decrease in 
total transglutaminase activity than SCC12F (Rubin and Rice, 1986) therefore explaining 
the incompetence of SCC12B in forming envelopes. It would be of interest to establish 
whether transglutaminase activity has also decreased in the transfectants of clone 19 
expressing high levels of mutant p53 or whether a separate event has caused a decrease 
in enzyme activity in SCC12B. iPhorbal ester tumour promoter TPA treatment of 
cultured keratinocytes has been shown to accelerate the appearance of keratins (Steinert 
and Yuspa, 1978), induce synthesis of epidermal transglutaminase (Yuspa, 1980) and 
increase the formation of comified envelopes (Reiners and Slaga, 1983). The method of 
stimulation of terminal differentiation by TPA is unknown and is independent of the 
hyperplasia caused by such agents but it may be due to an increase in protein synthesis. 
The results discussed above show that involucrin synthesis is stimulated by cell to cell 
contact but formation of envelopes is not affected to the same extent. This is likely to be 
due to the early synthesis of involucrin in the proliferative basal cells, whilst envelopes 
are not formed until intracellular calcium levels rise much later when cells are 
metabolically inactive and already committed to terminal differentiation.
Analysis of the cell morphology and DNA content during suspension showed slight 
nuclear shrinking and margination after five days in suspension in clone 19 but not in 
cells expressing high levels of mutant p53 (figure 5.17). This is in agreement with other 
data in this thesis showing terminal differentiation to be inhibited in cell lines with high 
levels of mutant p53. Degradation of the nucleus in an apoptotic manner also termed 
anoikis is part of the normal terminal differentiation pathway in keratinocytes (McCall 
and Cohen, 1991; Meredith et al., 1993; Frisch and Francis, 1994). As comified 
envelopes are formed the cells become permeable and calcium levels increase, the 
nucleus is digested some days later. 50% of HEK cells cultured in methylcellulose have 
lost their nucleus by day 8 (Green, 1977). A component of serum, plasminogen, has 
been shown to be essential for nuclear degradation and HEK cells are believed to contain 
an activator of this enzyme (Green, 1977) Nuclear degradation in keratinocytes is
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caused by a calcium dependent endonuclease which cleaves DNA into 200bp fragments 
which when run on an agarose gel displays a ladder pattern, a hallmark of apoptosis 
(McCall and Cohen, 1991). Preliminary results here show that increased levels of mutant 
p53 appears to prevent nuclear margination and elimination but more detailed analysis of 
DNA laddering and endonuclease activity needs to be carried out to clarify the affect of 
mutant p53 on apoptosis.
Results in this thesis j suggest that increased levels of mutant p53216 enables the 
cells to overcome suspension induced cell death (section 5.2.3.). The cloning efficiencies 
of the transfected cell lines 19 216(1)B and 19 216 (2) 3 were much higher after 
suspension in methylcellulose for 24 hours than the controls that express low levels of 
mutant p53 (figure 5.12 and figure 5.13). The colonies that were obtained from these 
cell lines appeared much bigger and stronger and were often fixed for counting before 
confluence three to four days before any other cell line. The control cell lines expressing 
the vector alone, 19 CMV 8 and 19 CMV 13 also showed a high survival rate relative to 
the original clone 19. It is unlikely that the CMV promoter or the neomycin gene 
conveyed any resistance to suspension induced cell death. It is more likely that during 
the G418 selection, there is an unconscious bias towards cloning larger colonies that 
often represent fitter cells. These control cell lines still showed a lower survival rate than 
cell lines expressing high levels of mutant p53. Cellular density also had a slight effect on 
the extent of survival as it did for conified envelope formation and involucrin synthesis 
described above. In cell lines 19 216(1)B and 19 216 (2) 3 survival dropped from 73% 
and 71% at low density, to 49% and 61% at higher density respectively. Once again 
cells have already started to differentiate in response to cellular crowding giving a lower 
survival rate after suspension culture compared to lower density cultures but the survival 
phenotype given by increased mutant p53 appears to be dominant to this signal and the 
cells expressing this mutant p53 are resistant to suspension induced cell death.
I These results indicate that an increase in mutant p53216 in clone 19 prevents 
the cells from responding to terminal differentiation signals when placed in suspension 
culture. These experiments therefore show that the different dosages of mutant p53 in
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SCC12F and SCC12B are responsible for the difference between the two cell lines in 
their ability to differentiate. Increasing the level of mutant p53 dosage in a clone of 
SCC12F, clone 19, produces a phenotype more like that of SCC12B with respect to 
terminal differentiation, and this is therefore an event that happens in the progression of 
this SCC.
The tumorigenicity of each cell line in nude mice was not as convincing as the 
terminal differentiation data (figure 5.18 and figure 5.19). In our hands SCC12B was 
not as tumorigenic as reported by others (Parkinson et al, 1984; Jaffe et al, 1992) this 
maybe due to the use of different mice or the more stringent criteria used in this thesis 
which required the tumour to remain for 3 months and reach a size of 1cm3. Relatively 
large tumours were visible after injection of the higher dose of SCC12B after only 2 
weeks but these regressed slowly in all mice. The lower injection dose (1.6 x 106 cells 
/site) appeared to be less affective at inducing tumours. In accordance with published 
results SCC 12F, clone 19 and clone 19 expressing vector alone all induced large cysts 
which regressed in all but 1 animal where it remained at a very small size (figure 5.18 and 
5.19). The tumorigenic potential of cell lines expressing large amounts of mutant p53216 
appeared to be clonal. 19 216(2) 3 did not induce tumours at any dose in either 
experiment nor did a second clone 19 216(2) 1 . 19 216(1) B
developed large tumours at the higher injection dose in all mice after only 8 weeks 
(figure 5.18). However these regressed and two tumours 1cm3 were noted with a latent 
period of 66 days. The mice were kept alive and one of these tumours regressed further 
leaving only one remaining 19 weeks post-injection. This latent period is much longer 
than that published for SCC12B (Jaffe et al, 1992). This data therefore shows that in 
our mice increasing the levels of mutant p53 does not increase the tumorigenic potential 
of a cell line. Only one clone (19 216(1) B) was slightly tumorigenic but this could not 
really be explained by the increase in mutant p53216 levels alone since 19 216(2) 3 was 
not tumorigenic. No correlation between degree of resistance to suspension induced 
terminal differentiation and tumorigenicity was apparent when comparing 19 216(1) B 
with 19 216(2) 3. Interestingly, this data has shown that resistant to terminal
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differentiation and tumorigenicity are separate events and cell lines can be resistant to 
terminal differentiation but not necessarily tumorigenic. It therefore appears that 
tumorigenicity depends on individual clones and increasing the levels of mutant p53 
alone is not sufficient to increase the tumorigenicity of the cell line. It may be that a 
slightly more tumorigenic phenotype was displayed by clone 19 216(1) B due to the 
presence of another unknown genetic event that acts in concert with the increase in 
mutant p53 giving a more tumorigenic phenotype.
Loss of the ability to respond to terminal differentiation signals, increased 
proliferation and loss of cloning efficiency are usually early events in the development of 
SCC-HN (Edington et al., 1995). SCC12F displays a more normal phenotype than 
SCC12B (Parkinson et al., 1983; Jaffe et al., 1992 and results in this thesis) and may 
have acquired only a few genetic events leading it a short way along the line to 
carcinogenesis. The results in this thesis show that a p53 mutation is acquired relatively 
early in the progression of this cancer as at least one mutant allele is present in both 
SCC12F and SCC12B. The rate limiting step in the progression of SCC12F to SCC12B 
therefore appears to be the accumulation of mutant p53 normally by the complete loss of 
the wild-type allele, but in this case by the loss of one of two wild-type alleles. This 
event dramatically changes the phenotype of SCC12F by further reducing its ability to 
respond to terminal differentiation and increasing its cloning efficiency after suspension 
culture. However a p53 mutation alone is not sufficient to affect the tumorigenic 
potential of the cell line and therefore another later event is required perhaps gained 
through genetic instability due to the loss of p53.
Interestingly, investigators have shown that expressing the latent membrane protein 
(LMP-1) from the Epstein-Barr virus (EBV) in SCC12F also inhibits its ability to 
terminally differentiate (Dawson et al., 1990). The transfectants were unable to form 
comified envelopes in response to treatment with the calcium ionophore A23187, nor 
were they able to express involucrin. Expression of LMP-1 in another human 
keratinocytes cell line (Rhek-1) was also shown to block differentiation and predisposes 
these cells to a more neoplastic phenotype (Zheng et al., 1994). LMP-1 expression in
174
rodent cell transformation assays resembled those produced by activated ras, therefore 
SCC12F was also transfected by a H-ras oncogene (Dawson et al., 1990). This 
produced a similar effect as LMP-1 with respect to differentiation. These experiments 
also showed the the LMP-1 trasnsfected SCC12F cells^mlike the highly malignant ras 
transfectants;produced tumours in nude mice only rarely and after a long latency period. 
H-ras has previously been shown not to be activated in SCC12F or SCC12B (Clark et 
al., 1993) and therefore in these experiments it may bypass the need for a p53 mutation 
in order to produce a tumorigenic phenotype. LMP-1 is a transmembrane protein with 
unknown function. Another EBV protein, EBNA5, has been shown to interact with p53 
and Rb-1 (Szekely et al., 1993) and it is therefore unlikely that the results obtained by 
transfection of SCC12F described above resemble those in this thesis by the ability of 
LMP-1 to inactivate p53 directly. Although LMP-1 is not a tyrosine kinase it still may 
act in a signalling pathway similar to integrin signalling promoting cellular proliferation 
and inhibiting p53 mediated differentiation as described in the next section.
6.3 A possible role for p53 in terminal differentiation of human 
epidermal keratinocytes.
The results in this thesis show that an increase in mutant p53 or conversely a 
decrease in active wild-type p53 prevent keratinocytes from responding to suspension 
induced terminal differentiation signals. The involvement of p53 in the control of 
terminal differentiation of keratinocytes is perhaps not surprising. Numerous 
investigators have shown that p53 is involved in the differentiation of many cell types 
(details in section I.4.3.8.). Interestingly, the differentiation pathways in such cell types 
involves DNA strand breaks followed by repair, for example B cell differentiation 
involves several DNA rearrangement events and therefore this step in differentiation may 
require the activities of p53 to halt cell cycle and repair DNA after rearrangements have 
occurred. During the differentiation of keratinocytes DNA fragmentation occurs in the 
upper granular layers as the cells degrade their nucleus by apoptosis (McCall and Cohen,
1991). It is very unlikely that this DNA damage triggers p53 activity as the only
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proliferating cells in the epithelium are in the basal layer and cells of the granular layer 
would be unable to synthesis p53 protein in response to such DNA fragmentation. It is 
more likely that the actions of p53 enables the cell to withdraw from the cell cycle and 
stop DNA replication as they migrate from the basal membrane. Recent experiments 
have shown that anchorage independent cells grown in suspension arrest in G1 
(Guadagno et al, 1993) which is a known action of p53. This thesis shows that mutation 
in p53 prevents terminal differentiation and would suggest therefore that upon 
withdrawal from the cell cycle wild-type p53 would stimulate the onset of terminal 
differentiation via an unknown pathway. Events so far shown to trigger p53 action are 
those that induce DNA damage, specifically strand breaks e.g. irradiation, actinomycin D 
and restriction enzymes. A trigger that activates p53 in keratinocyte terminal 
differentiation has not yet been identified but recent experiments show that when 
epithelial cells are prevented from contacting the basement membrane they undergo 
terminal differentiation (Watt et al, 1983) and an apoptotic-like phenomenon which has 
been termed anoikis (Meredith et al, 1993; Frisch and Francis, 1994). The basal surface 
of epithelial cells adheres to the basal lamina mostly via members of the integrin family 
receptors (Adams and Watt, 1991). Integrins are heterodimeric transmembrane proteins 
consisting of a  and (3 subunits (Hynes, 1992). Diversity in the integrin family is achieved 
by dimerisation between different subunits and each member binds to a different 
extracellular matrix protein such as fibronectin, collagens, laminin, nidogen and 
vitronectin and they also associate with cytoskeletal proteins such as actin. Integrins 
have been shown to translate external cues into signals that affect cytoskeletal 
organisation, cell shape and motility as well as cell-cell adhesion, cell migration and 
stratification. Recent evidence suggests that integrins mediate anchorage independent 
growth and are able to trigger terminal differentiation. More specifically the fibronectin 
integrin receptor asPjhas been shown to directly affect the cells ability to undergo 
terminal differentiation (Adams and Watt, 1989). Terminal differentiation can be 
inhibited in cells grown in suspension by the immediate addition of fibronectin (Adams 
and Watt, 1989). A delay in the exposure to fibronectin has no effect as the cells have 
already been committed to terminal differentiation, the ability of the receptor to bind
fibronectin is decreased (Adams and Watt, 1990) and the receptor is gradually lost from 
the cell surface. Binding of fibronectin to its receptor during adhesion to the basement 
membrane signals the clustering and retention of receptors into focal contacts and 
polymerisation of actin filaments providing a positive stimulus for cell adhesion and 
spreading. This ligand binding also sends a second signal independent of clustering that 
inhibits terminal differentiation. Integrin signalling is thought to be mediated via changes 
in cellular pH, calcium fluxes and phosphorylation events. Treatment of cells with an 
anti-integrin antibody or fibronectin increases the tyrosine phosphorylation of proteins in 
the cell (Juliano and Haskill, 1993). One such protein has been identified as FAK (focal 
adhesion kinase) which is also a substrate for c-src proteins. The phosphorylation of this 
protein along with others is thought to promote cell growth and inhibit terminal 
differentiation and anoikis. Detachment of epithelial and endothelial cells but not 
fibroblasts from extracellular matrix contacts has been shown to elicit anoikis (Meredith 
et al, 1993; Frisch and Francis, 1994). In vivo such a response would prevent detached 
cells from becoming inappropriately re-attached and helps maintain the stratification and 
polarity of the epithelia. Meredith et al, 1993 has shown that the addition of sodium 
orthovanidate which is an inhibitor of tyrosine phosphatases, to cells in suspension blocks 
programmed cell death therefore suggesting that apoptosis is triggered by signals from 
integrins via tyrosine phosphorylation. Apoptosis in these cells can be inhibited by the 
addition of anti-integrin antibodies (Meredith et al, 1993), scatter factor or transfection 
with bcl-2 (Frisch and Francis, 1994)). Interestingly, bcl-2 is expressed in the basal layer 
of the skin but not in other layers suggesting that this may be an in vivo mechanism for 
preventing apoptosis (Hockenbury et al, 1991). P53 has been shown to promote 
apoptosis (discussed in section 1.4.3.7.) and results in this thesis also shows its 
inactivation prevents terminal differentiation. It is therefore possible that p53 may 
respond to integrin signalling when cells lose contact with the extracellular matrix, 
arresting cells in G1 and triggering terminal maturation which includes apoptosis as the 
cells migrate towards the outer epithelial layers. Activation of p53 via an integrin 
pathway has not yet been proved but it is clear that p53 is able to promote apoptosis and 
this thesis shows it to play an important role in keratinocyte differentiation. Whether p53
acts directly by controlling the expression of specific differentiation proteins e.g. 
involucrin or transglutaminase or whether it acts indirectly by establishing an irreversible 
commitment to terminal differentiation via withdrawal from the cell cycle is not clear and 
further experiments are required to define further the involvement of p53 in keratinocyte 
terminal maturation
6.4. Wild-type p53 prevents the expression of an oncogenic phenotype.
Mice null for p53 are viable and exhibit normal development (Donehower et al.,
1992) making it hard to establish a role for wild-type p53 in normal differentiation 
pathways unless some form of redundancy has taken place in these mice which is difficult 
to prove. Wild-type p53 has been shown to induce growth inhibition (Kastan et al., 
1991a; Kuerbitz et al., 1992) and apoptosis (Yonish-Rouach et al., 1991) in response to 
DNA damage preventing the accumulation of mutations and gene amplifications that are 
associated with malignancy. For this reason there appears to be an immense pressure for 
the loss of wild-type p53 and indeed the majority of tumours have acquired a mutation in 
a p53 allele with the concurrent loss of the remaining allele. An alternative model for the 
involvement of mutant p53216 in the progression of the SCC-HN cancer dicussed in this 
thesis may be that its accumulation allows the expression of an oncogenic phenotype i.e. 
either an activated oncogene or an inactivated tumour suppressor gene which in turn 
blocks terminal differentiaion. The presence of wild-type p53 would normally prevent 
the expression of such a phenotype by inducing growth arrest or terminal differentiation. 
The expression of adenovirus El A (known to bind Rb-1) in untransformed cells leads to 
the nuclear stabilization of wild-type p53 and loss of viability of these cells by apoptosis 
(Lowe and Ruley, 1993b). Levels of p53 protein reverted to normal in cells that had lost 
El A expression. Similarly deregulated c-myc expression induces apoptosis in low serum 
conditions (Evan et al., 1992). E1B which is known to bind to p53 was shown to 
protect cells form this toxic effect of E1A suggesting the role for E1B in viral infection is 
to counter cellular responses to El A oncogene transformation (Lowe and Ruley, 1993b). 
The stabilization of p53 in these cells appears to guard cells against unscheduled
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proliferation induced by El A and p53 induced apoptosis may play a natural defense 
against tumour progression in vivo. The use of embryonic fibroblasts from p53 null mice 
highlighted the role of p53 in the suppression of oncogenic transformation. The absence 
of wild-type p53 enhances cell growth and survival in the presence of El A (Lowe et al., 
1994). Cells heterozygous for p53 when transfected with El A formed almost as many 
colonies as did null fibroblasts and displayed an intermediate resistance to apoptosis.
This dose-dependent suppression of oncogene transformation by p53 suggests that 
mutations leading to the partial loss of p53 (for example SCC12F) allows the outgrowth 
of cells that have completely lost wild-type p53 activity (such as SCC12B) and therefore 
can no longer suppress the oncogenic phenotype of the cell. In such a way the 
accumulation of a p53 mutation allows the progession of a tumour which was initiated by 
oncogenic events. Studies of tumour formation in null and heterozygous mice showed 
that loss of wild-type p53 is not an initiating event and does not give rise to an increased 
number of papillomas. It does however appear to enhance the rate of malignant 
progression (Kemp et al., 1993). The progresssion rate was also greater in heterozygous 
mice as compared to normals and was associated with the loss of the remaining wild-type 
allele (Kemp et al., 1993; Harvey et al., 1993b). Interestingly, this study also shows that 
the carcinomas from p53 null and heterozygous mice were markedly undifferentiated in 
comparison with wild-type carcinomas (Kemp et al., 1993). Similarly papillomas from 
the null mice also showed a similar undifferentiated phenotype compared to wild-type 
and showed areas of conversion to early stage carcinomas. Therefore not only does the 
inactivation of p53 increase the rate from benign to malignant conversion, it also 
influences the degree of differentiation and malignancy of a tumour. These results 
suggest that loss of wild-type p53 whilst not initiating allows the expression of oncogenic 
events that occur in multistep carcinogenesis which promotes malignant progression and 
dedifferentiation.
This thesis therefore shows that the accumulation of mutant p53216 is responsible 
for the progression of SCC12F to SCC12B. The increased levels of this mutant p53 may 
promote a more malignant phenotype in vivo by either one of the above mechanisms.
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Either by the direct inhibition of terminal differentiation induced by signalling from 
integrin receptors or indirectly by allowing the expression of an oncogene which intum 
blocks terminal differentiation and promotes proliferation.
The acquisition of mutant p53, whilst not an initiating event in carcinogenesis as 
previously discussed, appears to be an early event in the development of SCC-HN. In 
SCC12, a p53 mutation has occurred at an early stage in SCC12F before a more 
malignant phenotype has developed. There is intense pressure for this cancer to lose any 
active wild-type p53 in order for it to progress (SCC12B). A study of the epithelia at 
distant sites from the primary tumour in SCC-HN (Nees et al., 1993) showed that 
although these biopsies were histologically inconspicuous they contained high levels of 
p53 protein. This increased level of protein was not due to a response to DNA damage 
but was associated with a p53 mutation and an increase in cellular proliferation as shown 
by an increase in histone H3 mRNA. Whatsmore different tumour distant sites from the 
same biopsy expressed different p53 mutations suggesting the development of multiple 
primary tumours frequently seen in head and neck cancer patients is a multifocal 
polyclonal process. Cells that showed high levels of p53 also showed a dedifferentiated 
phenotype by the presence of high levels of cytokeratin 8 and 18 which are consistently 
detected in squamous cell carcinomas. Similar conclusions were drawn from the 
discovery of early p53 mutations in cases of Bowens disease (Campbell et a l , 1993) a 
pre-invasive lesion which shows a significant rate of progression to invasive SCC. 
Therefore taken together results from this thesis and and others (Nees et al., 1993; 
Campbell et al., 1993) suggest that the role of p53 mutation in SCC of the skin and head 
and neck are different from that seen in colonic cancer where a mutation rarely precedes 
invasion (Baker et al., 1989). On the contrary results here show that in vivo SCC12F 
acquired a p53 mutation early in its development which gave it a slight growth advantage 
and a delay in the response to terminal differentiation caused by rounding and cellular 
contact in the basal cells as compared to normal cells. This increased proliferation 
allowed other genetic events to occur in this cancer which were suppressed by the 
presence of the remaining wild-type p53. There was then increased pressure for the cells
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to lose wild-type p53 by the accumulation of more mutant p53 which resulted in a 
dramatic progression of cells to a more malignant phenotype (SCC12B).
6.5. Future prospects.
Experiments are currently underway to show that the inhibition of terminal 
differentiation shown in this thesis is directly dependent on the presence of mutant 
p53216 and not by any other effect of suspension culture. The mutant p53 is being 
expressed under the inducible metallothionein promoter in clone 19 and the experiments 
are being repeated in the presence and absence of mutant p53 expression. It is also 
important to establish whether it is the knockout of wild-type p53 activities by increased 
expression of the mutant or a novel function gained by the mutant protein that blocks 
suspension induced terminal differentiation. Experiments are planned whereby the 
activities of endogenous wild-type p53 protein in clone 19 can be inhibited either by 
HPV infection, transfection with antisense RNA or transfection with the C terminal 
fragment of p53 that acts by oligomerising with the wild-type protein and prevents its 
action. It will be interesting to see if the removal of wild-type activities from clone 19 
are sufficient to inhibit terminal differentiation and if so this would provide evidence to 
suggest that the mutant p53216 was acting in a dose-dependent dominant negative 
manner. If knocking out wild-type p53 is not sufficient to obtain the results shown in 
this thesis then it would suggest that the mutant had gained a property that interfered 
with terminal differentiation.
Further molecular analysis of the mutant p53216 would be interesting so as to 
understand how the mutation affects the protein. Analysis of its DNA binding and 
transcriptional activities using a CAT construct would show if it has retained any wild- 
type p53 characteristics. Also analysis of whether the mutant can knockout wild-type 
p53 transactivation of a reporter construct in vitro and whether such an activity is 
dependent on mutant dosage as seen in vivo in SCC12F and SCC12B would highlight
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whether the mutant acts in a dominant negative manner to prevent wild-type activites and 
inhibit terminal differentiation.
The experiments in this thesis did not investigate the extent to which each cell line 
can undergo apoptosis. As p53 has been implicated in controlling this process and 
keratinocytes have been shown to induce an apoptotic-like process when cells become 
detached from the substratum or are grown in suspension (McCall and Cohen.,1991; 
Meredith et al., 1993; Frisch and Francis, 1994), it would be of interest to study the 
effect of increased mutant p53 on this process. DNA laddering is technically quite 
difficult to show in some cell lines (Wyllie, 1980). Other markers of apoptosis such as 
protein crosslinking due to the activation of intracellular transglutaminases, detergent 
solubility of degraded DNA, and the expression of the apoptotis specific gene TRPM-2 
by northern analysis (Meredith et al., 1993) could be studied.
If the inability of the cells to respond to suspension induced terminal differentiation 
was due purely to the inactivation of wild-type p53 it would be interesting to establish 
just how wild-type p53 would normally trigger the differentiation pathway.
Identification of p53 consensus binding sites in promoters of epithelial differentiation 
proteins such as involucrin, keratins or transglutaminase, similar to that found in the 
muscle differentiation gene MCK promoter enhancer (Weintraub et al., 1991), would 
suggest a direct involvement of p53 in terminal differentiation of keratinocytes. If a 
positive involvement was identified it would be interesting to see how this pathway has 
become redundant in cells without wild-type p53 such as p53 knockout mice which 
clearly display normal development and differentiation of the epidermis. If p53 played a 
more indirect role by switching the commitment to terminal differentiation on, 
comparisons of the proportion of cells able to arrest in G1 during suspension culture or 
removal from the basement membrane in cell lines with high and low doses of mutant 
p53 would highlight a pathway for p53 involvement.
A closer examination of the relationship between integrin signalling and p53 
activation is required in order to support the model described above which proposes 
terminal maturation of keratinocytes is triggered by release of ligand from the integrin 
receptor and mediated by p53. Little is known of the pathways involved in integrin-
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mediated signalling either growth promoting or those involved in anoikis. Investigation 
of such pathways and any implication of p53 involvement could highlight an exciting new 
role for wild-type p53 in the terminal maturation of keratinocytes.
183
References
References
Adams, J.C. and Watt, F.M. (1989). Fibronectin inhibits the terminal differentiation of 
human keratinocytes. Nature, 340:307-309.
Adams, J.C. and Watt, F.M. (1990). Changes in keratinocyte adhesion during terminal 
differentiation: Reduction in fibronectin binding precedes a5(31 integrin loss from the cell 
surface. Cell, 63:425-435.
Adams, J.C. and Watt, F.M. (1991). Expression of |3j, P3, P4, and P5 integrins by human 
epidermal keratinocytes and non-differentiating keratinocytes. J.CellBiol. 115:829-841.
Agoff, S.N., Hou, J., Linzer, D.I.H. and Wu, B. (1993). Regulation of the human hsp70 
promoter by p53. Science, 259:84-87.
Ah-See, K.W., Cooke, T.G., Pickford, I., Soutar, D. and Balmain, A. (1994). An 
allelotype of squamous cell carcinoma of the head and neck using microsatellite markers. 
Cancer Res. 54:1617-1621.
Ahuja, H., Bar-Eli, M., Arlin, Z., Advani, S., S.L.., Goldman, J., Snyder, D., Foti, A. and 
Cline, M. (1991). The spectrum of molecular alterations in the evolution of chronic 
myelocytic leukemia. J. Clin.Invest. 87:2042-2047.
Allsopp, R.C., Vaziri, H., Patterson, C., Goldstein, S., Younglai, E.V., Futcher, A.B., 
Greider, C.W. and Harley, C.B. (1992). Telomere length predicts replicative capacity of 
human fibroblasts. Proc.Nat.Acad.Scl, U.S. A  89:10114-10118.
Almon, E., Goldfinger, N., Kapon, A., Schwartz, D., Levine, A.J. and Rotter, V. (1993). 
The p53 suppressor is expressed in spermatogenesis. Dev.Biol. 156:107-116.
Aloni Grinstein, R., Bar, I.Z., Alboum, I., Goldfinger, N. and Rotter, V. (1993). Wild- 
type p53 functions as a control protein in the differentiation pathway of the B cell 
lineage. Oncogene, 8:3297-3305.
Arnold, A., Kim, H.G., Gaz, R.D., Eddy, R.L., Fukushima, Y., Byres, M.G., Shows,
T.B. and Kronenberg, H.M. (1989). Molecular cloning and chromosomal mapping of 
DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma.
J. Clin.Invest. 83:2034-2040.
Baden, H.P., Kubilis, J., Kvedar, J.C., Steinberg, M.L. and Wolman, S.L. (1987). 
Isolation and characterisation of a spontaneously arising long-lived line of human 
keratinocytes (NMI). In Vitro Cell Dev. Biol 23:205-213.
Baker, S.J., Fearon, E.R., Nigro, J.M., Hamilton, S., Preisinger, A.C., Ledbetter, D.H., 
Jessup, J.M., vanTuinen, P., Barker, D.F., Nakamura, Y., Whyte, R. and Vogelstein, B. 
(1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. 
Science, 244:217-221.
Baker, SJ., Markowitz, S., Fearon, E.R., Willson, J.K.V. and Vogelstein, B. (1990). 
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 
249:912-914.
Balmain, A., Ramsden, M., Bowden, G.T. and Smith, J. (1984). Activation of the mouse 
cellular Harvey-ras gene in chemically induced benign skin papillomas. Nature, 307:658- 
660.
Banks, L., Matlashewski, G. and Crawford, L. (1986). Isolation of human p53 specific 
monclonal antibodies and their use in the studies of human p53 expression. 
Eur.J.Biochem. 159:529-534.
Barak, Y., Gottlieb, E., Gershon, TJ. and Oren, M. (1994). Regulation of mdm-2 
expression by p53: alternative promoters produce transcripts with nonidentical 
translation potential. Genes & Development, 8:1739-1749.
Bargonetti, J., Friedman, P.N., Kern, S.E., Vogelstein, B. and Prives, C. (1991). Wild- 
type, but not mutant p53 immunopurified proteins bind to sequences adjacent to the 
SV40 origin of replication. Cell, 65:1083-1091.
Bargonetti, J., Reynisdottir, I., Friedman, P.N. and Prives, C. (1992). Site-specific 
binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. 
Genes & Development, 6:1886-1898.
Bargonetti, J., Manfredi, J.J., Chen, X., Marshak, D.R. and Prives, C. (1993). A 
proteolytic fragment from the central region of p53 has marked sequence-specific DNA 
binding activity when generated from wild-type but not from oncogenic mutant p53 
protein. Genes & Development, 7:2565-2574.
185
Barrandon, Y. and Green, M. (1987). Cell migration is essential for sustained growth of 
keratinocyte colonies: The roles of transforming growth factor alpha and epidermal 
growth factor. Cell, 50:1131-1137.
Bhatia, K., Goldschmidt, S., Gutierrez,M., Gaidano, G., Dalla-Favera, R. and Magrath,
I. (1993). Hemi or homozygosity: A requirement for some but not other p53 mutant 
proteins to accumulate and exert a pathogenic effect. Faseb J. 7: 951-956.
Berenson, J.R., Koga, H., Yang, J., Pearl, J., Holmes, E.C. and Figlin, R. (1990). 
Frequent amplification of the BCL-1 locus in poorly differentiated squamous cell 
carcinoma of the lung. Oncogene, 5:1343-1348.
Berry, I.J., Bums, J.E. and Parkinson, E.K. (1994). Assignment of two human epidermal 
squamous cell carcinoma cell lines to more than one complementation group for the 
immortal phenotype. MolCarcin. 9:134-142.
Birch, J.M., Hartley, A.L., Santibanez-Koref, M.F., Tricker, KJ., Prosser, J., Condie,
A., Kelsey, A.M., Harris, M., Morris Jones, P.H., Binchy, A., Crowther, D., Craft, A.W., 
Eden, O.B., Evans, D.G.R., Thomson, E., Mann, J.R. and Martin, J. (1994). Prevalence 
and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. 
Cancer Res. 54:1298-1304.
Bischoff, F.Z., Yim, S.O., Pathak, S., Grant, G., Sicilano, M.J., Giovanella, B.C.,
Strong, L.C. and Tainsky, M.A. (1990a). Spontaneous abnormalities in normal 
fibroblasts from patients with Li-Fraumeni cancer syndrome: Aneuploidy and 
immortalisation. Cancer Res. 50:7979-7984.
Bischoff, J.R., Friedman, P.N., Marshak, D.R., Prives, C. and Beach, D. (1990b).
Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2.
Proc.Nat.Acad.ScL, U.S.A 87:4766-4770.
Boynton, R.F., Huang, Y., Blount, P.L., Reid, B J., Raskind, W.H., Haggitt, R.C., 
Newkirk, C., Resau, J.H., Yin, J., McDaniel, T. and Meltzer, S.J. (1991). Frequent loss 
of heterozygosity at the retinoblastoma locus in human esophageal cancers. Cancer Res. 
51:5766-5769.
Braithwaite, A.W., Sturzbecher, H.W., Addison, C., Palmer, C., Rudge, K. and Jenkins, 
J.R. (1987). Mouse p53 inhibits SV40 origin-dependant DNA replication. Nature, 
329:458-460.
186
Brash, D.E., Rudolph, J.A., Lin, A., McKenna, G.J., Baden, H.P., Halperin, AJ. and 
Ponten, J. (1991). A role for sunlight in skin cancer: UV induced p53 mutations in 
squamous cell carcinomas. Proc.Nat.Acad.Sci., U.S.A 88:10124-10128.
Buchkovich, K., Duffy, L.A. and Harlow, E. (1989). The retinoblastoma protein is 
phosphorylated during specific phases of the cell cycle. Cell, 58:1097-1105.
Buchman, V.L., Chumakov, P.M., Nirikina, N.N., Samarina, O.P. and Georgiev, G.P. 
(1988). A variation in the structure of the protein-coding region of the human p53 gene. 
Gene, 70:245-252.
Bums, J.E., Baird, M.C., Clark, L.J., Bums, P.A., Edington, K., Chapman, C., Mitchell, 
R., Robertson, G., Soutar, D. and Parkinson, E.K. (1993). Gene mutations and increased 
levels of p53 protein in human squamous cell carcinomas and their cell lines.
BrJ. Cancer, 67:1274-1284.
Bums, J.E., Clark, LJ., Yeudall, W.A. Mitchell, R., Mackenzie, K., Chang, S.E. and 
Parkinson, E.K. (1994a). The p53 status of cultured premalignant oral keratinocytes. 
BrJ. Cancer, 70:591-595.
Bums, J.E., McFarlane, R., Clark, LJ., Mitchell, R., Robertson, G., Soutar, D. and 
Parkinson, E.K. (1994b). Maintenance of identical p53 mutations throughout 
progression of squamous cell carcinomas of the tongue. Oral Oncol, Eur.J. Cancer 
30B:335-337.
Cairns, P., Shaw, M.E. and Knowles, M.A. (1993). Preliminary mapping of the deleted 
region of chromsome 9 in bladder cancer. Cancer Res. 53:1230-1232.
Calbretta, B., Kaczmarek, 1., Selleri, 1., Torelli, G., Ming, P.M.L., Ming, S.C. and 
Mercer, W.E. (1986). Growth dependent expression of human Mr 53,000 tumour 
antigen messenger RNA in normal and neoplastic cells. Cancer Res. 46:5738-5742.
Campbell, C., Quinn, A.G., Ro, Y.S., Angus, B. and Rees, J.L. (1993). p53 mutations 
are common and early events that precede tumour invasion in squamous cell neoplasia of 
the skin. J. Invest. Dermatol. 100:746-748.
Caron de Fromentel, C. and Soussi, T. (1992). TP53 tumour suppressor gene: A model 
for investigating human mutagenesis. Genes, chr. cancer. 4:1-15.
187
Casey, G., Lo-Hsueh, M., Lopez, M.E., Vogelstein, B. and Stanbridge, EJ. (1991). 
Growth suppression of human breast cancer cells by the introduction of a wild-type p53 
gene. Oncogene 6:1791-1797.
Cavenee, W.K., Dryja, T.P., Phillips, R.A., Benedict, W.F., Godbout, R., Gallie, B.L. 
and Murphree, A.L. (1983).Expression of recessive alleles by chromosomal mechanisms 
in retinoblastoma. Nature, 305:779-784.
Chang, S.E., Bhatia, P., Johnson, N.W., Morgan, P.R., McCormick, F., Young, B. and 
Hioms, L. (1991). Ras mutations in UK examples of oral malignancies are infrequent.
Int. J. Cancer, 48: 409-412.
Chellappan, S.P., Hiebert, S., Mudryj, M., Horowitz, J.M. and Nevins, J.R. (1991). The 
E2F transcription factor is a cellular target for the RB protein. Cell, 65:1053-1061.
Chen, J.Y., Funk, W., Wright, W.E., Shay, J. and Minna, J.D. (1993). Heterogeneity of 
transcriptional activity of mutant p53 proteins and p53 DNA target sequences.
Oncogene, 8:2159-2166.
Chen, P.L., Scully, P., Shew, J.Y., Wang, J.YJ. and Lee, W.H. (1989). Phosphorylation 
of the retinoblastoma gene product is modulated during the cell cycle and cellular 
differentiation. Cell, 58:1193-1198.
Chen, P.L., Chen, Y., Bookstein, R. and Lee, W.H. (1990). Genetic mechanisms of 
tumor suppression by the human p53 gene. Science, 250:1576-1580.
Chen, X., Farmer, G., Zhu, H., Prywes, R. and Prives, C. (1993). Cooperative DNA 
binding of p53 with TFIID (TBP) :a possible mechanism for transcriptional activation. 
Genes & Development, 7:1837-1849.
Cheng, J.Q., Jhanwar, S.C., Lu, Y. and Testa, J.R. (1993). Homozygous deletions within 
9p21-p22 identify a small critical region of chromosomal loss in human malignant 
mesotheliomas. Cancer Res. 53:4761-4763.
Cho, Y., Gorina, S., Jeffrey, P.D. and Pavletich, N.P. (1994). Crystal structure of a p53 
tumour suppressor-DNA complex: Understanding tumorigenic mutations. Science, 
265:346-355.
188
Clark, LJ., Edington, K.G., Swan, I.R.C., McLay, K.A., Newlands, W.J., Wills, L.C., 
Young, H.A., Johnston, P.W., Mitchell, R., Robertson, G., Soutar, D., Parkinson, E.K. 
and Bimie, G.D. (1993). The absence of Harvey ras mutations during development and 
progression of squamous cell carcinomas of the head and neck. BrJ. Cancer, 68:617- 
620.
Clarke, A.R., Purdie, C.A., Harrison, D.J., Morris, R.G., Bird, C.C., Hooper, M.L. and 
Wyllie, A.H. (1993). Thymocyte apoptosis induced by p53 dependent and independent 
pathways. Nature, 362:849-852.
Clore, G.M., Omichiniski, J.G., Sakaguchi, K., Zambrano, N., Sakamoto, H., Appella, E. 
and Gronenbom, A.M. (1994). High resolution structure of the oligomerisation domain 
of p53 by multi-dimensional NMR. Science, 265:386-391.
Counter, C.M., Avilion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider, C.W., Harley,
C.B. and Bacchetti, S. (1992). Telomere shortening associated with chromosome 
instability is arrested in immortal cells which express telomerase activity. Embo J, 
11:1921-1929.
Counter, C.M., Hirte, H.W., Bacchetti, S. and Harley, C.B. (1994). Telomerase activity 
in human ovarian carcinoma. Proc.Nat.Acad.Sci., U.S.A 91:2900-2904.
Cowley, G., Smith, J.A., Gusterson, B.A., Hendler, F.J. and Ozanne, B. (1984). The 
amount of EGF receptor is elevated on squamous cell carcinomas. Cancer cells, 1:5-10.
Cowley, G., Smith, J.A. and Gusterson, B.A. (1986). Increased epidermal growth factor 
receptors on human squamous cell carcinoma derived cell lines. Br.J. Cancer, 53:223- 
229.
Crook, T., Wrede, D., Tidy, J.A., Mason, W.P., Evans, DJ. and Vousden, K.H. (1992). 
Clonal p53 mutation in primary cervical cancer: association with HPV negative tumours. 
Lancet, 339:1070-1073.
Cuthbert, A.P., Trott, P.A., England, N.L., Jezzard, S., Ekong, R., Todd, C.M., Themis, 
M. and Newbold, R.F. (1995). Mapping human antiproliferative genes by microcell 
mediated monochromosome transfer: evidence for cellular senescence genes on 
chromosome 1 and 9. Genes, chr. cancer, In press.
Dawson, C.W., Rickinson, A.B. and Young, L.S. (1990). Epstein-Barr virus latent 
membrane protein inhibits human epithelial cell differentiation. Nature, 344:777-780.
189
Debbas, M. and White, E. (1993). Wild-type p53 mediates apoptosis by El A, which is 
inhibited by E1B. Genes & Development; 7:546-545.
DeCaprio, J.A., Ludlow, J.W., Figge, J., Shew, J., Huang, C.M., Lee, W., Marsilio, E., 
Paucha, E. and Livingston, D.M. (1988). SV40 large tumour antigen forms a specific 
complex with the product of the retinoblastoma susceptibility gene. Cell, 54:275-283.
DeLarco, J. and Todaro, G J. (1978). Growth factor from murine sarcoma virus 
transformed cells. Proc.Nat.Acad.Sci., U.S.A 75:4001-4006.
Delmolino, L., Band, H. and Band, V. (1993). Expression and stability of p53 protein in 
normal human mammary epithelial cells. Carcinogenesis, 14:827-832.
Diller, L., Kassel, J., Nelson, C.E., Gryka, M.A., Litwak, G., Gebhardt, M., Bressac, B., 
Ozturk, M., Baker, SJ., Vogelstein, B. and Friend, S.H. (1990). p53 functions as a cell 
cycle control protein in osteosarcomas. MolCellBiol. 10:5772-5781.
Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A.K., Moore, M., Finlay, C. and 
Levine, AJ. (1993). Gain of function mutations in p53. Nature Genet. 4:42-46.
Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, MJ., Montgomery, C.AJ., 
Butle, J.S. and Bradley, A. (1992). Mice deficient for p53 are developmentally normal 
but susceptible to spontaneous tumours. Nature, 356:215-221.
Dowdy, S.F., Hinds, P.W., Louie, K., Reed, S.I., Arnold, A. and Weinberg, R.A. (1993). 
Physical interactions of the retinoblastoma protein with human D cyclins. Cell, 73:499- 
511.
Dutta, A., Ruppert, J.M., Aster, J.C. and Winchester, E. (1993). Inhibition of DNA 
replication factor RPA by p53. Nature, 365:79-82.
Dyson, N., Howley, P.M., Munger, K. and Harlow, E. (1989). The human papilloma 
virus 16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 
243:934-937.
Easty, D.M., Easty, G.C., Carter, R.L., Monaghan, P. and Butler, L.J. (1981a). Ten 
human carcinoma lines derived from squamous carcinomas of the head and neck.
Br.J.Cancer, 43:772-785.
190
Easty, D.M., Easty, G.C., Carter, R.L., Monaghan, P., Pittam, M.R. and James, T. 
(1981b). Five human tumour cell lines derived from a primary sqquamous carcinoma of 
the tongue,two subsequent local recurrences and two nodal metastases. BrJ.Cancer, 
44:363-370.
Edington, K.G., Berry, IJ., O'Prey, M., Bums, J.E., Clark, LJ., Mitchell, R., Robertson, 
G., Soutar, D., Coggins, L.W. and Parkinson, E.K. (1994). In vitro analysis of multistage 
squamous cell carcinomav : defective terminal maturation is an early and ubiquitous 
event. In: R.I. Freshney (ed.), Culture of tumour cells, Culture of specialised cells, vol.4, 
New York: Wiley-Liss,Inc.: In Press.
Edington, K.G., Loughran, O.P., Berry, IJ. and Parkinson, E.K. (1995). Cellular 
immortality is a late event in the progressionof human squamous cell carcinoma of the 
head and neck and is associated with p53 alteration and a high frequency of allele loss. 
Mol Carcin. In press.
El-Deiry, W.S., Kem, S.E., Pietenpol, J.A., Kinzler, K.W. and Vogelstein, B. (1992). 
Definition of a consensus binding site for p53. Nature Genet. 1:45-49.
El-Deiry, W.S., Tokino, T., Velculescu, V., Levy, D.B., Parsons, R., Trent, J., M., Lin,
D., Mercer, W.E., Kinzler, K.W. and Vogelstein, B. (1993). WAF-1, a potential 
mediator of p53 tumor suppression. Cell, 75:817-825.
El-Naggar, A., Lee, M.S., Wang, G., Luna, M.A., Goepfert, H. and Batsakis, J.G.
(1993). Polymerase chain reaction-based restriction fragment length polymorphism 
analysis of the short arm of chromosom 3 in primary head and neck squamous 
carcinoma. Cancer, 72:881-886.
Eliyahu, D., Raz, A., Gruss, P., Givol, D., and Oren, M. Participation of p53 cellular 
tumour antigen in transformation of normal embryonic cells. Nature 312:646-651, 1984.
Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimni, O. and Oren, M. (1989). Wild- 
type p53 can inhibit oncogene mediated focus formation. Proc.Nat.Acad.Sci., U.S.A. 
86:8763-8767.
Evan, G.I., Wyllie, A.H., Gilbert, C.S., Littlewood, T.D., Land, H., Brooks, M., Waters, 
C.M., Penn, L.Z., Hancock, D.C. (1992). Induction of apoptosis in fibroblasts by c-myc 
protein. Cell 69:119-128.
191
Fakharzadeh, S.S., Trusko, S.P. and George, D.L. (1991). Tumorigenic potential 
associated with enhanced expression of a gene that is amplified in a mouse tumor cell 
line.EmboJ. 10:1565-1569.
Fantl, V., Richards, M.A., Smith, R., Lammie, G.A., Johnstone, G., Allen, D., Gregory, 
W., Peters, G., Dickson, C. and Barnes, D.M. (1990). Gene amplification on 
chromosome bend llq l3  and oestrogen receptor status in breast cancer. EurJ. Cancer, 
26:423-429.
Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R. and Prives, C. (1992). 
Wild-type p53 activates transcription in vitro. Nature, 358:83-86.
Farrell, PJ., Allan, G.J., Shanahan, F., Vousden, K.H. and Crook, T. (1991). p53 is 
frequently mutated in Burkitts lymphoma cell lines. Embo J. 10: 2879-2887.
Fearon, E.R. and Vogelstein, B. (1990). A genetic model for colorectal carcinogenesis. 
Cell, 61:759-767.
Feinstein, E., Cimino, G., Gale, R.P., Alimena, G., Berthier, R., Kishi, K., Goldman, J., 
Zaccaria, A., Berrebi, A. and Canaani, E. (1991). p53 in chronic myelogenous leukemia 
in acute phase. Proc.Nat.Acad.ScL, U.S.A 88:6293-6297.
Feinstein, E., Gale, R.P., Reed, J. and Canaani, E. (1992). Expression of the normal p53 
gene induces differentiation of K562 cells. Oncogene, 7:1853-1857.
Field, J.K., Spandidos, D.A., Malliri, A., Gosney, J.R., Yiagnisis, M. and Stell, P.M.
(1991). Elevated p53 expression correlates with a history of heavy smoking in squamous 
cell carcinoma of the head and neck. Br.J. Cancer, 64:573-577.
Fields, S. and Jang, S.K. (1990). Presence of a potent transcription activating sequence 
in the p53 protein. Science, 249:1046-1049.
Finlay, C.A., Hinds, P.W., Tan, T.H., Eliyahu, D., Oren, M. and Levine, A.J. (1988). 
Activating mutations for transformation by p53 produce a gene product that forms an 
Hsc-p53 complex with an altered half-life. Mol. Cell Biol. 8:531-539.
Finlay, C.A., Hinds, P.W. and Levine, A.J. (1989). The p53 proto-oncogene can act as a 
suppressor of transformation. Cell, 57:1083-1093.
192
Fiscella, M., Ullrich, SJ., Zambrano, N., Shields, M.T., Lin, D., Lees-Miller, S.P., 
Anderson, C.W., Mercer, W.E. and Appella, E. (1993). Mutation of the serine-15 
phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle 
progression. Oncogene, 8:1519-1528.
Fiscella, M., Zambrano, N., Ullrich, S.J., Unger, T., Lin, D., Cho, B., Mercer, E., 
Anderson, C.W. and Appella, E. (1994). The carboxy-terminal serine 392 
phosphorylation site of human p53 is not required for wild-type activities. Oncogene, 
9:3249-3257.
Frebourg, T., Kassel, J., Lam, K.T., Gryka, M.A., Barbier, N., Andersen, T.I., Borresen,
A.L. and Friend, S.H. (1992). Germ-line mutations of the p53 tumor suppressor gene in 
patients with high risk for cancer inactivate the p53 protein. Proc.Nat.Acad.Sci., U.S. A  
89:6413-6417.
Frebourg, T., Sadelain, M., Ng, Y.S., Kassel, J. and Friend, S.H. (1994). Equal 
transcription of wild-type and mutant p53 using bicistronic vectors results in the wild- 
type phenotype. Cancer Res. 54:878-881.
Friedman, P.N., Kern, S.E., Vogelstein, B. and Prives, C. (1990). Wild-type, but not 
mutant human p53 proteins inhibit the replication activities of SV40 large T antigen. 
Proc.Nat.Acad.Sci., U.S.A 87:9275-9279.
Friedman, P.N., Chen, X., Bargonetti, J. and Prives, C. (1993). The p53 protein is an 
unusually shaped tetramer that binds directly to DNA. Proc.Nat.Acad.Sci., U.S.A. 
90:3319-3323.
Frisch, S.M. and Francis, H. (1994). Disruption of epithelial cell-matrix interactions 
induces apoptosis. J. Cell Biol. 124:619-626.
Fuchs, E. and Byrne, C. (1994). The epidermis: rising to the surface. Curr.Opinion in 
Gene.Dev. 4:725-736.
Fuchs, E. and Green, H. (1980). Changes in keratin gene expression during terminal 
differentiation of the keratinocyte. Cell, 19:1033-1042.
Fuchs, E. and Green, H. (1981). Regulation of terminal differentiation of cultured human 
keratinocytes by vitamin A. Cell, 25:617-625.
193
Funk, W.D., Pak, D.T., Karas, R.H., Wright, W.E. and Shay, J.W. (1992). A 
transcriptionally active DNA-binding site for human p53 protein complexes. MoLCell 
Biol. 12:2866-2871.
Furlong, R.A., Lyall, J.E.N., Goudie, D.R., Leversha, M.A., Affara, N.A. and Ferguson- 
Smith, M.A. (1992). A dinucleotide repeat polymorphism at the D9S109 locus. 
NucLAcids Res. 20:925
Gannon, J.V., Greaves, R., Iggo, R. and Land, D.P. (1990). Activating mutations in p53 
produce a common conformational effect. A monoclonal antibody specific for mutant 
form. Embo J. 9:1595-1602.
Gannon, J.V. and Lane, D.P. (1987). p53 and DNA polymerase alpha compete for 
binding to SV40 T antigen. Nature, 329:456-458.
Geiger, B. and Ayalon, O. (1992). Cadherins. Annu.Rev.CellBiol. 8:307-332.
Ginsberg, D., Michalovitz, D. and Oren, M. (1991). Induction of growth arrest by a 
temperature-sensitive p53 mutant is correlated with increased nuclear localization and 
decreased stability of the protein. Mol Cell Biol. 11:582-585.
Goldsmith, L.A. and Martin, C.M. (1975). Human epidermal transamidase. Adv. 
Enzymol. 38: 109-191.
Gottlieb, E., Haffner, R., Von Ruden, T., Wagner, E.F. and Oren, M. (1994). Down- 
regulation of wild-type p53 activity interferes with apoptosis of IL-3 dependent 
hematopoietic cells following IL-3 withdrawal. Embo J. 13:1368-1374.
Graw and Kwiathowski, D J. (1993). Three dinucleotide repeat polymorphisms on 
chromosome 9 (D9S200,D9S201,D9S199). HuMol.Genet. 2:614
Green, H. (1977). Terminal differentiation of cultured human epidermal cells. Cell, 
11:405-416.
Green, H. (1978). Cyclic AMP in relation to proliferation of the epidermal cell: a new 
view. Cell, 15:801-811.
Greider, C.W. (1990). Telomeres,telomerase and senescence. Bioessays, 12:363-369.
194
Guadagno, T.M., Ohtsubo, M., Roberts, J.M. and Assoian, R.K. (1993). A link between 
cyclin A expression and adhesion-dependent cell cycle progression. Science, 262:1572- 
1575.
Gusterson, B.A., Anbazhagan, R., Warren, W., Midgely, C., Lane, D.P., 0;Hare, M., 
Stamps, A., Carter, R. and Jayatilake, H. (1991). Expression of p53 in premalignant and 
malignant squamous epithelium. Oncogene, 6:1785-1789.
Hainaut, P. and Milner, J. (1992). Interaction of heat shock protein 70 with p53 
translated in vivo : Evidence for interaction with dimeric p53 and for a role in the 
regulation of p53 conformation. Embo J. 11:3513-3520.
Hainaut, P. and Milner, J. (1993). A structural role for metal ions in the wild-type 
conformation of the tumour suppressor gene p53. Cancer Res. 53:1739-1742.
Halevy, O., Michalovitz, D. and Oren, M. (1990). Different tumor derived p53 mutants 
exhibit distinct biological activities. Science, 250:113-116.
Hao, M., Finlay, C. and Lozano, G. (1993). A functionally inactive p53 Li-Fraumeni 
syndrome mutant.Oncogene, 8:299-306.
Harlow, E., Williamson, N.M., Ralston, R., Helfman, D. and Adams, T. (1985). 
Molecular cloning and in vitro expression of a cDNA clone for human cellular tumor 
antigenp53. Mol.CellBiol 5:1601-1610.
Harper, J.W., Adami, G.R., Wei, N., Keyomavsi, K. and Elledge, SJ. (1993). The p21 
CDK-interacting protein CIP-1 is a potent inhibitor of G1 cyclin dependent kinases. Cell, 
75:805-816.
Harvey, M., Sands, A.T., Weiss, R., Hegi, M., Wiseman, R., Pantazis, P., Giovanella, B., 
Tainsky, M. and Bradley, A. (1993). In vitro growth characteristics of embryo fibroblasts 
isolated from p53 deficient mice. Oncogene, 8:2457-2467.
Harvey, M., McArthur, MJ., Montgomery Jr, C.A., Butel, J.S., Bradley, A. and 
Donehower, L.A. (1993b). Spontaneous and carcinogen-induced tumorigenesis in p53- 
deficient mice. Nature genetics 5:225-229.
Hermann, R., Rice, R.H. (1993). Rat esophageal and epidermal keratinocytes: intrinsic 
differences in culture and derivation of continuous lines. J.Cell Physiol. 117: 362-367.
195
Hinds, P.C., Finlay, C., Frey, A. and Levine, AJ. (1987). Immunological evidence for 
the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell 
lines. Mol. Cell Biol. 7:2863-2869.
Hinds, P., Finlay, C. and Levine, AJ. (1989). Mutation is required to activate the p53 
gene for cooperation with the ras oncogene and transformation. J. Virol. 63:739-746.
Hinds, P.W., Finlay, C.A., Quartin, R.S., Baker, SJ., Fearon, E.R., Vogelstein, B. and 
Levine, A.J. (1990). Mutant p53 DNA clones from human colon carcinomas cooperate 
with ras in transforming primary rat cells: a comparison of the "hot spot" mutant 
phenotypes. Cell Growth Differ. 1:571-580.
Hockenbury, D.M., Zutter, M., Hickey, W., Nahm,M. and Korsmeyer, S.J. (1991). Bcl-2 
protein is topographically restricted in tissues characterized by apoptotic cell death.
Proc.Nat.Acad.Sci., U.S.A 88:6961-6965.
Hodivala, KJ and Watt, F.M. (1994). Evidence that cadherins play a role in the 
downregulation of integrin expression that occurs during keratinocyte terminal 
differentiation. J.Cell Biol. 124:589-600.
Holland, E.A., Beaton, S.C., Edwards, B.G., Kefford, R.F. and Mann, GJ. (1994). Loss 
of heterozygosity and homozygous deletions on 9p21-22 in melanoma. Oncogene, 
9:1361-1365.
Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C.C. (1991). p53 mutations in 
human cancers. Science, 253:49-53.
Hotchin, N.A. and Watt, F.M. (1992). Transcriptional and post-translational regulation 
of (31 integrin expression during keratinocyte terminal differentiation. J.Biol. Chem. 
267:14852-14858.
Huang, Y., Meltzer, S.J., Yin, J., Tong, Y., Chang, E.H., Srivastava, S., McDaniel, T., 
Boynton, R.F. and Zou, Z. (1993). Altered messenger RNA and unique mutational 
profiles of p53 and RB in human esophageal carcinomas. Cancer Res. 53:1889-1894.
Hubbert, N.L., Sedman, S.A. and Schiller, J.T. (1992). Human papilloma virus type 16 
E6 increases the degradation rate of p53 in human keratinocytes. J. Virol. 66:6237-6241.
Hupp, T.R., Meek, D.W., Midgley, C.A. and Lane, D.P. (1992). Regulation of the 
specific DNA binding function of p53. Cell, 71:875-886.
196
Hynes, R.O. (1992). Integrins: versatility, modulation and signaling in cell adhesion.
Cell, 69:11-25.
Iwabuchi, K., Li, B., Bartel, P. and Fields, S. (1993). Use of the two hybrid system to 
identify the domain of p53 involved in oligomerisation. Oncogene, 8:1693-1696.
Jacks, T., Remington, L., Williams, B.O., Schmitt, E.M., Halachmi, S., Bronson, R.T. 
and Weinberg, R. A. (1994). Tumor spectrum analysis in p53 mutant mice. Current 
biology, 4:1-7.
Jaffe, D.R., Montero-Puemer, Y., Beckett, M.A., Cowan, J.M., Weichselbaum, R.R. and 
Diamond, A.M. (1992). Differential retention of tumor and differentiation suppressor 
functions in cells derived from a human squamous cell carcinoma. Mol Carcin. 5:278- 
285.
Jenkins, J.R., Rudge, K. and Currie, G.A. (1984). Cellular immortalisation by a cDNA 
clone encoding the transformation associated phosphoprotein p53. Nature, 312:651-654.
Jiang, H., Lin, J., Su, Z.Z., Huberman, E. and Fisher, P.B. (1994). Induction of 
differentation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, 
expression in the absence of p53. Oncogene, 9:3397-3406.
Jiang, W., Kahn, S.M., Tomita, N., Zhang, Y., Lu, S. and Weinstein, B. (1992). 
Amplification and overexpression of the human cyclin D1 gene in esophageal cancer. 
Cancer Res. 52:2980-2983.
Johnson, M., Dimitrov, D., Vojta, PJ., Barrett, J.C., Noda, A., Pereira-Smith, O. and 
Smith, J.R. (1994). Evidence for a p53-independent pathway for upregulation of 
SDIl/WAFl/p21 RNA in human cells. Mol Carcin. 11:59-64.
Jones, M.H. and Nakamura, Y. (1992). Deletion mapping of chromosome 3p in female 
genital tract malignancies using microsatellite polymorphisms. Oncogene, 7:1631-1634.
Juliano, R.L. and Haskill, S. (1993). Signal transduction from the extracellular matrix.
J. Cell Biol 120:577-585.
Jussawalla, D J. and Deshpande, V.A. (1971). Evolution of cancer risk in tobacco 
chewers and smokers: an epidemiologic assessment. Cancer, 28:244-252.
197
Juven, T., Barak, Y., Zauberman, A., George, D.L. and Oren, M. (1993). Wild-type p53 
can mediate sequence specific transactivation of an internal promoter within the mdm-2 
gene. Oncogene, 8:3411-3416.
Kaebling, M., Bark, R.D., Atkins, N.B., Johnson, A.B. and Klinger, H.P. (1992). Loss of 
heterozygosity on chromosome 17p and mutant p53 in HPV negative cervical 
carcinomas. Lancet, 340:140-142.
Kallioniemi, A., Kallioniemi, O.P., Sudar, D., Rutovitz, D., Gray, J.W., Waldman, F. and 
Pinkel, D. (1992). Comparative genomic hybridization for molecular cytogenetic analysis 
of solid tumours. Science, 258:818-821.
Kamb, A., Gruis, N.A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S.V., 
Stockert, E., Day, R.S.I., Johnson, B.E. and Scolnick, M.H.A. (1994). A cell cycle 
regulator potentially involved in genesis of many tumour types. Science, 264:436-440.
Kastan, M.B., Onyekwere, 0., Sidransky, D., Vogelstein, B., and Craig, R.W. (1991a). 
Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 
51:6304-6311.
Kastan, M.B., Radin, A.I., Kuerbitz, J., Onyekwere, O., Wolkow, C.A., Civin, C.I., 
Stone, K.D., Woo, T., Ravindranath, Y. and Craig, R.W. (1991b). Levels of p53 protein 
increase with maturation in human hematopoietic cells. Cancer Res. 51:4279-4286.
Kastan, M.B., Zhan, Q., El-Deiry, W.D., Carrier, F., Jacks, T., Walsh, W.V., Plunkett,
B.S., Vogelstein, B. and Fomace Jr, AJ. (1992). A mammalian cell cycle checkpoint 
pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71:587- 
597.
Kato, J., Matsushime, H., Hiebert, S.W., Ewen, M.E. and Sherr, CJ. (1993). Direct 
binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation 
by the cyclin-dependent kinase cdk4. Genes & Development, 7:331-342.
Kelman, Z., Prokocimer, M., Peller, S., Kahn, Y., Rechaui, G., Manor, Y., Cohen, A. 
and Rotter, V. (1989). Rearrangements in the p53 gene in Philadelphia chromosome 
positive chronic myelogenous leukemia. Blood, 74:2318-2324.
Kemp, C.J., Donehower, L.A., Bradley, A. and Balmain, A. (1993). Reduction of p53 
gene dosage does not increase initiation or promotion but enhances malignant 
progression of chemically induced skin tumours. Cell, 74:813-822.
198
Kern, S.E., Kinzler, K.W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C. and 
Vogelstein, B. (1991). Identification of p53 as a sequence-specific DNA-binding protein. 
Science, 252:1708-1711.
Kern, S.E., Pietenpol, J.A., Thiagalingam, S., Seymour, A., Kinzler, K.W. and 
Vogelstein, B. (1992). Oncogenic forms of p53 inhibit p53-regulated gene expression. 
Science, 256:827-829.
Kessis, T.D., Slebos, RJ., Nelson, W.G., Kastan, M.B., Plunkett, B.S., Han, S.M., 
Lorincz, A.T., Hedrick, L. and Cho, K.R. (1993). Human papillomavirus 16 E6 
expression disrupts the p53 mediated cellular response to DNA damage. 
Proc.Nat.Acad.Scl, U.S.A 90:3988-3992.
Kley.N., Chung, R.Y., Fay, S., Loeffler, J.P. and Seizinger, B.R. (1993). Repression of 
the basal c-fos promoter by wild-type p53. Nucl. Acids Res. 20:4083-4087.
Knudson, A.GJ. (1971). Mutation and cancer: Statistical study of retinoblastoma. 
Proc.Nat.Acad.Scl, U.S.A 68:820-823.
Kopan, R., Traska, G. and Fuchs, E. (1987). Retinoids as important regulators of 
terminal differentiation: Examining keratin expression in individual epidermal cells at 
various stages of keratinization. J. CellBiol. 105:427-440.
Kuerbitz, SJ., Plunkett, B.S., Walsh, W.V. and Kastan, M.B. (1992). Wild type p53 is a 
cell cycle checkpoint determinant following irradiation. Proc.Nat.Acad.Scl, U.S. A  
89:7491-7495.
Kwiatkowski, D.J. (1991). Dinucleotide repeat polymorphism at the ABL locus.
Nucl.Acids Res. 19:967
Kwiatkowski, DJ. and Gusella, J.F. (1992). Dinucleotide repeat poymorphism at 
D9S116 locus. Nucl. Acids Res. 20:931
Kwiatkowski, DJ., Henske, E.P., Weimer, K., Ozelius, L., Giusella, J.F. and Haines, J.
(1992). Construction of a GT polymorphism map of human 9q. Genomics, 12:229-240.
Kwiatkowski, DJ., Armour, J., Bale, A.E., Fountain, J.W., Goudie, D., Haines, J.L., 
Knowles, M.A., Pilz, A., Slaugenhaupt, S. and Povey, S. (1993). Report on the second 
international workshop on human chromosome 9. Cytogenet. Cell. Genet. 64:94-103.
199
LaForgia, S., Morse, B., Levy, J., Bamea, G., cannizzaro, L.A., Li, F., Nowell, P.C., 
Sell, L.B., Glick, J., Weston, A., Harris, C.C., Drabkin, H., Patterson, D., Croce, C.M., 
Schlessinger, J. and Huebner, K. (1991). Receptor protein -tyrosine phosphatase y is a 
candidate tumour suppressor gene at human chromosome region 3p21.
Proc.Nat.Acad.Sci., U.S.A 88:5036-5040.
Lamb, P. and Crawford, L.V. (1986). Characterisation of the human p53 gene. MolCell 
Biol. 6:7-14.
Lammie, G.A. and Peters, G. (1991). Chromosome llq l3  abnormalities in human 
cancer. Cancer cells, 3:413-420.
Land, H., Parada, L.F. and Weinberg, R.A. (1983). Tumorigenic conversion of primary 
embryo fibroblasts requires at least two cooperating oncogenes. Nature, 304:596-602.
Landesman, Y., Bringold, F. and Kimchi, A. (1994). p53 undergoes epitopic changes in 
vitro by sodium-vanadate. Oncogene, 9:1241-1245.
Lane, D.P. and Crawford, L.V. (1979). T antigen is bound to a host protein in SV40 
transformed cells. Nature, 278:261-263.
Latif, F., Fivash, M., Glenn, G., Tory, K., Orcutt, M.K., Hampsch, K., Delisio, J., 
Lermann, M., Corvan, J., Beckett, M. and Weichselbaum, R.R. (1992). Chromosome 3 
deletions in head and neck carcinomas: statistical ascertainment of allelic loss. Cancer 
Res. 52:1451-1456.
Lavker, R.M. and Matoltsy, A.G. (1970). Formation of homy cells:the fate of cell 
organelles and differentiation products in ruminal epithelium. J.CellBiol. 44:501-512.
Law, J.C., Strong, L.C., Chidambaram, A. and Ferrell, R.E. (1991). A germline mutation 
in exon 5 of the p53 gene in an extended cancer family. Cancer Res. 51:6385-6387.
Leder, A., Pattengale, P.K., Kuo, A., Stewart, T.A., Leder, P. (1986). Consequences of 
widespread deregulation of the c-myc gene in transgenic mice: Multiple neoplasms and 
normal development. Cell. 45: 485-495.
Lees-Miller, S.P., Sakaguchi, K., Ullrich, SJ., Appella, E. and Anderson, C.W. (1992). 
Human DNA-activated protein kinase phosphorylates serines 14 and 37 in the amino- 
terminal transactivation domain of human p53. Mol. Cell Biol. 12:5041-5049.
200
Li, F.P., Fraumeni, J.F., Mulvihill, JJ., Blattner, W.A., Dreyfus, M.G., Tucker, M.A. and 
Miller, R.W. (1988). A cancer family syndrome in 24 kindreds. Cancer Res. 48:5358- 
5362.
Linzer, D.I.H. and Levine, A J. (1979). Characterization of a54kd cellular SV40 tumour 
antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells.
Cell. 17:43-52.
Livingstone, L.R., White, A., Sprouse, J., Livanos, E., Jacks, T. and Tlsty, T.D. (1992). 
Altered cell cycle arrest and gene amplification potential accompany loss of wild-type 
p53. Cell, 70:923-935.
Loughran, O., Edington, K.G., Berry, I.J., Clark, LJ. and Parkinson, E.K. (1994). Loss 
of heterozygosity of chromosome 9p21 is associated with the immortal phenotype of 
neoplastic human head and neck keratinocytes. Cancer Res. 54:5045-5049.
Lowe, S.W., Schmitt, E.M., Smith, S.W., Osbourne, B.A. and Jacks, T. (1993a). p53 is 
required for radiation induced apoptosis in mouse thymocytes. Nature, 362:847-849.
Lowe, S.W. and Ruley, H.E. (1993b). Stabilization of the p53 tumour suppressor is 
induced by adenovirus 5 E1A and accompanies apoptosis. Genes & Development, 7:535- 
545.
Lowe, S.W., Jacks, T., Housman, D.E. and Ruley, H.E. (1994). Abrogation of 
oncogene-associated apoptosis allows transformation ofp53-deficient cells. 
Proc.Nat.Acad.Sci., U.S.A 91:2026-2030.
Lu, X. and Lane, D.P. (1993). Differential induction of transcriptionally active p53 
following UV or ionizing radiation: Defects in chromosome instability syndromes? Cell, 
75:765-778.
Lyall, J.E.N., Furlong, R.A., Yuille, M.A.R., Goudie, D.R., Leversha, M.A., Affard,
N.A. and Ferguson-Smith, M.A. (1992). A dinucleotide repeat polymorphism at 
D9S127. NuclAcids Res. 20:925
Mack, D.H., Vartikar, J., Pipas, J.M. and Laimins, L. (1993). Specific repression of 
TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature, 
363:281-283.
201
Maestro, R., Dolcetti, R., Gasparotto, C., Doglioni, C., Pelucci, S., Barzan, L., Grandi, 
E. and Boiocchi, M. (1992). High frequency of p53 gene alterations associated with 
protein overexpression in human squamous cell carcinoma of the larynx. Oncogene, 
7:1159-1166.
Maestro, R., Gasparotto, D., Vukosavljevic, T., Barzan, L., Sulfaro, S. and Boiocchi, M.
(1993). Three discrete regions of deletion at 3p in head and neck cancers. Cancer Res. 
53:5775-5779.
Malkin, D., Li, F.P., Strong, L.C., Fraumeni, J.F.J., Nelson, C.E., Kim, D.H., Kassel, J., 
Gryka, M.A., Bischoff, F.Z., Tainsky, M.A. and Friend, S.H. (1990). Germline p53 
mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. 
Science, 250:1233-1238.
Malkin, D., Jolly, K.W., Strong, L.C., Barbier, N., Look, A.T., Friend, S.H., Gebhardt, 
M.C., Anderson, T.I., Borresen, A.L., Li, F.P., Garber, J. and Strong, L.C. (1992). 
Germline mutations of the p53 tumor-suppressor gene in children and young adults with 
second malignant neoplasms. New Engl J. Med. 326:1309-1315.
Maltzman, W. and Czyzyk, L. (1984). UV irradiation stimulates levels of p53 cellular 
tumor antigen in nontransformed mouse cells. Mol. Cell Biol. 4:1689-1694.
Mancianti, M. and Herlyn, M. (1989). Carcinogenesis, a comprehensive survey. 369-386.
Martinez, J., Georgoff, I. and Levine, A.J. (1991). Cellular localization and cell cycle 
regulation by a temperature-sensitive p53 protein. Genes & Development, 5:151-159.
Masui, H., Kawamoto, T., Sato, J.D., Wolf, B., Sato, G. and Mendelsohn, J. (1984). 
Growth inhibition of human tumour cells in athymic mice by anti-epidermal growth 
factor receptor monoclonal antibodies. Cancer Res. 44:1002-1007.
Matsushime, H., Roussel, M., Ashmun, R. and Sherr, CJ. (1991). Colony stimulating 
factor 1 regulates novel cyclins during G1 phase of the cell cycle. Cell, 65:701-713.
Matsushime, H., Quelle, D.E., Shurtleff, S.A., Shibuya, M., Sherr, C J. and Kato, J-Y.
(1994). D-type cyclin dependent kinase activity in mammalian cells. Mol.Cell.Biol. 
14:2066-2076.
202
McBride, O.W., Merry, D. and Givo, I.D. (1986). The gene for human p53 cellular 
tumour antigen is located on chromosome 17 short arm (17pl3).
Proc.Nat.Acad.Sci., U.S.A 83:130-134.
McCall, C.A., and Cohen, J J. (1991). Programmed cell death in terminally differentiating 
keratinocytes: Role of endogenous endonuclease. J.Invest.Dermatol. 97:111-114.
Meek, D.W., Simons, S. and Kikkawa, U. (1990). The p53 tumor suppressor protein is 
phosphorylated at serine 386 by casein kinase II. Embo J. 9:3253-3260.
Mercer, W.E., Nelson, D., DeLeo, A.B., Old, LJ. and Baserga, R. (1982).
Microinjection of monoclonal antibody to the protein p53 inhibits serum-induced DNA 
synthesis in 3T3 cells. Proc.Nat.Acad.Sci.,U.S.A 79:6309-6312.
Mercer, W.E., Avignolo, C. and Baserga, R. (1984). Role of the p53 protein in cell 
proliferation as studied by microinjection of monoclonal antibodies. MolCell Biol. 
4:276-281.
Mercer, W.E., Shields, M.T., Amin, M., Sauve, GJ., Appella, E., Romano, J.W. and 
Ullrich, S J. (1990). Negative growth regulation in a glioblastoma tumor cell line that 
conditionally expresses human wild type p53. Proc.Nat.Acad.Scl, U.S. A  87:6166-6170.
Mercer, W.E., Shields, M.T., Lin, D., Appella, E. and Ullrich, S.J. (1991). Growth 
suppression induced by wild-type p53 protein is accompanied by selective down- 
regulation of proliferating-cell nuclear antigen expression. Proc.Nat.Acad.Sci., U.S.A. 
88:1958-1962.
Meredith, J.E., Fazeli, B and Schwartz, M.A. (1993). The extracellular matrix as a cell 
survival factor. Mol. Biol. Cell. 4: 953-961.
Meyerson, M. and Harlow,E. (1994). Identification of G1 kinase activity for cdk6, a 
novel cyclin D partner. Mol.Cell.Biol. 14:2077-2086.
Michalovitz, D., Halevy, O. and Oren, M. (1990). Conditional inhibition of 
transformation and of cell proliferation by a temperature sensitive mutant of p53. Cell, 
62:671-680.
Million, R.R., Cassisi, N J. and Clark, J.R. (1989). Cancer of the head and neck. 488- 
590.
203
Milne, D.M., Palmer, R.H., Campbell, D.G. and Meek, D.W. (1992a). Phosphorylation 
of the tumour supressor protein at three N-terminal sites by a novel casein kinase 1-like 
enzyme. Oncogene, 7:1361-1369.
Milne, D.M., Palmer, R.H. and Meek, D.W. (1992b). Mutation of the casein kinase II 
phosphorylation site abolishes the anti-proliferative activity of p53. NucLAcids Res. 
20:5565-5570.
Milne, D.M., Campell, D.G., Caudwell, F.B. and Meek, D.W. (1994). Phosphorylation 
of the tumour suppressor protein p53 by mitogen activated protein (MAP) kinases. 
J.Biol.Chem. 269:9253-9260.
Milner, J. (1984). Different forms of p53 detected by monoclonal antibodies in dividing 
and non-dividing lymphocytes. Nature, 310:143-145.
Milner, J. (1994). Forms and functions of p53. Sem.Canc.Biol 5:5738-5742.
Milner, J. and Medcalf, E.A. (1991). Cotranslation of activated mutant p53 with wild- 
type drives the wild-type p53 protein into the mutant conformation. Cell, 65:765-774.
Milner, J. and Sheldon, M. (1987). A new anti-p53 monoclonal antibody, previously 
reported to be directed against the large T antigen of simian virus 40. Oncogene, 1:453- 
455.
Moles, J.P., Moyret, C., Guillot, B., Jeanteur, P., Guilhou, JJ., Theillet, C. and Seguin, 
N.B. (1993). p53 gene mutations in human epithelial skin cancers. Oncogene, 8:583-588.
Momand, J., Zambetti, G.P., Olsen, D.C., George, D. and Levine, A.J. (1992). The 
mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53- 
mediated transactivation. Cell, 69:1237-1245.
Murakami, Y., Hayashi, K., Hirohashi, S. and Sekiya, T. (1991). Aberrations of the 
tumour suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. 
Cancer Res. 51:2318-2324.
Nawroz, H., van der Riet, P., Hruban, R.H., Koch, W., Ruppert, J.M. and Sidransky, D. 
(1994). Allelotype of head and neck squamous cell carcinoma. Cancer Res. 54:1152- 
1155.
204
Nees, M., Homann, N., Discher, H., Andl, T., Enders, C., Herold-Mende, C., Schumann,
A. and Bosch, F.X. (1993). Expression of mutated p53 occurs in tumour-distant epithelia 
of head and neck cancer patients: A possible molecular basis for the development of 
multiple tumours. Cancer Res. 53:4189-4196.
Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K.,
Bigner, S.H., Davidson, N., Baylin, S., Deville, P., Glover, T., Collins, F.S., Weston, A., 
Modali, R., Harris, C.C. and Vogelstein, B. (1989). Mutations in the p53 gene occur in 
diverse human tumour types. Nature, 342:705-708.
Nikolic, M., Edington, K., Peters, G., Dickson, C., Bolger, B., Cooke, T., Clarke, L., 
Robertson, G., Soutar, D., Parkinson, E.K. and Ozanne, B. (1995). Cyclin D1 expression 
in human squamous cell carcinoma cell lines and tumours. Submitted for publication.
Ning, Y., Weber, J.L. Killary, A.M., Ledbetter, D.H., Smith, J.R. and Pereira-Smith, 
O.M. (1991). Genetic analysis of indefinite division in human cells: evidence for a cell 
senescence-related gene(s) on human chromosome 4. Proc.Nat.Acad.Sci., U.S.A 
88:5635-5639.
Nobori, T., Miura, K., Wu, DJ., Lois, A., Takabayaski, K. and Carson, D.A. (1994), 
Deletions of the cyclin-dependent kinase 4 inhibitor gene in multiple human cancers. 
Nature, 368:753-755.
Nowell, P. (1976). The clonal evolution of tumor cell populations. Science, 194:23-28.
Ogata, T., Ayusawa, D., Namba, M., Takahashi, E., Oshimura, M. and Oishi, M. (1993). 
Chromosome 7 suppress indefinite division of non-tumorigenic immortalised human 
fibroblast cell lines KMST-6 and SUSM-1. Mol.Cell.Biol. 13:6036-6043.
Ohgaki, H., Eibi, R.H., Schwab, M., Reichel, M.B., Mariani, L., Gehring, M., Peterson,
I., Holl, T., Wiestler, O.D. and Kleihus, P. (1993). Mutations of the p53 tumour 
suppressor gene in neoplasms of the human nervous system. Mol. Carcin. 8:74-80.
Oliner, J.D., Kinzler, K.W., Meltzer, P.S., George, D.L. and Vogelstein, B. (1992). 
Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature, 
358:80-83.
Oliner, J.D., Pientenpol, J.A., Thiagalingam, S„ Gyuris, J., Kinzler, K.W. and 
Vogelstein, B. (1993). Oncoprotein MDM2 conceals the activation domain of tumour 
suppressor p53. Nature, 362:857-860.
205
Olson, D.C., Marechal, V., Momand, J., Chen, J., Romocki, C. and Levine, AJ. (1993). 
Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein 
complexes. Oncogene, 8:2353-2360.
Otto, A. and Deppert, W. (1993). Upregulation of mdm-2 expression in meth A tumor 
cells tolerating wild-type p53. Oncogene, 8:2591-2603.
Ozanne, B., Richards, C.S., Hendler, F., Bums, D. and Gusterson, B. (1986). Over­
expression of the EGF receptor is a hallmark of squamous cell carcinoma. J. Pathol 
149:9-14.
Parada, L.F., Land, H., Weinberg, R.A., Wolf, D. and Rotter, V. (1984). Co-operation 
between gene encoding p53 tumour antigen and ras in cellular transformation. Nature, 
312:649-651.
Paraskeva, C., Buckle, B.G., Sheer, D. and Wigley, C.B. (1984). The isolation and 
characterisation of colorectal epithelial cell lines at different stages in malignant 
transformation from familial polyposis coli patients. Int.J. Cancer, 34:49-56.
Parkinson, E.K., Grabham, P. and Emmerson, A. (1983). A subpopulation of cultured 
human keratinocytes which is resistant to the induction of terminal differentiation-related 
changes by phorbal,12-myristae, 13-acetate: evidence for an increase in the resistant 
population following transformation. Carcinogenesis, 7:857-861.
Parkinson, E.K., Pera, M.F., Emmerson, A. and Gorman, P.A. (1984). Differential 
effects of complete and second-stage tumour promoters on normal but not transformed 
human and mouse keratinocytes. Carcinogenesis, 5:1071-1077.
Pavletich, N.P., Chambers, K.A. and Pabo, C.O. (1993). The DNA binding domain of 
p53 contains the four conserved regions and the major mutation hotspots. Genes & 
Development, 7:2556-2564.
Pereira-Smith, O.M. and Smith, J.R. (1981). Expression of SV40 T antigen in finite 
lifespan hybrids of normal and SV40-transformed fibroblasts. Somat. Cell Genet 7:411- 
421.
Perry, M.E., Piette, J., Zawadzki, J.A., Harvey, D. and Levine, A.J. (1993). The mdm-2 
gene is induced in response to UV light in a p53-dependent manner.
Proc.NatAcad.Sci., U.S.A 90:11623-11627.
206
Picksley, S.M., Vojtesek, B., Sparks, A. and Lane, D.P. (1994). Immunochemical 
analysis of the interaction of p53 with mdm-2;-fine mapping of the mdm-2 binding site on 
p53 using synthetic peptides. Oncogene, 9:2523-2529.
Pierceall, W.E., Mukhopadhyay, T., Goldberg, L.H. and Ananthaswamy, H.N. (1991). 
Mutations in the p53 tumour suppressor gene in human cutaneous squamous cell 
carcinomas. Mol. Carcin. 4:445-449.
Pinborg, J J. (1984). Control of oral cancer in developing countries. Bull WHO, 62:817- 
830.
Price, B.D. and Calderwood, S.K. (1993). Increased sequence-specific p53 DNA binding 
activity after DNA damage is attenuated by phorbol esters. Oncogene, 8:3055-3062.
Price, B.D. and Park, SJ. (1994). DNA Damage Increases the Levels of MDM2 
Messenger RNA in wtp53 Human Cells. Cancer Res. 54:896-899.
Prime, S.S. and et al. (1990). The behaviour of human oral squamous cell carcinoma in 
cell culture. J.Path, 160:259-269.
Proctor, A.J., Coombs, L.M., Cairns, J.P. and Knowles, M.A. (1991). Amplification at 
chromosome llq l3  in transitional cell tumours of the bladder. Oncogene, 6:789-795.
Quinn, A.G., Campell, C., Healy, E. and Rees, J.L. (1994). Chromosome 9 allele loss 
occurs in both basal and squamous cell carcinomas of the skin. J.Invest.Dermatol. 
102:300-303.
Radna, R.L., Caton, Y., Jha, K.K., Kaplan, P., Li, G., Traganos, F. and Ozer, H.L.
(1989). Growth of immortal simian virus 40 tsA transformed human fibroblasts is 
temperature dependent. MolCellBiol. 9:3093-3095.
Raycroft, L., Wu, H. and Lozano, G. (1990). Transcriptional activation by wild-type but 
not transforming mutants of the p53 anti-oncogene. Science, 249:1049-1051.
Raycroft, L., Schmidt, J.R., Yaos, K., Hao, M. and Lozano, G. (1991). Analysis of p53 
mutants for transcriptional activity. MolCell Biol. 11:6067-6074.
Reich, N.C. and Levine, AJ. (1984). Growth regulation of a cellular tumour antigen, p53 
in nontransformed cells. Nature, 308:199-201.
207
Reiners, J.J. and Slaga, TJ. (1983). Effects of tumour promoters on the rate and 
commitment to terminal differentiation of subpopulations of murine keratinocytes. Cell 
32:247-255.
Rheinwald, J.G. and Green, H. (1975a). Formation of a keratinising epithelium in culture 
by a cloned cell line derived from a teratoma. Cell, 6:317-330.
Rheinwald, J.G. and Green, H. (1975b). Serial cultivation of strains of human epidermal 
keratinocytes: the formation of keratinising colonies from single cells. Cell, 6:331-344.
Rheinwald, J.G. and Green, H. (1977). Epidermal growth factor and the multiplication of 
cultured human epidermal keratinocytes. Nature, 265:421-424.
Rheinwald, J.G. and Beckett, M.A. (1980). Defective terminal differentiation in culture 
as a consistent and selectable character of malignant human keratinocytes. Cell, 22:629- 
632.
Rheinwald, J.G. (1980). Serial cultivation of normal human epidermal keratinocytes. 
Methods cell Biol. 21:229-254.
Rheinwald, J.G. and Beckett, M.A. (1981). Tumorigenic keratinocyte lines requiring 
anchorage and fibroblast support cultured from human squamous cell carcinomas.
Cancer Res. 41:1657-1663.
Rice, R.H. and Green, H. (1977). The comified envelope of terminally differentiated 
human epidermal keratinocytes consists of cross-linked protein. Cell 11:417-422.
Rice, R.H. and Green, H. (1978). Relationship of protein synthesis and transglutaminase 
activity to formation of the cross-linked envelope during terminal differentiation of the 
cultured human epidermal keratinocyte. J. Cell Biol. 76:705-711.
Rice, R.H. and Green, H. (1979). Presence in human epidermal cells of a soluble protein 
precursor of the cross-linked envelope: Activation of the cross-linking by calcium ions. 
Cell 18: 681-694.
Rimessi, P., Gualandi, F., Morelli, C., Trabanelli, C., Wu, Q., Possati, L., Montesi, M., 
Barrett, J.C. and Brodano, G.B. (1994). Transfer of human chromosome 3 to an ovarian 
carcinoma cell line identifies three regions on 3p involved in ovarian cancer. Oncogene, 
9:3467-3474.
208
Riou, G., Favre, M., Jeannel, D., LeDoussal, V. and Orth, G. (1990). Association 
between poor prognosis in early-stage invasive cervical carcinoma and non-detection of 
HPV DNA. Lancet, 335:1171-1174.
Rodrigues, N.R., Rowan, A., Smith, M.E.F., Kerr, I.B., Bodmer, W.F., Gannon, J.V. 
and Lane, D.P. (1990). p53 mutations in colorectal cancer. Proc.Nat.Acad.Sci., U.S.A 
87:7555-7559.
Rosenberg, C.L., Wong, E., Petty, E.M., Bale, A.E., Tsujimoto, Y., Harris, N.L. and 
Arnold, A. (1991). PRAD1, a candidate BCL1 oncogene: Mapping and expression in 
centrocytic lymphoma. Proc.Nat.Acad.Sci.,U.S.A 88:9638-9642.
Rotter, V., Schwartz, D., Almon, E., Goldfinger, E., Kapu, Meshorer, A., Donehower, 
L.A. and Levine, A.J. (1993). Mice with reduced levels of p53 exhibit the testicular giant 
cell degenerative syndrome. Proc.Nat.Acad.Sci., U.S.A. 90:9075-9079.
Rowden, G. (1975). Ultrastructural studies of keratinized epithelia of the mouse HI. 
Determination of the volumes of nuclei and cytoplasm of cells in murine epidermis. 
J.Invest.Dermatol. 64:1-3.
Rubin, A.L. and Rice, R.H. (1986). Differential regulation by retinoic acid and calcium of 
transglutaminases in cultured neoplastic and normal keratinocytes. Cancer Res. 46:2356- 
2361.
Rudniki, M.A., Braun, T„ Hinuma, S. and Jaenisch, R. (1992). Inactivation of MyoD in 
mice leads to upregulation in the HLH gene Myf5 and results in apparently normal 
muscle development. Cell, 71:383-390.
Rupriak, H.T., Rowlatt, C., Lane, E.B., Steele, J.G., Trejdosiewicz, L.K., Lakierwicz,
B., Povey, S. and Hill, B.T. (1985). Characteristics of four new human cell lines derived 
from squamous cell carcinomas of the head and neck. J.Nat.Cancer Inst, 75:621-635.
Sakai, E. and Tsuchida, N. (1992). Most human squamous cell carcinomas in the oral 
cavity contain mutated p53 tumour suppressor genes. Oncogene, 7:927-933.
Sakamoto, H., Lewis, M.S., Kodama,H., Appella, E., Sakaguchi, K. (1994). Specific 
sequences from the carboxyl terminus of human p53 gene product form antiparallel 
tetramers in solution. Proc.Nat.Acad.Sci.,U.S.A. 91: 8974-8978.
209
Sambrook, J. and Fritsch, E.F., Maniatis, T., (1989). Molecular cloning: A laboratory 
manual. (2nd edition) Cold spring harbor laboratory press.
Santhanam, U., Ray, A. and Sehgal, P.B. (1991). Repression of the interleukin 6 gene 
promoter by p53 and the retinoblastoma susceptibility gene product.
Proc.Nat.Acad.Sci., U.S.A 88:7605-7609.
Saranath, D., Chang, S.E., Bhoite, L.T., Panchal, R.G., Kerr, I.B., Mehta, A.R., 
Johnson, N.W. and Deo, M.C. (1991). High frequency mutations in codons 12 and 61 of 
H-ras oncogene in chewing tobacco related human oral carcinoma in India. Br.J. Cancer, 
63:573-578.
Savage, C.R., Inagami, T. and Cohen, S. (1972). The primary structure of epidermal 
growth factor. J.Biol. Chem. 247:7612-7621.
Scharer, E. and Iggo, R. (1992). Mammalian p53 can function as a transcription factor in 
yeast. Nucl. Acids Res. 20:1539-1545.
Scheffner, M., Wemess, B.A., Huibregtse, J.M., Levine, A.J. and Howley, P.M. (1990). 
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the 
degradation of p53. Cell, 63:1129-1136.
Schwartz, D., Goldfinger, N. and Rotter, V. (1993). Expression of p53 protein in 
spermatogenesis is confined to the tetraploid pachytene primary spermatocytes. 
Oncogene, 8:1487-1494.
Serrano, M., Hannon, G.J. and Beach, D. (1993). A new regulatory motif in cell cycle 
control causing specific inhibition of cyclinD/cdk4. Nature, 366:704-707.
Sharma, V., Brown, D., Smith, L., Magenis, R.E. and Litt, M. (1991). Dinucleotide 
repeat polymorphism at D9S55 locus. NuclAcids Res. 19:4023
Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A. and Rotter, V. (1990). Nuclear 
accumulation of p53 protein is mediated by several nuclear localisation signals and plays 
a role in tumorigenesis. MolCell Biol. 10:6565-6577.
Shaulsky, G., Goldfinger, N., Peled, A. and Rotter, V. (1991). Involvement of wild-type 
p53 in pre-B cell differentiation in vitro. Proc.Nat.Acad.Sci., U.S.A 88:8982-8986.
210
Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B. and Costa, J. (1992). Induction of 
apoptosis by wild-type p53 in a human colon tumour derived cell line. 
Proc.Nat.Acad.Sci., U.S.A 89:4495-4499.
Shay, J.W., Wright, W.E. and Werbin, H. (1991). Defining the molecular mechanisms of 
human cell immortalisation. Biochim.Biophys.Acta, 1072:1-7.
Sheng, Z.M., Barrois, M., Klijanienko, J., Micheau, C., Richard, J.M. and Riou, G.
(1990). Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and 
expression in lymph node metastases of human head and neck carcinomas. Br.J. Cancer, 
62:398-404.
Sidransky, D., Mikkelson, T., Rosenblum, M.L., Cavanee, W. and Vogelstein, B. (1992). 
Clonal expansion of p53 mutant cells is associated with brain tumour progression.
Nature, 355:846-847.
Simon, M. and Green, H. (1984). Participation of membrane associated proteins in the 
formation of the cross-linked envelope of the keratinocyte. Cell. 36:827-834.
Slingerland, J.M., Jenkins, J.R. and Benchimol, S. (1993). The transforming and 
suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, 
oligomerization and nuclear translocation. Embo J. 12:1029-1037.
Smith, M.L., Chen, I.T., Zhan, Q., Bae, Z., Chen, C.Y., Glimer, T.M., Kastan, M.B., 
O'Connor, P.M. and Fomace Jr, AJ. (1994). Interaction of the p53 regulated protein 
Gadd45 with proliferating cell nuclear antigen. Science, 266:1376-1380.
Soussi, T., Caron de Fromentel, C. and May, P. (1990). Structural aspects of the p53 
protein in relation to gene evolution. Oncogene, 5:945-952.
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W. and Chang, E.H. (1990). Germline 
transmission of a mutated p53 gene in cancer-prone family with Li-Fraumeni syndrome. 
Nature, 348:747-749.
Srivistava, S., Tong, Y.A., Devadas, K., Zou, Z.Q., Chen, Y., Pirollo, K. and Chang,
E.H. (1992a). The status of the p53 gene in human papilloma virus positive or negative 
cervical carcinoma cell lines. Carcinogenesis, 13:1273-1275.
211
Srivistava, S., Tong, Y.A., Devadas, K., Zou, Z.Q., Sykes, V.W., Chen, Y., Blattner, 
W.A., Pirollo, K. and Chang, E.H. (1992b). Detection of both mutant and wild-type p53 
protein in normal skin fibroblasts and demonstration of a shared ‘second hit’ on p53 in 
diverse tumors from a cancer-prone family with Li-Fraumeni syndrome. Oncogene, 7: 
987-991.
Stanton, P., Richards, S., Reeves, J., Nikolic, M., Edington, K., Clark, L., Robertson,
G., Soutar, D., Mitchell, R., Hendler, FJ., Cooke, T., Parkinson, E.K. and Ozanne, B.W.
(1994). Epidermal growth factor receptor expression by human squamous cell 
carcinomas of the head and neck, cell lines and xenografts. BrJ.Cancer, 70:427-433.
Steinert, P. and Yuspa, S.H. (1978). Biochemical evidence for keratinization by mouse 
epidermal cells in culture. Science, 200:1491-1493.
Steinman, R.A., Hoffman, B., Iro, A., Guillouf, C., Liebermann, D.A. and El-Houseini, 
M.E. (1994). Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene, 9:3389- 
3396.
Steinmeyer, K., Maake, H. and Deppert, W. (1990). Cell cycle control by p53 in normal 
(3T3) and chemically transformed (MethA) mouse cells. Regulation of p53 expression. 
Oncogene, 5:1691-1699.
Stenger, J.E., Mayr, G. A., Mann, K. and Tegtmeyer, P. (1992). Formation of stable p53 
homotetramers and multiples of tetramers. MolCarcin. 5:102-106.
Stephen, C.W. and Lane, D.P. (1992) Mutant conformations of p53 : precise epitope 
mapping using a filamentous phage epitope library. J.MoLBiol. 225:577-583.
Sturzbecher, H.W., Maimets, T., Chumakov, P., Brain, R., Addison, C., Simanis, V., 
Rudge, K., Philp, R., Grimaldi, M., Court, W. and Jenkins, J.R. (1990). p53 interacts 
with p34 cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. 
Oncogene, 5:795-801.
Sturzbecher, H.W., Brain, R., Addison, C., Rudge, K., Remm, M., Grimaldi, M.,
Keenan, E. and Jenkins, J.R. (1992). A C-terminal alpha helix plus basic region motif is 
the major structural determinant of p53 tetramerization. Oncogene, 7:1513-1523.
Sugawara, O., Oshimura, M., Koi, M., Annab, L.A. and Barrett, J.C. (1990). Induction 
of cellular senescence in immortalised cells by human chromosome 1. Science, 247:707- 
710.
212
Sun, T. and Green, H. (1976). Differentiation of the epidermal keratinocyte in culture: 
formation of the comified envelope. Cell, 9:511-521.
Sim, T. and Green, H. (1978). Immunofluorescent staining of keratin fibres in cultured 
cells. Cell, 14:469-476.
Sun, Y., Dong, Z., Nakamura, K. and Colburn, N. (1993). Dosage-dependent dominance 
over wild-type p53 of a mutant p53 isolated from nasopharyngeal carcinoma. Faseb J, 
7:944-950.
Suzuki, H., Takahashi, T., Kurishi, T., Suyamo, M., Ariyoshi, Y. and Veda, R. (1992). 
p53 mutations in NSCLC in Japan: association between mutation and smoking. Cancer 
Res. 52:734-736.
Szekely, L., Selivanova, G., Magnusson, K.P., Klein, G. and Wiman, K.G. (1993). 
EBNA-5, an Epstein-Barr virus encoded nuclear antigen, binds to the retinoblastoma and 
p53 proteins. Proc.Nat.Acad.Sci., U.S.A, 90:5455-5459.
Takeichi, M. 1991. Cadherin cell adhesion receptors as morphogenetic regulator. Science 
251: 1451-1455.
Tatake, R.J., Rajaram, N., Damle, R.N., Balsara, B., Bhisey, A.N. and Gangal, S.G.
(1990). Establishment and characterisation of four new squamous cell carcinoma cell 
lines derived from oral tumors. Cancer Res. Clin. Oncol. 116:179-86.
Usty, T.D., White, A. and Sanchez, J. (1992). Suppression of gene amplification in 
human cell hybrids. Science, 255:1425-1427.
Truant, R., Xiao, H., Ingles, J. and Greenblatt, J. (1993). Direct interaction between the 
transcriptional actvation domain of human p53 and the TATA box binding protein. 
J.Biol.Chem. 268:2284-2287.
Tsujimoto, Y., Jaffe, E., Cossman, J., Gorham, J., Nowell, P.C. and Croce, C.M. (1985). 
Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the 
t(ll;14) chromosome translocation. Nature, 315:340-343.
Tsukada, T., Tomooka, Y., Takai, S., Ueda, Y., Nishikawa, S., Yagi, T., Tokunaga, T., 
Takeda, N., Suda, Y., Abe, S., Matsuo, I., Ikawa, Y. and Aizawa, S. (1993). Enhanced 
proliferative potential in culture of cells from p53-deficient mice. Oncogene, 8:3313- 
3322.
213
Ullrich, SJ., Anderson, C.W., Mercer, W.E. and Appella, E. (1992). The p53 tumour 
suppressor protein, a modulator of cell proliferation. J.Biol.Chem. 267:15259-15262.
Unger, T., Nau, M.M., Segal, S. and Minna, J.D. (1992). p53: a transdominant regulator 
of transcription whose function is ablated in mutations occurring in human cancer. Embo 
J. 11:1383-1390.
Van der Riet, P., Nawroz, H., Hruban, R.H., Corio, R„ Tokino, K., Koch, W. and 
Sidransky, D. (1994a). Frequent loss of chromosome 9p21-22 early in head and neck 
cancer progression. Cancer Res. 54:1156-1158.
van der Riet, P., Karp, D., Farmer, E., Wei, Q., Grossman, L., Tokino, K., Ruppert, J.M. 
and Sidransky, D. (1994b). Progression of basal cell carcinoma through loss of 
chromosome 9q and inactivation of a single p53 allele. Cancer Res. 54:25-27.
Vogelstein, B., Fearon, E.R., Hamilton, S.R., Kern, S.E., Preisinger, A.C., Leppert, M., 
Nakamura, Y., White, R., Smits, A.M.M. and Bos, J.L. (1988). Genetic alterations 
during colorectal tumour development. N.EnglJ.Med. 319:525-532.
Vojtesek, B., Bartek, J., Midgley, C.A. and Lane, D.P. (1992). An immunochemical 
analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and 
epitope mapping using recombinant p53. J.ImmunoLMethods, 151:237-244.
Volz, A., Boyle, J.M., Cann, H.M., Cottingham, R.W., Orr, H.T. and Ziegler, A. (1994). 
Report of the second international workshop on human chromosome 6. Genomics 
21:464-472.
Von Deimling, A., Eibi, R.H., Ohgaki, H., Loius, D.N., Von Ammon, K., Petersen, I., 
Kleihues, P., Chung, R.Y., Wiestler, O.D. and Siezinger, B.R. (1992). p53 mutations are 
associated with 17p allelic loss in grade II and grade HI astrocytomas. Cancer Res. 
52:2987-2990.
Von der Weth, A. and Deppert, W. (1993). Wild-type p53 is not a negative regulator of 
simian virus 40 DNA replication in infected monkey cells. J. Virol. 67:886-893.
Wang, E.H., Friedman, P.N. and Prives, C. (1989). p53 protein blocks replication of 
SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen. Cell, 
57:379-392.
214
Wang, X. W., Lin, X., Klein, C.B., Bhamra, R.K., Lee, Y-W. and Costa, M. (1992). A 
conserved region in human and Chinese hamster X chromosomes can induce cellular 
senescence of nickel-transformed Chinese hamster cell lines. Carcinogenesis 13:555- 
561.
Wang, Y. and Eckhart, W. (1992). Phosphorylation sites in the amino-terminal region of 
mouse p53. Proc.Nat.Acad.ScL, U.S.A 89:4231-4235.
Wang, Y., Reed, M., Wang, P., Stenger, J.E., Mayr, G., Anderson, M.E., Schwedes, J.F. 
and Tegtmeyer, P. (1993). p53 domains: Identification and characterisation of two 
autonomous DNA binding regions. Genes & Development, 12:2575-2586.
Watt, F.M. (1983). Involucrin and other markers of keratinocyte terminal differentiation. 
J.InvestDermatol. 81:100-103.
Watt, F.M. and Green, H. (1981). Involucrin synthesis is correlated with cell size in 
human epidermal cultures. J.CelLBiol. 90:738-742.
Watt, F.M., Jordan, P.W. and O'Neill, C.H. (1988). Cell shape controls terminal 
differentiation of human epidermal keratinocytes. Proc.Nat.Acad.Sci., U.S.A 85:5576- 
5580.
Weber, J.L. and May, P.E. (1989). Abundant class of human DNA poymorphisms which 
can be typed using the polymerase chain reaction. Am. J. Hum. Genet. 44:388-396.
Weichselbaum, R.R., Beckett, M.A., Dahlberg, W. and Dritschilo, A. (1988). 
Heterogeneity of radiation response of a parent human epidermoid carcinoma cell line 
and four clones. Int.J.Radiat. Oncol.Biol.Phys. 14:907-912.
Weichselbaum, R.R., Dunphy, E.J., Beckett, M.A., Tybor, A.G., Moran, WJ., Goldman, 
M.E., Vokes, E.E. and Panje, W.R. (1989). Epidermal growth factor gene amplification 
and expression in head and neck cancer cell lines. Head and Neck, 11:437-442.
Weinberg, R.A. (1991). Tumour suppressor genes. Science, 254:1138-1146.
Weinberg, R.A. (1985). The action of oncogenes in the cytoplasm and the nucleus. 
Science, 230:770-776.
Weinberg, R.A. (1989). Oncogenes, antioncogenes, and the molecular bases of 
multistage carcinogenesis. Cancer Res. 49:3713-3721.
215
Weintraub, H., Hauschka, S. and Tapscott, S J. (1991). The MCK enhancer contains a 
p53 responsive element. Proc.Nat.Acad.Sci.,U.S.A 88:4570-4571.
Weissenbach, J., Gyapay, G., Dib, C., Vignal, A., Morissette, J., Millasseau, P.,
Vaysseix, G. and Lathrop, M. (1992). A second generation linkage map of the human 
genome. Nature, 359:794-801.
Whyte, P., Buchkovich, J J., Horowitz, J.M., Friend, S.H., Raybuck, M., Weinberg, R.A. 
and Harlow, E. (1988). Association between an oncogene and an antioncogene: the 
adenovirus El A protein binds to the retinoblastoma gene product. Nature, 334:124-129.
Withers, D.A., Harvey, R.C., Faust, J.B., Melnyk, O., Carey, K. and Meeker, T.C.
(1991). Characterisation of a candidate BCL-1 gene. MolCell Biol. 11:4846-4853.
Wolf, D., Admon, S., Oren, M. and Rotter, V. (1984). Abelson murine leukemia virus- 
transformed cells that lack p53 protein synthesis express aberrant p53 mRNA species. 
MolCell Biol. 4:552-558.
Won, K.A., Xiong, Y., Beach, D. and Gilman, M.Z. (1992). Growth regulated 
expression of D-type cyclin genes in human diploid fibroblasts.
Proc.Nat.Acad.Sci.,U.S.A 89: 9910-9914.
Woodworth, C.D., Wang, H., Simpson, S., Alvarez-Salas, L. and Notario, V. (1993). 
Overexpression of wild-type p53 alters growth and differentiation of normal human 
keratinocytes but not human papillomavirus expressing cell lines. Cell Growth Differ. 
4:367-376.
Wrede, D., Tidy, J.A., Crook, T., Lane, D. and Vousden, K.H. (1991). Expression of Rb 
and p53 proteins in HPV positive and HPV negative cervical carcinoma cell lines. 
MolCarcin. 4:171-175.
Wright, W., Pereira-Smith, O.M. and Shay, J.W. (1989). Reversible cellular senescence: 
Implications for immortalization of normal human diploid fibroblasts. Mol. Cell Biol 
9:3088-3092.
Wyllie, A.H. (1980). Glucocorticoid-induced thymocyte apoptosis is associated with 
endogenous endonuclease activation. Nature 284:555-556.
216
Wynder, E.L. and Stellman, S.D. (1977). Comparative epidemiology of tobacco-related 
cancers .Cancer Res. 37:4608-4622.
Xiong, Y., Hannon, G.J., Zhang, H., Casso, D., Kobayashi, R. and Beach, D. (1993). 
p21 is a universal inhibitor of cyclin kinases. Nature, 366:701-704.
Yin, Y., Tainsky, M.A., Bischoff, F.Z., Strong, L.C. and Wahl, G.M. (1992). Loss of 
normal p53 allele in Li-Fraumeni fibroblasts correlates with loss of cell cycle control.
Cell, 70:937-648.
Yoo, G.H., Xu, HJ., Brennan, J.A., Westra, W., Hruban, R.H., Koch, W., Benedict, 
W.F. and Sidransky, D. (1994). Infrequent inactivation of the retinoblastoma gene 
despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. 
Cancer Res. 54:4603-4606.
Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A. and Oren, M.
(1991). Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by 
Interleukin-6. Nature, 352:345-347.
Yonish-Rouach, E., Grunwald, D., Wilders, S., Kimchi, A., May, E., Lawrence, JJ., 
May, P. and Oren, M. (1993). P53 mediated cell death: Relationship to cell cycle control. 
MolCell Biol 13:1415-1423.
Yuspa, S.H., Ben, T., Hennings, H. and Lichti, U. (1980). Phorbol ester tumour 
promoters induce epidermal transglutaminase activity. Biochem. Biophys. Res. Commun. 
97:700-708.
Zhang, S.Y., Klein-Szanto, A.J.P., Souter, E.R., Shafarenko, M., Mitsunaga, S., Nobori, 
T., Carson, D.A., Ridge, J.A. and Goodrow, T.L. (1994). Higher frequency of 
alterations in the pl6/CDKN2 gene in squamous cell carcinoma cell lines than in primary 
tumours of the head and neck. Cancer Res. 54:5050-5053.
Zhang, W., Funk, W., Wright, W., Shay, J. and Deisseroth, A.B. (1993). Novel DNA 
binding of p53 mutants and their role in transcriptional activation. Oncogene, 8:2555- 
2559.
Zhang, W., Shay, J.W. and Deisseroth, A. (1993). Inactive p53 mutants may enhance the 
transcriptional activity of wild-type p53. Cancer Res. 53:4772-4775.
217
Zheng, X., Yuan, F., Hu, L., Chen, F., Klein, G. and Christensson, B. (1994). Effect of
beta lymphocyte and NPC derived EBV-LMP1 gene expression on in vitro growth and 
differentiation of human epithelial cells. IntJ.Canc. 57:747-753.
Zhu, Y.M., Bradbury, D.A. and Russell, N.H. (1994). Wild-type p53 is required for 
apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. 
BrJ. Cancer, 69:468-472.
GLASGOW
UNIVERSITY
218
